



Publications IUCT-O & CRCT 2018

1. Abbo, O., Pinnagoda, K., Brouchet, L., Leobon, B., Savagner, F., Oliver, I., Galinier, P., Castex, M.-P., Pasquet, M., 2018. **Wilms tumor, pleuropulmonary blastoma, and DICER1: case report and literature review.** *World J Surg Oncol* 16, 164. <https://doi.org/10.1186/s12957-018-1469-4>
2. Aboudaram, A., Khalifa, J., Massabeau, C., Simon, L., Hadj Henni, A., Thureau, S., 2018. **[Image-guided radiotherapy in lung cancer]**. *Cancer Radiother* 22, 602–607. <https://doi.org/10.1016/j.canrad.2018.06.009>
3. Abravanel, F., Pique, J., Couturier, E., Nicot, F., Dimeglio, C., Lhomme, S., Chiabrande, J., Saune, K., Péron, J.-M., Kamar, N., Evrard, S., de Valk, H., Cintas, P., Izopet, J., HEV study group, 2018. **Acute hepatitis E in French patients and neurological manifestations.** *J. Infect.* <https://doi.org/10.1016/j.jinf.2018.06.007>
4. Adam, J., Le Stang, N., Rouquette, I., Cazes, A., Badoual, C., Pinot-Roussel, H., Tixier, L., Danel, C., Damiola, F., Damotte, D., Penault-Llorca, F., Lantuéjoul, S., 2018a. **Multicenter French harmonization study for PD-L1 IHC testing in non-small cell lung cancer.** *Ann. Oncol.* <https://doi.org/10.1093/annonc/mdy014>
5. Adam, J., Le Stang, N., Rouquette, I., Cazes, A., Badoual, C., Pinot-Roussel, H., Tixier, L., Danel, C., Damiola, F., Damotte, D., Penault-Llorca, F., Lantuéjoul, S., 2018b. **Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.** *Ann. Oncol.* 29, 953–958. <https://doi.org/10.1093/annonc/mdy014>
6. Adam, K., Cartel, M., Lambert, M., David, L., Yuan, L., Besson, A., Mayeux, P., Manenti, S., Didier, C., 2018. **A PIM-CHK1 signaling pathway regulates PLK1 phosphorylation and function during mitosis.** *J. Cell. Sci.* 131. <https://doi.org/10.1242/jcs.213116>
7. Adès, L., Thomas, X., Guerci Bresler, A., Raffoux, E., Spertini, O., Vey, N., Marchand, T., Récher, C., Pigneux, A., Girault, S., Deconinck, E., Gardin, C., Tournilhac, O., Lambert, J.F., Chevallier, P., de Botton, S., Lejeune, J., Dombret, H., Chevret, S., Fenaux, P., French Belgian Swiss APL group, 2018. **Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.** *Haematologica.* <https://doi.org/10.3324/haematol.2018.198614>
8. Aleissa, M., Konstantinou, M.P., Samimi, M., Lamant, L., Gaboriaud, P., Touze, A., Ceppi, C., Bulai Livideanu, C., Paul, C., 2018. **Trichodysplasia spinulosa associated with HIV infection: clinical response to acitretin and valganciclovir.** *Clin. Exp. Dermatol.* 43, 231–233. <https://doi.org/10.1111/ced.13286>
9. Allaire, M., Bazille, C., Selves, J., Salamé, E., Altieri, M., 2018. **Hepatitis E virus infection mimicking acute graft rejection in a liver transplant recipient.** *Clin Res Hepatol Gastroenterol.* <https://doi.org/10.1016/j.clinre.2017.12.005>
10. Allodji, R.S., Haddy, N., Vu-Bezin, G., Dumas, A., Fresneau, B., Mansouri, I., Demoor-Goldschmidt, C., El-Fayech, C., Pacquement, H., Munzer, M., Bondiau, P.-Y., Berchery, D., Oberlin, O., Rubino, C., Diallo, I., de Vathaire, F., 2018. **Risk of subsequent colorectal cancers after a solid tumor in childhood: Effects of radiation therapy and chemotherapy.** *Pediatr Blood Cancer* e27495. <https://doi.org/10.1002/psc.27495>
11. Almont, T., Couteau, C., Etienne, H., Bondil, P., Guimbaud, R., Schover, L., Huyghe, É., 2018a. **Sexual health and needs for sexology care in digestive cancer patients undergoing chemotherapy: a 4-month cross-sectional study in a French University Hospital.** *Support Care Cancer.* <https://doi.org/10.1007/s00520-018-4125-1>
12. Almont, T., Farsi, F., Krakowski, I., El Osta, R., Bondil, P., Huyghe, É., 2018b. **Sexual health in cancer: the results of a survey exploring practices, attitudes, knowledge, communication, and professional interactions in oncology healthcare providers.** *Support Care Cancer.* <https://doi.org/10.1007/s00520-018-4376-x>
13. Ame van der Beek, N., Nelson, I., Froissart, R., Levade, T., Garcia, V., Lacene, E., Boland, A., Masson, C., Romero, N.B., Stojkovic, T., Bonne, G., Béhin, A., 2018. **A new case of SMA phenotype without epilepsy due to biallelic variants in ASAH1.** *Eur. J. Hum. Genet.* <https://doi.org/10.1038/s41431-018-0250-z>
14. Andrique, C., Morardet, L., Linares, L.K., Cissé, M.Y., Merle, C., Chibon, F., Provot, S., Haÿ, E., Ea, H.-K., Cohen-

- Solal, M., Modrowski, D., 2018. **Calpain-6 controls the fate of sarcoma stem cells by promoting autophagy and preventing senescence.** JCI Insight 3. <https://doi.org/10.1172/jci.insight.121225>
15. Angeles, M.A., Martínez-Gómez, C., Martínez, A., Ferron, G., 2018a. **Laparoscopic hand-assisted Miami Pouch after pelvic exenteration in 10 steps.** Gynecol. Oncol. <https://doi.org/10.1016/j.ygyno.2018.06.010>
 16. Angeles, M.A., Martínez-Gómez, C., Martínez, A., Ferron, G., 2018b. **En bloc pelvic resection for ovarian carcinomatosis: Hudson procedure in 10 steps.** Gynecol. Oncol. <https://doi.org/10.1016/j.ygyno.2018.12.006>
 17. Angeles, M.A., Martínez-Gómez, C., Migliorelli, F., Voglimacci, M., Figurelli, J., Motton, S., Tanguy Le Gac, Y., Ferron, G., Martínez, A., 2018c. **Novel Surgical Strategies in the Treatment of Gynecological Malignancies.** Curr Treat Options Oncol 19, 73. <https://doi.org/10.1007/s11864-018-0582-5>
 18. Antonia, S.J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K.H., de Wit, M., Cho, B.C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y.-C., Karapetis, C.S., Hirt, S., Ostoros, G., Kubota, K., Gray, J.E., Paz-Ares, L., de Castro Carpeño, J., Faivre-Finn, C., Reck, M., Vansteenkiste, J., Spigel, D.R., Wadsworth, C., Melillo, G., Taboada, M., Dennis, P.A., Özgüroğlu, M., PACIFIC Investigators, [collab: [Mazières, J.](#)] 2018. **Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.** N. Engl. J. Med. 379, 2342–2350. <https://doi.org/10.1056/NEJMoa1809697>
 19. Appay, R., Tabouret, E., Macagno, N., Touat, M., Carpentier, C., Colin, C., Ducray, F., Idbaih, A., Mokhtari, K., [Uro-Coste, E.](#), Dehais, C., Figarella-Branger, D., POLA Network, 2018a. **IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas.** Neuro-oncology 20, 716–718. <https://doi.org/10.1093/neuonc/ny014>
 20. Appay, R., Tabouret, E., Touat, M., Carpentier, C., Colin, C., Ducray, F., Idbaih, A., Mokhtari, K., [Uro-Coste, E.](#), Dehais, C., Figarella-Branger, D., POLA network, 2018b. **Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome.** Acta Neuropathol Commun 6, 89. <https://doi.org/10.1186/s40478-018-0594-1>
 21. [Astudillo, L.](#), Laure, A., Fabry, V., Pugnet, G., Maury, P., Labrunée, M., Sailer, L., Pavy-Le Traon, A., 2018. **[Postural tachycardia syndrome (PoTS): An up-to-date].** Rev Med Interne. <https://doi.org/10.1016/j.revmed.2018.04.017>
 22. [Attal, J.](#), [Chaltiel, L.](#), Lubrano, V., Sol, J.C., [Lanaspeze, C.](#), [Vieilleigne, L.](#), Latorzeff, I., [Cohen-Jonathan Moyal, E.](#), 2018. **Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation.** J. Neurooncol. 136, 413–419. <https://doi.org/10.1007/s11060-017-2669-4>
 23. Augeul-Meunier, K., Chretien, M.-L., Stoppa, A.-M., Karlin, L., Benboubker, L., Diaz, J.M.T., Mohty, M., Yakoub-Agha, I., Bay, J.-O., Perrot, A., Bulabois, C.-E., [Huynh, A.](#), Mercier, M., Frenzel, L., [Avet-Loiseau, H.](#), de Latour, R.P., Cornillon, J., 2018. **Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC.** Bone Marrow Transplant. <https://doi.org/10.1038/s41409-018-0122-8>
 24. [Avet-Loiseau, H.](#), 2018. **Introduction to the review series on advances in multiple myeloma.** Blood. <https://doi.org/10.1182/blood-2018-11-877795>
 25. Bahleda, R., Varga, A., [Bergé, Y.](#), Soria, J.-C., Schnell, D., Tschöepe, I., Uttenreuther-Fischer, M., [Delord, J.-P.](#), 2018. **Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.** Br. J. Cancer. <https://doi.org/10.1038/bjc.2017.436>
 26. Baik, H., Boulanger, M., Hosseini, M., Kowalczyk, J., Zaghdoudi, S., Salem, T., [Sarry, J.E.](#), Hicheri, Y., Cartron, G., Piechaczyk, M., Bossis, G., 2018. **Targeting the SUMO pathway primes all-trans retinoic acid-induced differentiation of non-promyelocytic acute myeloid leukemias.** Cancer Res. <https://doi.org/10.1158/0008-5472.CAN-17-3361>
 27. Bailly, C., Carlier, T., Jamet, B., Eugene, T., Touzeau, C., [Attal, M.](#), Hulin, C., Facon, T., Leleu, X., Perrot, A., Garderet, L., Macro, M., Caillot, D., Moreau, P., Kraeber-Bodere, F., Bodet-Milin, C., 2018. **Interim PET analysis in first line therapy of multiple myeloma: Prognostic value of ΔSUVmax in the FDG-avid patients of the IMAJEM study.** Clin. Cancer Res. <https://doi.org/10.1158/1078-0432.CCR-18-0741>
 28. Baldiny, C., [Mourey, L.](#), Liposits, G., 2018. **Perspectives on geriatric oncology research presented at the 2018 European Society for Medical Oncology: Young international society of geriatric oncology report.** J Geriatr Oncol. <https://doi.org/10.1016/j.jgo.2018.12.007>
 29. Baran, R., Robert, C., [Sibaud, V.](#), 2018. **Asymmetric Acral Spared Phenomenon Related to Systemic Anticancer Therapies.** Skin Appendage Disord 4, 315–319. <https://doi.org/10.1159/000486021>
 30. Barthes, J., Dollinger, C., Muller, C.B., Liivas, U., [Dupret-Bories, A.](#), Knopf-Marques, H., Vrana, N.E., 2018. **Immune Assisted Tissue Engineering via Incorporation of Macrophages in Cell-Laden Hydrogels Under Cytokine Stimulation.** Front Bioeng Biotechnol 6, 108. <https://doi.org/10.3389/fbioe.2018.00108>
 31. Battipaglia, G., Ruggeri, A., Labopin, M., Volin, L., Blaise, D., Socié, G., Tabrizi, R., Cornelissen, J.J., Ghavamzadeh, A., [Huynh, A.](#), Wu, D., Yakoub-Agha, I., Maertens, J., Chevallier, P., Mohty, M., Nagler, A., 2018. **Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia.** Bone Marrow Transplant. <https://doi.org/10.1038/s41409-018-0169-6>
 32. Bayó-Puxan, N., Terrasso, A.P., Creyssels, S., Simão, D., Begon-Pescia, C., Lavigne, M., Salinas, S., Bernex, F., Bosch, A., Kalatzis, V., [Levade, T.](#), Cuervo, A.M., Lory, P.,

- Consiglio, A., Brito, C., Kremer, E.J., 2018. **Lysosomal and network alterations in human mucopolysaccharidosis type VII iPSC-derived neurons.** *Sci Rep* 8, 16644. <https://doi.org/10.1038/s41598-018-34523-3>
33. Beaudoux, O., Riffaud, L., Barbe, C., Grange, F., 2018. **Prognostic factors and incidence of primary mucosal melanoma: a population-based study in France.** *Eur J Dermatol.* <https://doi.org/10.1684/ejd.2018.3398>
34. Beauvais, D., Goossens, J.-F., Boyle, E., Allal, B., Lafont, T., Chatelut, E., Herbaux, C., Morschhauser, F., Genay, S., Odou, P., Danel, C., 2018. **Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.** *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 1093–1094, 158–166. <https://doi.org/10.1016/j.jchromb.2018.06.026>
35. Beauval, J.-B., Lorient, Y., Hennequin, C., Rozet, F., Barthelemy, P., Borchiellini, D., Schlürmann Constans, F., Gross, E., Maillet, D., Pasticier, G., Pignot, G., Timsit, M.-O., Vincendeau, S., Ploussard, G., Sargos, P., 2018a. **Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG.** *Crit. Rev. Oncol. Hematol.* 122, 144–149. <https://doi.org/10.1016/j.critrevonc.2017.12.012>
36. Beauval, J.-B., Peyronnet, B., Benoit, T., Cabarrou, B., Seisen, T., Roumiguié, M., Pradere, B., Khene, Z.-E., Manach, Q., Verhoest, G., Thoulouzan, M., Parra, J., Doumerc, N., Mathieu, R., Vaessen, C., Soulié, M., Roupert, M., Bensalah, K., 2018b. **Long-term oncological outcomes after robotic partial nephrectomy for renal cell carcinoma: a prospective multicentre study.** *World J Urol.* <https://doi.org/10.1007/s00345-018-2208-8>
37. Beltoise, A.-S., Audouin-Pajot, C., Lucas, P., Tournier, E., Rice, G.-I., Crow, Y.-J., Mazereeuw-Hautier, J., 2018. **[Familial chilblain lupus: Four cases spanning three generations].** *Ann Dermatol Venereol.* <https://doi.org/10.1016/j.annder.2018.07.014>
38. Berbon, C., Bourgade, G., Le Goualher, L., Balardy, L., Lemaitre, É., Chassaigne, M.-C., 2018. **[Nurse telephone follow-up, a beneficial tool in geriatric oncology].** *Rev Infirm* 67, 37–38. <https://doi.org/10.1016/j.revinf.2018.10.030>
39. Bernard, I., Sacquin, A., Kassem, S., Benamar, M., Colacios, C., Gador, M., Péral, C., Fazilleau, N., Saoudi, A., 2018. **A Natural Variant of the Signaling Molecule Vav1 Enhances Susceptibility to Myasthenia Gravis and Influences the T Cell Receptor Repertoire.** *Frontiers in Immunology* 9. <https://doi.org/10.3389/fimmu.2018.02399>
40. Bertoli, S., Paubelle, E., Bérard, E., Saland, E., Thomas, X., Tavitian, S., Larcher, M.-V., Vergez, F., Sarry, A., Huguet, F., Larrue, C., Bosc, C., Farge, T., Sarry, J.E., Michallet, M., Récher, C., 2018a. **Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels and their functional as well as prognostic roles in acute myeloid leukemia.** *Eur. J. Haematol.* <https://doi.org/10.1111/ejh.13183>
41. Bertoli, S., Picard, M., Bérard, E., Griessinger, E., Larrue, C., Mouchel, P.-L., Vergez, F., Tavitian, S., Yon, E., Ruiz, J., Delabesse, E., Luquet, I., Linares, L.K., Saland, E., Carroll, M., Danet-Desnoyers, G., Sarry, A., Huguet, F., Sarry, J.-E., Récher, C., 2018b. **Dexamethasone in hyperleukocytic acute myeloid leukemia.** *Haematologica.* <https://doi.org/10.3324/haematol.2017.184267>
42. Bertoli, S., Tavitian, S., Berard, E., Gadaud, N., Luquet, I., Huynh, A., Sarry, A., Huguet, F., Récher, C., 2018c. **Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies.** *Leuk. Lymphoma* 1–4. <https://doi.org/10.1080/10428194.2018.1464156>
43. Bertoli, S., Tavitian, S., Picard, M., Huguet, F., Vergez, F., Delabesse, E., Sarry, A., Bérard, E., Récher, C., 2018d. **Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis.** *Leuk. Res.* 75, 7–10. <https://doi.org/10.1016/j.leukres.2018.10.015>
44. Bessis, D., Petit, A., Battistella, M., Bourrat, E., Girard, C., Pallure, V., Marque, M., Lacour, J.-P., Vitetta, A., Bieth, É., Selves, J., Solassol, J., Vendrell, J., 2018. **Naevoid acanthosis nigricans or RAVEN (rounded and velvety epidermal naevus) and mosaic FGFR3 and FGFR2 mutations.** *Br. J. Dermatol.* <https://doi.org/10.1111/bjd.17581>
45. Besson, L., Charrier, E., Karlin, L., Allatif, O., Marçais, A., Rouzaire, P., Belmont, L., Attal, M., Lombard, C., Salles, G., Walzer, T., Viel, S., 2018. **One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.** *Front Immunol* 9, 704. <https://doi.org/10.3389/fimmu.2018.00704>
46. Bétous, R., Gouillet de Rugy, T., Pelegrini, A.L., Queille, S., de Villartay, J.-P., Hoffmann, J.-S., 2018. **DNA replication stress triggers Rapid DNA Replication Fork Breakage by Artemis and XPF.** *PLoS Genet.* 14, e1007541. <https://doi.org/10.1371/journal.pgen.1007541>
47. Bettoun, A., Joffre, C., Zago, G., Surdez, D., Vallerand, D., Gundogdu, R., Sharif, A.A.D., Gomez, M., Cascone, I., Meunier, B., White, M.A., Codogno, P., Parrini, M.C., Camonis, J.H., Hergovich, A., 2018. **Correction: Mitochondrial clearance by the STK38 kinase supports oncogenic Ras-induced cell transformation.** *Oncotarget* 9, 22870. <https://doi.org/10.18632/oncotarget.25335>
48. Bidet, A., Dulucq, S., Smol, T., Marceau-Renaut, A., Morisset, S., Coiteux, V., Noël-Walter, M.-P., Nicolini, F.-E., Tigaud, I., Luquet, I., Struski, S., Gaillard, B., Penther, D., Tondeur, S., Nadal, N., Hermet, E., Véronèse, L., Réa, D., Gervais, C., Theisen, O., Terré, C., Cony-Makhoul, P., Lefebvre, C., Gaillard, J.-B., Radford, I., Vervaeke, A.-L., Barin, C., Chapiro, E., Nguyen-Khac, F., Etienne, G., Preudhomme, C., Mahon, F.X., Roche-Lestienne, C., 2018. **Poor prognosis of chromosome 7 clonal**

aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukaemia. *Haematologica*. <https://doi.org/10.3324/haematol.2018.208801>

49. Bielle, F., Di Stefano, A.-L., Meyronet, D., Picca, A., Villa, C., Bernier, M., Schmitt, Y., Giry, M., Rousseau, A., Figarella-Branger, D., Maurage, C.-A., Uro-Coste, E., Lasorella, A., Iavarone, A., Sanson, M., Mokhtari, K., 2018. **Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.** *Brain Pathol.* 28, 674–683. <https://doi.org/10.1111/bpa.12563>
50. Bigay-Gamé, L., Bota, S., Greillier, L., Monnet, I., Madroszyk, A., Corre, R., Mastroianni, B., Falchero, L., Mazières, J., Colineaux, H., Lepage, B., Chouaid, C., GFPC Investigators, 2018. **Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France.** *Oncology* 1–7. <https://doi.org/10.1159/000489784>
51. Bignon, L., Fricker, J.-P., Nogues, C., Mouret-Fourme, E., Stoppa-Lyonnet, D., Caron, O., Lortholary, A., Faivre, L., Lasset, C., Mari, V., Gesta, P., Gladieff, L., Hamimi, A., Petit, T., Velten, M., 2018. **Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.** *Breast J* 24, 269–277. <https://doi.org/10.1111/tbj.12887>
52. Blanchard, P., Graff-Cailleaud, P., Bossi, A., 2018. **[Prostate brachytherapy: New techniques, new indications].** *Cancer Radiother.* <https://doi.org/10.1016/j.canrad.2017.11.012>
53. Boghanim, T., Murriss, M., Lamon, T., Huynh, A., Mazières, J., Marquette, C.-H., Didier, A., 2018. **Thoracic Air-Leak Syndrome Complicating Allogeneic Hematopoietic Stem-Cell Transplantation.** *Lung.* <https://doi.org/10.1007/s00408-018-0173-z>
54. Boilève, A., Carlo, M.I., Barthélémy, P., Oudard, S., Borchiellini, D., Voss, M.H., George, S., Chevreau, C., Landman-Parker, J., Tabone, M.-D., Chism, D.D., Amin, A., Bilen, M.A., Bosse, D., Coulomb-L'hermine, A., Su, X., Choueiri, T.K., Tannir, N.M., Malouf, G.G., 2018. **Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.** *J Immunother Cancer* 6, 159. <https://doi.org/10.1186/s40425-018-0482-z>
55. Bolli, N., Biancon, G., Moarii, M., Gimondi, S., Li, Y., de Philippis, C., Maura, F., Sathiseelan, V., Tai, Y.-T., Mudie, L., O'Meara, S., Raine, K., Teague, J.W., Butler, A.P., Carniti, C., Gerstung, M., Bagratuni, T., Kastiritis, E., Dimopoulos, M., Corradini, P., Anderson, K.C., Moreau, P., Minvielle, S., Campbell, P.J., Papaemmanuil, E., Avet-Loiseau, H., Munshi, N.C., 2018. **Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.** *Leukemia*. <https://doi.org/10.1038/s41375-018-0037-9>
56. Bolli, N., Maura, F., Minvielle, S., Gloznik, D., Szalat, R., Fullam, A., Martincorena, I., Dawson, K.J., Samur, M.K., Zamora, J., Tarpey, P., Davies, H., Fulciniti, M., Shammas, M.A., Tai, Y.T., Magrangeas, F., Moreau, P., Corradini, P., Anderson, K., Alexandrov, L., Wedge, D.C., Avet-Loiseau, H., Campbell, P., Munshi, N., 2018. **Genomic patterns of progression in smoldering multiple myeloma.** *Nat Commun* 9, 3363. <https://doi.org/10.1038/s41467-018-05058-y>
57. Bompas, E., Campion, L., Italiano, A., Le Cesne, A., Chevreau, C., Isambert, N., Toulmonde, M., Mir, O., Ray-Coquard, I., Piperno-Neumann, S., Saada-Bouzid, E., Rios, M., Kurtz, J.-E., Delcambre, C., Dubray-Longeras, P., Duffaud, F., Karanian, M., Le Loarer, F., Soulié, P., Penel, N., Blay, J.-Y., 2018. **Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study.** *Cancer Med.* <https://doi.org/10.1002/cam4.1374>
58. Bonnevalle, P., Marcheix, P.-S., Nicolau, X., Arboucalot, M., Lebaron, M., Chantelot, C., Mainard, D., Ehlinger, M., members of the Getraum, 2018. **Interprosthetic femoral fractures: Morbidity and mortality in a retrospective, multicenter study.** *Orthop Traumatol Surg Res.* <https://doi.org/10.1016/j.otsr.2018.07.026>
59. Bories, P., Lamy, S., Simand, C., Bertoli, S., Delpierre, C., Malak, S., Fornecker, L., Moreau, S., Récher, C., Nebout, A., 2018. **Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey.** *Haematologica*. <https://doi.org/10.3324/haematol.2018.192468>
60. Börjesson, C., Guinard, E., Tauber, M., Konstantinou, M.-P., Bulai Livideanu, C., Mazereeuw-Hautier, J., Meyer, N., Paul, C., 2018. **Compounded topical preparations in plaque psoriasis: still a place for it in 2018?** *Dermatol Ther* e12780. <https://doi.org/10.1111/dth.12780>
61. Boros, A., Ribrag, V., Deutsch, É., Chargari, C., Izar, F., 2018. **[Radiation therapy planning for Hodgkin lymphoma: Focus on intensity-modulated radiotherapy, gating, protons. Which techniques to best deliver radiation?].** *Cancer Radiother* 22, 404–410. <https://doi.org/10.1016/j.canrad.2018.07.007>
62. Bouaoud, J., Temam, S., Cozic, N., Galmiche-Rolland, L., Belhous, K., Kolb, F., Bidault, F., Bolle, S., Dumont, S., Laurence, V., Plantaz, D., Tabone, M.-D., Marec-Berard, P., Quassemyar, Q., Couloigner, V., Picard, A., Gomez-Brouchet, A., Le Deley, M.-C., Mahier-Ait Oukhatar, C., Kadlub, N., Gaspar, N., 2018. **Ewing's Sarcoma of the Head and Neck: Margins are not just for surgeons.** *Cancer Med.* <https://doi.org/10.1002/cam4.1801>
63. Boughzala-Bennadji, R., Stoeckle, E., Le Péchoux, C., Méeus, P., Honoré, C., Attal, J., Duffaud, F., De Pinieux, G., Bompas, E., Thariat, J., Leroux, A., Bertucci, F., Isambert, N., Delcambre, C., Blay, J.-Y., Sunyach, M.-P., Coindre, J.-M., Sargos, P., Penel, N., Bonvalot, S., 2018. **Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy.** *Int. J. Radiat. Oncol. Biol. Phys.* 102, 399–406. <https://doi.org/10.1016/j.ijrobp.2018.05.055>

64. Boyrie, S., Delmas, C., Lemarié, A., Lubrano, V., Dahan, P., Malric, L., Luis, J., Gilhodes, J., Tosolini, M., Mouly, L., Lehmann, M., Toulas, C., Cohen-Jonathan Moyal, E., Monferran, S., 2018. **RND1 regulates migration of human glioblastoma stem-like cells according to their anatomical localization and defines a prognostic signature in glioblastoma.** *Oncotarget* 9, 33788–33803. <https://doi.org/10.18632/oncotarget.26082>
65. Breda, A., Territo, A., Gausa, L., Tuğcu, V., Alcaraz, A., Musquera, M., Decaestecker, K., Desender, L., Stockle, M., Janssen, M., Fornara, P., Mohammed, N., Siena, G., Serni, S., Guirado, L., Facundo, C., Doumerc, N., 2018. **Robot-assisted Kidney Transplantation: The European Experience.** *Eur. Urol.* 73, 273–281. <https://doi.org/10.1016/j.eururo.2017.08.028>
66. Bretaudeau, C., Vaysse, C., Guerby, P., Lairez, O., Soule-Tholy, M., Vidal, F., Chantalat, E., 2018. **Pericarditis After Breast Implant Rupture: A Case Report.** *Cardiol Res* 9, 381–384. <https://doi.org/10.14740/cr756w>
67. Brinas, P., Chalret du Rieu, M., Tuyeras, G., Julio, C.H., Kirzin, S., Ghouti, L., Carrere, N., 2018. **Mid-term outcomes after biologic mesh use: Does their performance meet our expectations?** *J Visc Surg.* <https://doi.org/10.1016/j.jviscsurg.2018.03.007>
68. Brodowicz, T., Mir, O., Wallet, J., Italiano, A., Blay, J.-Y., Bertucci, F., Eisterer, W., Chevreau, C., Piperno-Neumann, S., Bompas, E., Ryckewaert, T., Liegl-Antzwager, B., Thery, J., Penel, N., Le Cesne, A., Le Deley, M.-C., 2018. **Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma.** *Eur. J. Cancer* 99, 28–36. <https://doi.org/10.1016/j.ejca.2018.05.008>
69. Brun, T., Bachaud, J.-M., Graff-Cailleaud, P., Malavaud, B., Portalez, D., Popotte, C., Aziza, R., Lusque, A., Filleron, T., Ken, S., 2018a. **New approach of ultra-focal brachytherapy for low- and intermediate-risk prostate cancer with custom-linked I-125 seeds: A feasibility study of optimal dose coverage.** *Brachytherapy.* <https://doi.org/10.1016/j.brachy.2018.01.011>
70. Brun, T., Ferron, G., Filleron, T., Bonnet, J., Martinez, A., Ducassou, A., Corbiere, F., Delannes, M., 2018b. **Experimental study of pelvic perioperative brachytherapy with iodine 125 seeds (I-125) in an animal model.** *J Contemp Brachytherapy* 10, 463–469. <https://doi.org/10.5114/jcb.2018.79470>
71. Bruyère, F., Doumerc, N., 2018. **Robotic kidney transplantation: dream or future?** *Curr Opin Urol* 28, 139–142. <https://doi.org/10.1097/MOU.0000000000000476>
72. Bryere, J., Dejardin, O., Launay, L., Colonna, M., Grosclaude, P., Launoy, G., French Network of Cancer Registries (FRANCIM), 2018. **Socioeconomic status and site-specific cancer incidence, a Bayesian approach in a French Cancer Registries Network study.** *Eur. J. Cancer Prev.* 27, 391–398. <https://doi.org/10.1097/CEJ.0000000000000326>
73. Cabarrou, B., Dalenc, F., Leconte, E., Boher, J.-M., Filleron, T., 2018a. **Focus on an infrequently used quantity in the context of competing risks: The conditional probability function.** *Comput. Biol. Med.* 101, 70–81. <https://doi.org/10.1016/j.compbimed.2018.08.002>
74. Cabarrou, B., Sfumato, P., Leconte, E., Boher, J.M., Filleron, T., 2018. **Designing phase II clinical trials to target subgroup of interest in a heterogeneous population: A case study using an R package.** *Comput. Biol. Med.* 100, 239–246. <https://doi.org/10.1016/j.compbimed.2018.06.034>
75. Cabarrou, B., Sfumato, P., Mourey, L., Leconte, E., Balardy, L., Martinez, A., Delord, J.-P., Boher, J.-M., Brain, E., Filleron, T., 2018b. **Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology.** *Eur. J. Cancer* 103, 120–126. <https://doi.org/10.1016/j.ejca.2018.07.136>
76. Cabel, L., Carton, M., Cheaib, B., Pierga, J.-Y., Dalenc, F., Mailliez, A., Levy, C., Jacot, W., Debled, M., Leheurteur, M., Desmoulins, I., Lefevre, C., Gonçalves, A., Uwer, L., Ferrero, J.-M., Eymard, J.-C., Petit, T., Mouret-Reynier, M.-A., Perrocheau, G., Piot, I., Pérol, D., Simon, G., Lerebours, F., 2018. **Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.** *Breast Cancer Res. Treat.* <https://doi.org/10.1007/s10549-018-5017-2>
77. Cacheux, J., Brut, M., Bancaud, A., Cordelier, P., Leichlé, T., 2018. **Spatial Analysis of Nanofluidic-Embedded Biosensors for Wash-Free Single-Nucleotide Difference Discrimination.** *ACS Sens.* <https://doi.org/10.1021/acssensors.7b00667>
78. Cadranel, J., Cortot, A.B., Lena, H., Mennequier, B., Do, P., Dansin, E., Mazieres, J., Chouaid, C., Perol, M., Barlesi, F., Robinet, G., Friard, S., Thiberville, L., Audigier-Valette, C., Vergnenegre, A., Westeel, V., Slimane, K., Buturuga, A., Moro-Sibilot, D., Besse, B., 2018. **Real-life experience of ceritinib in crizotinib-pretreatedALK+advanced non-small cell lung cancer patients.** *ERJ Open Res* 4. <https://doi.org/10.1183/23120541.00058-2017>
79. Caers, J., Garderet, L., Kortüm, K.M., O'Dwyer, M.E., van de Donk, N.W.C.J., Binder, M., Dold, S.M., Gay, F., Corre, J., Beguin, Y., Ludwig, H., Larocca, A., Driessen, C., Dimopoulos, M.A., Boccadoro, M., Gramatzki, M., Zweegman, S., Einsele, H., Cavo, M., Goldschmidt, H., Sonneveld, P., Delforge, M., Auner, H.W., Terpos, E., Engelhardt, M., 2018. **An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when.** *Haematologica.* <https://doi.org/10.3324/haematol.2018.189159>
80. Calvayrac, O., Nowosad, A., Cabantous, S., Lin, L., Figarol, S., Jeannot, P., Serres, M.P., Callot, C., Perchey, R.T., Creff, J., Taranchon-Clermont, E., Rouquette, I., Favre, G., Pradines, A., Manenti, S., Mazieres, J., Lee, H., Besson, A., 2018a. **Cytoplasmic p27^{Kip1} promotes**

- tumorigenesis via suppression of RhoB activity. The Journal of Pathology path.5167. <https://doi.org/10.1002/path.5167>
81. Calvayrac, O., Pradines, A., Favre, G., 2018b. **RHOB expression controls the activity of serine/threonine protein phosphatase PP2A to modulate mesenchymal phenotype and invasion in non-small cell lung cancers.** Small GTPases 9, 339–344. <https://doi.org/10.1080/21541248.2016.1234429>
 82. Calvayrac, O., Pradines, A., Mazières, J., Favre, G., 2018c. [The Ras-related GTPase RhoB, a relevant actor in the adaptive resistance to EGFR tyrosine kinase inhibitors in lung cancers]. Med Sci (Paris) 34, 12–14. <https://doi.org/10.1051/medsci/20183401003>
 83. Campone, M., Lacroix-Triki, M., Roca, L., Spielmann, M., Wildiers, H., Cottu, P., Kerbrat, P., Levy, C., Desmoulins, I., Bachelot, T., Winston, T., Eymard, J.-C., Uwer, L., Duhoux, F.P., Verhoeven, D., Jaubert, D., Coeffic, D., Orfeuvre, H., Canon, J.L., Asselain, B., Martin, A.-L., Lemonnier, J., Roché, H., 2018. **UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.** Eur. J. Cancer 103, 184–194. <https://doi.org/10.1016/j.ejca.2018.06.025>
 84. Campredon, P., Imbert, P., Mouly, C., Grunenwald, S., Mazières, J., Caron, P., 2018. **Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment.** Eur Thyroid J 7, 84–87. <https://doi.org/10.1159/000485742>
 85. Canivet, C., Gourgou-Bourgade, S., Napoléon, B., Palazzo, L., Flori, N., Guibert, P., Piessen, G., Farges-Bancel, D., Seitz, J.-F., Assenat, E., Vendrely, V., Truant, S., Vanbiervliet, G., Berthelémy, P., Garcia, S., Gomez-Brouchet, A., Buscaill, L., Bournet, B., BACAP Consortium, 2018. **A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort.** BMC Cancer 18, 986. <https://doi.org/10.1186/s12885-018-4906-4>
 86. Carrère, S., Tetreau, R., Honoré, C., Tzanis, D., Delhorme, J.-B., Fau, M., Decanter, G., Llacer, C., Firmin, N., Stoeckle, E., Meeus, P., Ferron, G., Cupissol, D., Quénet, F., Meunier, B., Bonvalot, S., GSF-GETO, 2018. [What is the best management for a spermatic cord sarcoma in 2018?]. Prog. Urol. <https://doi.org/10.1016/j.purol.2018.09.010>
 87. Casaos, J., Huq, S., Lott, T., Felder, R., Choi, J., Gorelick, N., Peters, M., Xia, Y., Maxwell, R., Zhao, T., Ji, C., Simon, T., Sesen, J., Scotland, S.J., Kast, R.E., Rubens, J., Raabe, E., Eberhart, C.G., Jackson, E.M., Brem, H., Tyler, B., Skuli, N., 2018. **Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors.** Oncotarget 9, 8054–8067. <https://doi.org/10.18632/oncotarget.23883>
 88. Casassa, E.A., Mailhol, C., Tournier, E., Laurent, C., Degboe, Y., Eischen, M., Kirsten, N., Moreau, J., Evrard, S.M., Mansat-De Mas, V., Lamant, L., Dubreuil, P., Apoil, P.A., Hermine, O., Paul, C., Bulai Livideanu, C., 2018. **Mast cell activation syndrome: High frequency of skin manifestations and anaphylactic shock.** Allergol Int. <https://doi.org/10.1016/j.alit.2018.07.003>
 89. Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., Chanson, P., Cortet, C., Do Cao, C., Drui, D., Haissaguerre, M., Hescot, S., Illouz, F., Kuhn, E., Lahlou, N., Merlen, E., Raverot, V., Smati, S., Verges, B., Borson-Chazot, F., 2018. **Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions.** Ann. Endocrinol. (Paris). <https://doi.org/10.1016/j.ando.2018.07.005>
 90. Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., Chanson, P., Cortet, C., Do Cao, C., Drui, D., Haissaguerre, M., Hescot, S., Illouz, F., Kuhn, E., Lahlou, N., Merlen, E., Raverot, V., Smati, S., Verges, B., Borson-Chazot, F., 2018. **French Endocrine Society Guidance on endocrine side-effects of immunotherapy.** Endocr. Relat. Cancer. <https://doi.org/10.1530/ERC-18-0320>
 91. Caulier, A., Drumez, E., Gauthier, J., Robin, M., Blaise, D., Beguin, Y., Michallet, M., Chevallier, P., Bay, J.-O., Vigouroux, S., Desbrosses, Y., Cornillon, J., Nguyen, S., Dauriac, C., de Latour, R.P., Lioure, B., Rohrlich, P.-S., Carré, M., Bourhis, J.-H., Huynh, A., Suarez, F., Garnier, F., Duhamel, A., Yakoub-Agha, I., 2018. **Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC.** Curr Res Transl Med. <https://doi.org/10.1016/j.retram.2018.08.003>
 92. Cavallier, Z., Sarini, J., Maisongrosse, V., Dupret-Bories, A., 2018. **Lesion of the thyroid cartilage.** Eur Ann Otorhinolaryngol Head Neck Dis. <https://doi.org/10.1016/j.anorl.2018.09.008>
 93. Chabrilac, E., Morinière, S., Jegoux, F., Blanchard, D., Choussy, O., Hans, S., Vergez, S., 2018. **Transoral robotic resection of benign tumors of the upper aerodigestive tract: Experience of the French group of GETTEC.** Head Neck. <https://doi.org/10.1002/hed.25197>
 94. Chaigneau, L., Patrikidou, A., Ray-Coquard, I., Valentin, T., Linassier, C., Bay, J.O., Moureau Zabotto, L., Bompas, E., Piperno-Neumann, S., Penel, N., Alcindor, T., Laigre, M., Guillemet, C., Salas, S., Hugli, A., Domont, J., Sunyach, M.P., Lecesne, A., Blay, J.Y., Nerich, V., Isambert, N., 2018. **Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO).** Oncologist. <https://doi.org/10.1634/theoncologist.2017-0136>
 95. Chauvin, M., Florén, H.-G., Friis, M., Jackson, M., Kamae, T., Kataoka, J., Kawano, T., Kiss, M., Mikhalev, V., Mizuno, T., Ohashi, N., Stana, T., Tajima, H., Takahashi, H., Uchida, N., Pearce, M., 2018. **Publisher Correction: Shedding new light on the Crab with polarized X-rays.**

- Sci Rep 8, 7975. <https://doi.org/10.1038/s41598-018-24853-7>
96. Chevrier, R., Basuyau, F., Benard-Thierry, I., Devys, C., Divanon, F., Duban, M., Favier, B., Ferry, I., Fougereau, E., Escalup, L., Delbey, S., Exinger, D., Latour, J.-F., Lemare, F., Lortal, B., Pinguet, F., Puisset, F., Prebay, D., Rey, J.-B., 2018. **Apports des consultations pharmaceutiques dans la prise en charge des anticancéreux oraux.** *Innovations & Thérapeutiques en Oncologie* 4, 45–51. <https://doi.org/10.1684/ito.2018.0108>
 97. Chibon, F., Lesluyes, T., Valentin, T., Le Guellec, S., 2018. **Cinsarc signature as a prognostic marker for clinical outcome in sarcomas and beyond.** *Genes Chromosomes Cancer*. <https://doi.org/10.1002/gcc.22703>
 98. Cintas, C., Douché, T., Therville, N., Arcucci, S., Ramos-Delgado, F., Basset, C., Thibault, B., Guillermet-Guibert, J., 2018. **Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics.** *Cancers (Basel)* 10. <https://doi.org/10.3390/cancers10060174>
 99. Claro, G., Meyer, N., Meresse, T., Gangloff, D., Grolleau, J.-L., Chaput, B., 2018. **Does needle biopsy cause an increased risk of extracapsular extension in the diagnosis of metastatic lymph node in melanoma?** *Int. J. Dermatol.* 57, 410–416. <https://doi.org/10.1111/ijd.13936>
 100. Classe, J.-M., Loaec, C., Gimbergues, P., Alran, S., de Lara, C.T., Dupre, P.F., Rouzier, R., Faure, C., Paillocher, N., Chauvet, M.P., Houvenaeghel, G., Gutowski, M., De Blay, P., Verhaeghe, J.L., Barranger, E., Lefebvre, C., Ngo, C., Ferron, G., Palpacuer, C., Campion, L., 2018. **Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.** *Breast Cancer Res. Treat.* <https://doi.org/10.1007/s10549-018-5004-7>
 101. Cleyne, A., Samur, M., Perrot, A., Buisson, L., Maheo, S., Fulciniti, M., Attal, M., Munshi, N., Avet-Loiseau, H., Corre, J., 2018. **Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14).** *Blood*. <https://doi.org/10.1182/blood-2018-09-876433>
 102. Cohen, C., Tessier, W., Gronnier, C., Renaud, F., Pasquer, A., Théreaux, J., Gagnière, J., Meunier, B., Collet, D., Piessen, G., Mariette, C., FREGAT (French Eso-Gastric Tumors working group) – FRENCH (Fédération de Recherche en Chirurgie) – AFC (Association Française de Chirurgie), [collab : Carrère, N.] 2018. **Salvage Surgery for Esophageal Cancer: How to Improve Outcomes?** *Ann. Surg. Oncol.* 25, 1277–1286. <https://doi.org/10.1245/s10434-018-6365-1>
 103. Cohen, E.E.W., Soulières, D., Le Tourneau, C., Dinis, J., Licitra, L., Ahn, M.-J., Soria, A., Machiels, J.-P., Mach, N., Mehra, R., Burtness, B., Zhang, P., Cheng, J., Swaby, R.F., Harrington, K.J., KEYNOTE-040 investigators, [collab : Delord, J.-P.] 2018. **Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.** *Lancet*. [https://doi.org/10.1016/S0140-6736\(18\)31999-8](https://doi.org/10.1016/S0140-6736(18)31999-8)
 104. Cohen, R.B., Delord, J.-P., Doi, T., Piha-Paul, S.A., Liu, S.V., Gilbert, J., Algazi, A.P., Damian, S., Hong, R.-L., Le Tourneau, C., Day, D., Varga, A., Elez, E., Wallmark, J., Saraf, S., Thanigaimani, P., Cheng, J., Keam, B., 2018. **Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.** *Am. J. Clin. Oncol.* <https://doi.org/10.1097/COC.0000000000000429>
 105. Colonna, M., Boussari, O., Cowppli-Bony, A., Delafosse, P., Romain, G., Grosclaude, P., Jooste, V., French Network of Cancer Registries (FRANCIM), 2018a. **Time trends and short term projections of cancer prevalence in France.** *Cancer Epidemiol* 56, 97–105. <https://doi.org/10.1016/j.canep.2018.08.001>
 106. Colonna, M., Boussari, O., Cowppli-Bony, A., Delafosse, P., Romain, G., Grosclaude, P., Jooste, V., French Network of Cancer Registries (FRANCIM), 2018b. **Erratum to “Time trends and short term projections of cancer prevalence in France” [Cancer Epidemiol. 56 (2018) 97-105].** *Cancer Epidemiol.* <https://doi.org/10.1016/j.canep.2018.10.001>
 107. Comont, T., Moulis, G., Delavigne, K., Cougoul, P., Parant, O., Guyard-Boileau, B., Derumeaux, H., Adoue, D., Beyne-Rauzy, O., 2018a. **Re: Severe Primary Autoimmune Thrombocytopenia (ITP) in Pregnancy: a national cohort study Primary immune thrombocytopenia management during pregnancy.** *A French study.* *BJOG* 125, 629–630. <https://doi.org/10.1111/1471-0528.14856>
 108. Comont, T., Sibaud, V., Mourey, L., Cougoul, P., Beyne-Rauzy, O., 2018b. **Immune checkpoint inhibitor-related acral vasculitis.** *J Immunother Cancer* 6, 120. <https://doi.org/10.1186/s40425-018-0443-6>
 109. Compérat, E., Babjuk, M., Algaba, F., Amin, M., Brimo, F., Grignon, D., Hansel, D., Hes, O., Malavaud, B., Reuter, V., van der Kwast, T., 2018. **SIU-ICUD on bladder cancer: pathology.** *World J Urol.* <https://doi.org/10.1007/s00345-018-2466-5>
 110. Congras, A., Caillet, N., Torossian, N., Quelen, C., Daugrois, C., Brousset, P., Lamant, L., Meggetto, F., Hoareau-Aveilla, C., 2018. **Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells.** *Oncotarget* 9, 14539–14551. <https://doi.org/10.18632/oncotarget.24465>
 111. Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A.C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J.J., Lecomte, T., Assenat, E., Faroux, R., Ychou, M., Volet, J., Sauvanet, A., Breysacher, G., Di Fiore, F., Cripps, C., Kavan, P., Texereau, P., Bouhier-Leporrier, K., Khemissa-Akouz, F., Legoux, J.-L., Juzyna, B., Gourgou, S., O’Callaghan, C.J., Jouffroy-Zeller, C., Rat, P., Malka, D., Castan, F., Bachet, J.-B., Canadian Cancer Trials Group and the Unicancer-GI-PRODIGE Group, [collab :

- Guimbaud, R.] 2018. **FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer**. *N. Engl. J. Med.* 379, 2395–2406. <https://doi.org/10.1056/NEJMoa1809775>
112. Conte, C., Palmaro, A., Grosclaude, P., Daubisse-Marliac, L., Despas, F., Lapeyre-Mestre, M., 2018. **A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases**. *Medicine (Baltimore)* 97, e9418. <https://doi.org/10.1097/MD.00000000000009418>
113. Conzatti, G., Cavalie, S., Gayet, F., Torrisani, J., Carrère, N., Tourrette, A., 2018. **Elaboration of a thermosensitive smart biomaterial: From synthesis to the ex vivo bioadhesion evaluation**. *Colloids Surf B Biointerfaces* 175, 91–97. <https://doi.org/10.1016/j.colsurfb.2018.11.084>
114. Cordelier, P., 2018. **Keep Quiet and Stay in Line! Smart Polymers to Keep an Eye on Pancreatic Tumors**. *Mol. Ther.* <https://doi.org/10.1016/j.ymthe.2018.03.006>
115. Cornud, F., Roumiguié, M., Barry de Longchamps, N., Ploussard, G., Bruguière, E., Portalez, D., Malavaud, B., 2018. **Precision Matters in MR Imaging-targeted Prostate Biopsies: Evidence from a Prospective Study of Cognitive and Elastic Fusion Registration Transrectal Biopsies**. *Radiology* 162916. <https://doi.org/10.1148/radiol.2017162916>
116. Corre, J., Cleyne, A., Robiou du Pont, S., Buisson, L., Bolli, N., Attal, M., Munshi, N., Avet-Loiseau, H., 2018. **Multiple myeloma clonal evolution in homogeneously treated patients**. *Leukemia*. <https://doi.org/10.1038/s41375-018-0153-6>
117. Costantini, A., Grynovska, M., Lucibello, F., Moisés, J., Pagès, F., Tsao, M.S., Shepherd, F.A., Bouchaab, H., Garassino, M., Aerts, J.G.J.V., Mazières, J., Mondini, M., Berghmans, T., Meert, A.-P., Cadranel, J., 2018. **Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly**. *Eur. Respir. J.* 51. <https://doi.org/10.1183/13993003.02072-2017>
118. Cottreau, A.-S., Buvat, I., Kanoun, S., Versari, A., Casasnovas, O., Chauvie, S., Clerc, J., Gallamini, A., Meignan, M., 2018. **Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?** *Eur. J. Nucl. Med. Mol. Imaging*. <https://doi.org/10.1007/s00259-018-4005-4>
119. Cottu, P., D'Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P.-E., Duhoux, F.P., Levy, C., Mouret-Reynier, M.-A., Dalenc, F., Frenel, J.-S., Jouannaud, C., Venat-Bouvet, L., Nguyen, S., Ferrero, J.-M., Canon, J.-L., Grenier, J., Callens, C., Gentien, D., Lemonnier, J., Vincent-Salomon, A., Delaloge, S., 2018. **Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer**. *Ann. Oncol.* <https://doi.org/10.1093/annonc/mdy448>
120. Courtot, L., Hoffmann, J.-S., Bergoglio, V., 2018. **The Protective Role of Dormant Origins in Response to Replicative Stress**. *Int J Mol Sci* 19. <https://doi.org/10.3390/ijms19113569>
121. Covin, B., Roumiguié, M., Quintyn-Ranty, M.-L., Graff, P., Khalifa, J., Aziza, R., Ploussard, G., Portalez, D., Malavaud, B., 2018. **Refining the risk-stratification of transrectal biopsy-detected prostate cancer by elastic fusion registration transperineal biopsies**. *World J Urol.* <https://doi.org/10.1007/s00345-018-2459-4>
122. Cresson, C., Péron, S., Jamrog, L., Rouquié, N., Prade, N., Dubois, M., Hébrard, S., Lagarde, S., Gerby, B., Mancini, S.J.C., Cogné, M., Delabesse, E., Delpy, L., Broccardo, C., 2018. **PAX5A and PAX5B isoforms are both efficient to drive B cell differentiation**. *Oncotarget* 9, 32841–32854. <https://doi.org/10.18632/oncotarget.26003>
123. Croce, S., Ducoulombier, A., Ribeiro, A., Leslyes, T., Noel, J.-C., Amant, F., Guillou, L., Stoeckle, E., Devouassoux-Shisheboran, M., Penel, N., Floquet, A., Arnould, L., Guyon, F., Mishellany, F., Chakiba, C., Cuppens, T., Zikan, M., Leroux, A., Frouin, E., Farre, I., Genestie, C., Valo, I., MacGrogan, G., Chibon, F., 2018a. **Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors**. *Mod. Pathol.* <https://doi.org/10.1038/modpathol.2017.185>
124. Croce, S., Leslyes, T., Delespaul, L., Bonhomme, B., Pérot, G., Velasco, V., Mayeur, L., Rebier, F., Ben Rejeb, H., Guyon, F., McCluggage, W.G., Floquet, A., Querleu, D., Chakiba, C., Devouassoux-Shisheboran, M., Mery, E., Arnould, L., Averous, G., Soubeyran, I., Le Guellec, S., Chibon, F., 2018b. **GREB1-CTNNB1 fusion transcript detected by RNA-sequencing in a uterine tumor resembling ovarian sex cord tumor (UTROSCT): a novel CTNNB1 rearrangement**. *Genes Chromosomes Cancer*. <https://doi.org/10.1002/gcc.22694>
125. Culetto, A., Rouanet, M., Bournet, B., Buscail, L., 2018. **Genetic Testing in Young Adult Patients With Idiopathic Acute Pancreatitis**. *Am. J. Gastroenterol.* 113, 624. <https://doi.org/10.1038/ajg.2017.467>
126. Culié, D., Garrel, R., Viotti, J., Schiappa, R., Chamorey, E., Fakhry, N., Lallemand, B., Vergez, S., Dupret-Bories, A., Dassonville, O., Poissonnet, G., Santini, J., Peyrade, F., Benezery, K., Sudaka, A., Jourdan-Soulier, F., Chapel, F., Guelfucci, B., Bozec, A., 2018a. **Impact of HPV-associated p16-expression and other clinical factors on therapeutic decision-making in patients with oropharyngeal cancer: A GETTEC multicentric study**. *Eur J Surg Oncol* 44, 1908–1913. <https://doi.org/10.1016/j.ejso.2018.05.022>
127. Culié, D., Garrel, R., Viotti, J., Schiappa, R., Chamorey, E., Fakhry, N., Lallemand, B., Vergez, S., Dupret-Bories, A., Dassonville, O., Poissonnet, G., Santini, J., Peyrade, F., Benezery, K., Sudaka, A., Jourdan-Soulier, F., Chapel, F., Guelfucci, B., Bozec, A., 2018b. **Impact of HPV-associated p16-expression and other clinical factors on therapeutic decision-making in patients with**

- oropharyngeal cancer: A GETTEC multicentric study.** Eur J Surg Oncol. <https://doi.org/10.1016/j.ejso.2018.05.022>
128. Dadone-Montaudié, B., Alberti, L., Duc, A., Delespaul, L., Lesluyes, T., Pérot, G., Lançon, A., Paindavoine, S., Di Mauro, I., Blay, J.-Y., de la Fouchardière, A., Chibon, F., Karanian, M., MacGrogan, G., Kubiniek, V., Keslair, F., Cardot-Leccia, N., Michot, A., Perrin, V., Zekri, Y., Coindre, J.-M., Tirode, F., Pedeutour, F., Ranchère-Vince, D., Le Loarer, F., Pissaloux, D., 2018. **Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions.** Mod. Pathol. <https://doi.org/10.1038/s41379-018-0089-4>
129. Dalenc, F., Ribet, V., Rossi, A.B., Guyonnaud, J., Bernard-Marty, C., de Lafontan, B., Salas, S., Ranc Royo, A.-L., Sarda, C., Levasseur, N., Massabeau, C., Leveccq, J.-M., Dulguerova, P., Guerrero, D., Sibaud, V., 2018. **Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study.** Eur J Cancer Care (Engl) 27. <https://doi.org/10.1111/ecc.12735>
130. Dalgaard, L.P., Zare, R., Gaya, J.M., Redorta, J.P., Roumiguié, M., Filleron, T., Malavaud, B., 2018. **Prospective evaluation of the performances of narrow-band imaging flexible videoscopies relative to white-light imaging flexible videoscopies, in patients scheduled for transurethral resection of a primary NMIBC.** World J Urol. <https://doi.org/10.1007/s00345-018-2537-7>
131. Dalmau, N., Andrieu-Abadie, N., Tauler, R., Bedia, C., 2018a. **Untargeted lipidomic analysis of primary human epidermal melanocytes acutely and chronically exposed to UV radiation.** Mol Omics 14, 170–180. <https://doi.org/10.1039/c8mo00060c>
132. Dalmau, N., Andrieu-Abadie, N., Tauler, R., Bedia, C., 2018b. **Phenotypic and lipidomic characterization of primary human epidermal keratinocytes exposed to simulated solar UV radiation.** J. Dermatol. Sci. <https://doi.org/10.1016/j.jdermsci.2018.07.002>
133. De Almeida Chaves, S., Moulis, G., Pugnet, G., Sailler, L., Astudillo, L., 2018. **Camptocormia with trigeminal involvement revealing myositis with anti-Ku antibodies.** Joint Bone Spine. <https://doi.org/10.1016/j.jbspin.2018.03.013>
134. De Barros, S., Vayr, F., Despas, F., Strumia, M., Podevin, C., Gauthier, M., Delabesse, E., Soulat, J.-M., Laurent, G., Huguet, F., Herin, F., 2018. **The impact of chronic myeloid leukemia on employment: the French prospective study.** Ann. Hematol. <https://doi.org/10.1007/s00277-018-3549-5>
135. de Bataille, C., Sibaud, V., Prioul, A., Laprie, A., Vigarios, E., 2018. **Management of radiation-induced mucosal necrosis with photobiomodulation therapy.** Support Care Cancer 26, 2491–2492. <https://doi.org/10.1007/s00520-017-3899-x>
136. de Bonnecaze, G., Chaput, B., Dupret-Bories, A., Vergez, S., Serrano, E., 2018a. **Functional outcome after long-term low-dose trimethoprim/sulfamethoxazole in chronic rhinosinusitis with purulence: a prospective study.** J Laryngol Otol 1–5. <https://doi.org/10.1017/S0022215118000452>
137. de Bonnecaze, G., Vairel, B., Dupret-Bories, A., Serrano, E., Vergez, S., 2018b. **Transoral robotic surgery of the tongue base for obstructive sleep apnea: Preliminary results.** Eur Ann Otorhinolaryngol Head Neck Dis 135, 411–415. <https://doi.org/10.1016/j.anorl.2018.09.001>
138. de Bonnecaze, G., Verillaud, B., Chaltiel, L., Fierens, S., Chapelier, M., Rumeau, C., Malard, O., Gavid, M., Dufour, X., Righini, C., Uro-Coste, E., Rives, M., Bach, C., Baujat, B., Janot, F., de Gabory, L., Vergez, S., 2018. **Clinical characteristics and prognostic factors of sinonasal undifferentiated carcinoma: a multicenter study.** Int Forum Allergy Rhinol. <https://doi.org/10.1002/alr.22143>
139. de Crevoisier, R., Bayar, M.A., Pommier, P., Muracciole, X., Pène, F., Dudouet, P., Latorzeff, I., Beckendorf, V., Bachaud, J.-M., Laplanche, A., Supiot, S., Chauvet, B., Nguyen, T.-D., Bossi, A., Créhange, G., Lagrange, J.L., 2018. **Daily versus weekly prostate cancer image-guided radiotherapy: Phase 3 multicenter randomized trial.** Int. J. Radiat. Oncol. Biol. Phys. <https://doi.org/10.1016/j.ijrobp.2018.07.2006>
140. de Gabory, L., Verillaud, B., Rumeau, C., Herman, P., Jankowski, R., Michel, J., de Kermadec, H., Coste, A., Mortuaire, G., Righini, C., Rey, E., Choussy, O., Trévilot, V., Crampette, L., Serrano, E., Tsaranazy, A., Bastier, P.-L., Vergez, S., 2018. **Multicenter assessment of exclusive endoscopic endonasal approach for the treatment of 53 olfactory neuroblastomas.** Head Neck. <https://doi.org/10.1002/hed.25064>
141. De Magis, A., Manzo, S.G., Russo, M., Marinello, J., Morigi, R., Sordet, O., Capranico, G., 2019. **DNA damage and genome instability by G-quadruplex ligands are mediated by R loops in human cancer cells.** Proc. Natl. Acad. Sci. U.S.A. 116, 816–825. <https://doi.org/10.1073/pnas.1810409116>
142. de Swart, L., Smith, A., Haase, D., Fenaux, P., Symeonidis, A., Cermak, J., Sanz, G., Stauder, R., Mittelman, M., Hellström-Lindberg, E., Malcovati, L., Langemeijer, S., Skov-Holm, M., Mądry, K., Germing, U., Almeida, A.M., Tatic, A., Savic, A., Šimec, N.G., van Marrewijk, C., Guerci-Bresler, A., Sanhes, L., Luño, E., Culligan, D., Beyne-Rauzy, O., Burgstaller, S., Blijlevens, N., Bowen, D., de Witte, T., 2018. **Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS.** Leuk. Res. 67, 21–26. <https://doi.org/10.1016/j.leukres.2018.01.022>
143. Deau, B., Amorim, S., Perrot, A., Quittet, P., Cornillon, J., Chaoui, D., Marolleau, J.P., Oberic, L., Le Du, K., Fornecker, L.-M., Tournilhac, O., Veillard, A.S., Chailiol, I., Robin, M., Tamburini, J., Brice, P., 2018. **Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.** Br. J. Haematol. <https://doi.org/10.1111/bjh.15184>

144. Decroocq, J., Itzykson, R., Vigouroux, S., Michallet, M., Yakoub-Agha, I., Huynh, A., Beckerich, F., Suarez, F., Chevallier, P., Nguyen-Quoc, S., Ledoux, M.-P., Clement, L., Hicheri, Y., Guillermin, G., Cornillon, J., Contentin, N., Carre, M., Maillard, N., Mercier, M., Mohty, M., Beguin, Y., Bourhis, J.-H., Charbonnier, A., Dauriac, C., Bay, J.-O., Blaise, D., Deconinck, E., Jubert, C., Raus, N., Peffault de Latour, R., Dhedin, N., 2018. **Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.** *Am. J. Hematol.* 93, 416–423. <https://doi.org/10.1002/ajh.25004>
145. Dejoie, T., Corre, J., Caillon, H., Moreau, P., Attal, M., Loiseau, H.A., 2018. **Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements.** *Leukemia.* <https://doi.org/10.1038/s41375-018-0339-y>
146. Delanoy, N., Michot, J.-M., Comont, T., Kramkimel, N., Lazarovici, J., Dupont, R., Champiat, S., Chahine, C., Robert, C., Herbaux, C., Besse, B., Guillemin, A., Mateus, C., Pautier, P., Saiag, P., Madonna, E., Maerevoet, M., Bout, J.-C., Leduc, C., Biscay, P., Quere, G., Nardin, C., Ebbo, M., Albigès, L., Marret, G., Levrat, V., Dujon, C., Vargaftig, J., Laghouati, S., Croisille, L., Voisin, A.-L., Godeau, B., Massard, C., Ribrag, V., Marabelle, A., Michel, M., Lambotte, O., 2018. **Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.** *Lancet Haematol.* [https://doi.org/10.1016/S2352-3026\(18\)30175-3](https://doi.org/10.1016/S2352-3026(18)30175-3)
147. Delaunay, M., Caron, P., Sibaud, V., Godillot, C., Collot, S., Milia, J., Prévoit, G., Mazières, J., 2018. [Toxicity of immune checkpoints inhibitors]. *Rev Mal Respir.* <https://doi.org/10.1016/j.rmr.2017.08.006>
148. Delcroix, V., Mauduit, O., Tessier, N., Montillaud, A., Lesluyes, T., Ducret, T., Chibon, F., Van Coppenolle, F., Ducreux, S., Vacher, P., 2018. **The Role of the Anti-Aging Protein Klotho in IGF-1 Signaling and Reticular Calcium Leak: Impact on the Chemosensitivity of Dedifferentiated Liposarcomas.** *Cancers (Basel)* 10. <https://doi.org/10.3390/cancers10110439>
149. Delhorme, J.-B., Severac, F., Averous, G., Glehen, O., Passot, G., Bakrin, N., Marchal, F., Pocard, M., Lo Dico, R., Eveno, C., Carrere, S., Sgarbura, O., Quenet, F., Ferron, G., Goéré, D., Brigand, C., French National Network of Peritoneal Surface Malignancies (RENAPE), 2018. **Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.** *Br J Surg.* <https://doi.org/10.1002/bjs.10716>
150. Delporte, G., Henon, F., Ploussard, G., Briganti, A., Rizk, J., Rozet, F., Touijer, K., Ouzzane, A., 2018. **Radical prostatectomy for locally advanced and high-risk prostate cancer: A systematic review of the literature.** *Prog. Urol.* <https://doi.org/10.1016/j.purol.2018.08.007>
151. Delyon, J., Chevret, S., Jouary, T., Dalac, S., Dalle, S., Guillot, B., Arnault, J.-P., Avril, M.-F., Bedane, C., Bens, G., Pham-Ledard, A., Mansard, S., Grange, F., Machet, L., Meyer, N., Legoupil, D., Saiag, P., Idir, Z., Renault, V., Deleuze, J.-F., Hindie, E., Battistella, M., Dumaz, N., Mourah, S., Lebbe, C., GCC (French Group of Skin Cancer), 2018. **STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.** *J. Invest. Dermatol.* 138, 58–67. <https://doi.org/10.1016/j.jid.2017.07.839>
152. Demoor, C., Supiot, S., Mahé, M.-A., Oberlin, O., Allodji, R., Haddy, N., Helfre, S., Vigneron, C., Brillaud-Meflah, V., Bernier, B., Laprie, A., Ducassou, A., Claude, L., Diallo, I., de Vathaire, F., 2018. **Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy.** *Br J Radiol* 20170824. <https://doi.org/10.1259/bjr.20170824>
153. Dercle, L., Billey, C., Cognet, T., Cassol, E., Sinigaglia, M., Pascal, P., Berry, L., Otal, P., Bureau, C., Lairez, O., 2018. **Spleno-hepatic index to predict portal hypertension by equilibrium radionuclide ventriculography.** *Nucl Med Commun* 39, 1138–1142. <https://doi.org/10.1097/MNM.0000000000000927>
154. Derrioux, C., Freynet, N., Frayfer, J., Delabesse, E., Clappier, E., Defasque, S., Broutier, H., Fouillard, L., 2018. **A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia.** *Leuk. Lymphoma* 1–4. <https://doi.org/10.1080/10428194.2018.1430796>
155. Desandes, E., Brugières, L., Molinié, F., Defosse, G., Delafosse, P., Jehannin-Ligier, K., Velten, M., Trétarre, B., Amadéo, B., Marrer, E., Woronoff, A.-S., Ganry, O., Monnereau, A., d'Almeida, T., Troussard, X., Daubisse-Marliac, L., Bara, S., Guizard, A.-V., Baldi, I., Launoy, G., Clavel, J., Lacour, B., 2018. **Adolescent and young adult oncology patients in France: Heterogeneity in pathways of care.** *Pediatr Blood Cancer* e27235. <https://doi.org/10.1002/psc.27235>
156. Devillier, R., Labopin, M., Chevallier, P., Ledoux, M.-P., Socié, G., Huynh, A., Bourhis, J.-H., Cahn, J.-Y., Roth-Guepin, G., Mufti, G., Desmier, D., Michallet, M., Fegueux, N., Ciceri, F., Baron, F., Blaise, D., Nagler, A., Mohty, M., 2018. **Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation.** *Bone Marrow Transplant.* <https://doi.org/10.1038/s41409-017-0043-y>
157. Díez-Campelo, M., Lorenzo, J.I., Itzykson, R., Rojas, S.M., Berthon, C., Luño, E., Beayne-Rauzy, O., Perez-Oteyza, J., Vey, N., Bargay, J., Park, S., Cedena, T., Bordessoule, D., Muñoz, J.A., Gyan, E., Such, E., Visanica, S., López-

- Cadenas, F., de Botton, S., Hernández-Rivas, J.M., Ame, S., Stamatoullas, A., Delaunay, J., Salanoubat, C., Isnard, F., Guieze, R., Pérez Guallar, J., Badiella, L., Sanz, G., Cañizo, C., Fenaux, P., 2018. **Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.** *Br. J. Haematol.* <https://doi.org/10.1111/bjh.15190>
158. Dimopoulos, M.A., San-Miguel, J., Belch, A., White, D., Benboubker, L., Cook, G., Leiba, M., Morton, J., Ho, P.J., Kim, K., Takezako, N., Moreau, P., Kaufman, J.L., Sutherland, H.J., Lalancette, M., Magen, H., Iida, S., Kim, J.S., Prince, H.M., Cochrane, T., Oriol, A., Bahlis, N.J., Chari, A., O' Rourke, L., Wu, K., Schecter, J.M., Casneuf, T., Chiu, C., Soong, D., Sasser, A.K., Khokhar, N.Z., Avet-Loiseau, H., Usmani, S.Z., 2018. **Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.** *Haematologica.* <https://doi.org/10.3324/haematol.2018.194282>
159. Doazan, M., Hans, S., Morinière, S., Lallemand, B., Vergez, S., Aubry, K., De Monès, E., Espitalier, F., Jegoux, F., Pradat, P., Céruse, P., 2018. **Oncologic outcomes with transoral robotic surgery for supraglottic squamous cell carcinoma: Results of the French Robotic Surgery Group of GETTEC.** *Head Neck.* <https://doi.org/10.1002/hed.25199>
160. Donadieu, J., Lamant, M., Fieschi, C., Sicre de Fontbrune, F., Caye, A., Ouachee, M., Beaupain, B., Bustamante, J., Poirel, H.A., Isidor, B., Van Den Neste, E., Neel, A., Nimubona, S., Toutain, F., Barlogis, V., Schleinitz, N., Leblanc, T., Rohrlisch, P., Suarez, F., Ranta, D., Abou Chahla, W., Bruno, B., Terriou, L., Francois, S., Lioure, B., Ahle, G., Bachelier, F., Preudhomme, C., Delabesse, E., Cavé, H., Bellanné-Chantelot, C., Pasquet, M., French GATA2 working party, 2018. **Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.** *Haematologica.* <https://doi.org/10.3324/haematol.2017.181909>
161. Drilon, A., Lin, J.J., Filleron, T., Ni, A., Milia, J., Bergagnini, I., Hatzoglou, V., Velcheti, V., Offin, M., Li, B., Carbone, D.P., Besse, B., Mok, T., Awad, M.M., Wolf, J., Owen, D., Camidge, D.R., Riely, G.J., Peled, N., Kris, M.G., Mazieres, J., Gainor, J.F., Gautschi, O., 2018. **Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET-Rearranged Lung Cancers.** *J Thorac Oncol.* <https://doi.org/10.1016/j.jtho.2018.07.004>
162. Druel, V., Hayet, H., Esman, L., Clavel, M., Rougé Bugat, M.-E., 2018. **Assessment of cancers' diagnostic stage in a Deaf community - survey about 4363 Deaf patients recorded in French units.** *BMC Cancer* 18, 93. <https://doi.org/10.1186/s12885-017-3972-3>
163. Ducassou, A., Padovani, L., Chaltiel, L., Bolle, S., Habrand, J.-L., Claude, L., Carrie, C., Muracciole, X., Coche-Dequeant, B., Alapetite, C., Supiot, S., Demoor-Goldschmidt, C., Bernier-Chastagner, V., Huchet, A., Leseur, J., Le Prise, E., Kerr, C., Truc, G., Nguyen, T.D., Bertozzi, A.-I., Frappaz, D., Boetto, S., Sevely, A., Tensaouti, F., Laprie, A., **Pediatric French Radiation Oncologist Group (GFRP) and the French Society of Children With Cancer (SFCE), 2018. Pediatric Localized Intracranial Ependymomas: A Multicenter Analysis of the Société Française de lutte contre les Cancers de l'Enfant (SFCE) from 2000 to 2013.** *Int. J. Radiat. Oncol. Biol. Phys.* 102, 166–173. <https://doi.org/10.1016/j.ijrobp.2018.05.036>
164. Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E., Delcambre, C., Kalbacher, E., Italiano, A., Collard, O., Chevreau, C., Saada, E., Isambert, N., Delaye, J., Schiffler, C., Bouvier, C., Vidal, V., Chabaud, S., Blay, J.-Y., French Sarcoma Group, 2018. **Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.** *Lancet Oncol.* [https://doi.org/10.1016/S1470-2045\(18\)30742-3](https://doi.org/10.1016/S1470-2045(18)30742-3)
165. Dumontet, C., Hulin, C., Dimopoulos, M.A., Belch, A., Dispenzieri, A., Ludwig, H., Rodon, P., Van Droogenbroeck, J., Qiu, L., Cavo, M., Van de Velde, A., Lahuerta, J.J., Allangba, O., Lee, J.H., Boyle, E., Perrot, A., Moreau, P., Manier, S., Attal, M., Roussel, M., Mohty, M., Mary, J.Y., Civet, A., Costa, B., Tinel, A., Gaston-Mathé, Y., Facon, T., 2018. **A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.** *Leukemia.* <https://doi.org/10.1038/s41375-018-0133-x>
166. Dupont, R., Longué, M., Galinier, A., Frais, C.C., Ingueneau, C., Astudillo, L., Arlet, P., Adoue, D., Alric, L., Prévot, G., Cabarrou, B., Sailler, L., Pugnet, G., 2018. **Impact of micronutrient deficiency & malnutrition in systemic sclerosis: Cohort study and literature review.** *Autoimmun Rev.* <https://doi.org/10.1016/j.autrev.2018.05.010>
167. Dupuis, F., Lamant, L., Gerard, E., Torossian, N., Chaltiel, L., Filleron, T., Beylot-Barry, M., Dutriaux, C., Prey, S., Gros, A., Jullie, M.-L., Meyer, N., Vergier, B., 2018. **Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.** *Br. J. Cancer.* <https://doi.org/10.1038/s41416-018-0168-9>
168. Durrieu-Gaillard, S., Dumay-Odelot, H., Boldina, G., Tourasse, N.J., Allard, D., André, F., Macari, F., Choquet, A., Lagarde, P., Drutel, G., Leste-Lasserre, T., Petitet, M., Lesluyes, T., Lartigue-Faustin, L., Dupuy, J.-W., Chibon, F., Roeder, R.G., Joubert, D., Vagner, S., Teichmann, M., 2018. **Regulation of RNA polymerase III transcription during transformation of human IMR90 fibroblasts with defined genetic elements.** *Cell Cycle* 17, 605–615. <https://doi.org/10.1080/15384101.2017.1405881>
169. Ehler, K., Levade, T., Di Rocco, M., Lanino, E., Albert, M.H., Führer, M., Jarisch, A., Güngör, T., Ayuk, F., Vormoor, J., 2018. **Allogeneic hematopoietic cell**

- transplantation in Farber disease.** *J. Inherit. Metab. Dis.* <https://doi.org/10.1007/s10545-018-0171-6>
170. Elez, E., Gomez-Roca, C., Soto Matos-Pita, A., Argiles, G., Valentin, T., Coronado, C., Iglesias, J., Macarulla, T., Betrian, S., Fudio, S., Zaragoza, K., Tabernero, J., Delord, J.-P., 2018. **First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.** *Invest New Drugs.* <https://doi.org/10.1007/s10637-018-0674-x>
171. Emens, L.A., Cruz, C., Eder, J.P., Braiteh, F., Chung, C., Tolaney, S.M., Kuter, I., Nanda, R., Cassier, P.A., Delord, J.-P., Gordon, M.S., ElGabry, E., Chang, C.-W., Sarkar, I., Grossman, W., O'Hear, C., Fassò, M., Molinero, L., Schmid, P., 2018. **Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.** *JAMA Oncol.* <https://doi.org/10.1001/jamaoncol.2018.4224>
172. Escayola, C., Torrent, J.J., Ferron, G., Quenet, F., Querleu, D., 2018. When and Who Should Perform Epithelial Ovarian Cancer Surgery? *Int. J. Gynecol. Cancer* 28, 594–599. <https://doi.org/10.1097/IGC.0000000000001188>
173. Espinosa, E., Valitutti, S., 2018. **New roles and controls of mast cells.** *Curr. Opin. Immunol.* 50, 39–47. <https://doi.org/10.1016/j.coi.2017.10.012>
174. Espinosa, E., Valitutti, S., Laroche, M., Laurent, C., Apoil, P.A., Hermine, O., Lavit, M., Paul, C., Livideanu, C.B., 2018. **Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases.** *Clin. Immunol.* <https://doi.org/10.1016/j.clim.2018.07.004>
175. Esposito, F., Lim, C., Sa Cunha, A., Pessaux, P., Navarro, F., Azoulay, D., French Colorectal Liver Metastases Working Group, Association Française de Chirurgie (AFC), [collab : Muscari, F.]2018. **Primary Tumor Versus Liver-First Approach for Synchronous Colorectal Liver Metastases: An Association Française de Chirurgie (AFC) Multicenter-Based Study with Propensity Score Analysis.** *World J Surg.* <https://doi.org/10.1007/s00268-018-4711-x>
176. Essilini, A., Comont, T., Germain, J., Brun, N., Dingremont, C., Castel, B., Arista, S., Madaule, S., Sailler, L., Lapeyre-Mestre, M., Beyne-Rauzy, O., Godeau, B., Adoue, D., Moulis, G., CARMEN investigators group, 2018. **Pretreatment with standard-dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (ITP).** *Eur. J. Haematol.* 100, 412–418. <https://doi.org/10.1111/ejh.13032>
177. Ettl, J., Quek, R.G.W., Lee, K.-H., Rugo, H.S., Hurvitz, S., Gonçalves, A., Fehrenbacher, L., Yerushalmi, R., Mina, L.A., Martin, M., Roché, H., Im, Y.-H., Markova, D., Bhattacharyya, H., Hannah, A.L., Eiermann, W., Blum, J.L., Litton, J.K., 2018. **Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.** *Ann. Oncol.* <https://doi.org/10.1093/annonc/mdy257>
178. Evrard, S.M., Péricart, S., Grand, D., Amara, N., Escuidé, F., Gilhodes, J., Bories, P., Traverse-Glehen, A., Dubois, R., Brousset, P., Parrrens, M., Laurent, C., 2018. **Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and /or BCL6 rearrangements.** *Haematologica.* <https://doi.org/10.3324/haematol.2018.198572>
179. Facon, T., Dimopoulos, M.A., Dispenzieri, A., Catalano, J.V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N.J., Banos, A., Tiab, M., Delforge, M., Cavenagh, J.D., Gerales, C., Lee, J.-J., Chen, C., Oriol, A., De La Rubia, J., White, D., Binder, D., Lu, J., Anderson, K.C., Moreau, P., Attal, M., Perrot, A., Arnulf, B., Qiu, L., Roussel, M., Boyle, E., Manier, S., Mohty, M., Avet-Loiseau, H., Leleu, X., Ervin-Haynes, A., Chen, G., Houck, V., Benboubker, L., Hulin, C., 2018. **Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.** *Blood* 131, 301–310. <https://doi.org/10.1182/blood-2017-07-795047>
180. Faivre, J.C., Bibault, J.E., Bellesoeur, A., Salleron, J., Wack, M., Biau, J., Cervellera, M., Janoray, G., Leroy, T., Lescut, N., Martin, V., Molina, S., Pichon, B., Teyssier, C., Thureau, S., Mazeron, J.J., Roché, H., Culine, S., 2018. **Choosing a career in oncology: results of a nationwide cross-sectional study.** *BMC Med Educ* 18, 15. <https://doi.org/10.1186/s12909-018-1117-2>
181. Faivre, J.-C., Bibault, J.-E., Leroy, T., Agopiantz, M., Salleron, J., Wack, M., Janoray, G., Roché, H., Culine, S., Rivera, S., 2018. Evaluation of the Theoretical Teaching of Postgraduate Radiation Oncology Medical Residents in France: a Cross-Sectional Study. *J Cancer Educ* 33, 383–390. <https://doi.org/10.1007/s13187-017-1170-2>
182. Falk, A.T., Yazbeck, N., Guibert, N., Chamorey, E., Paquet, A., Ribeyre, L., Bence, C., Zahaf, K., Leroy, S., Marquette, C.-H., Cohen, C., Mograbi, B., Mazières, J., Hofman, V., Brest, P., Hofman, P., Ilié, M., 2018. **Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients.** *Lung Cancer* 121, 70–75. <https://doi.org/10.1016/j.lungcan.2018.05.009>
183. Fares, N., Robic, M.-A., Péron, J.-M., Muscari, F., Otal, P., Suc, B., Vinel, J.-P., Bureau, C., 2018. **Transjugular intrahepatic portosystemic shunt placement before abdominal intervention in cirrhotic patients with portal hypertension: lessons from a pilot study.** *Eur J Gastroenterol Hepatol* 30, 21–26. <https://doi.org/10.1097/MEG.0000000000000990>
184. Faruch Bilfeld, M., Cavaignac, E., Wytrykowski, K., Constans, O., Lapègue, F., Chiavassa Gandois, H., Larbi, A., Sans, N., 2018. **Anterolateral ligament injuries in knees with an anterior cruciate ligament tear: Contribution of ultrasonography and MRI.** *Eur Radiol* 28, 58–65. <https://doi.org/10.1007/s00330-017-4955-0>

185. Faucher, C., Adam, C., Bancillon, N., Bertrand, E., Colledani, F., de Berranger, E., Denis, V., Girard, I., Hamzy, F., Loukili, N., Mannone, L., Mercier, L., Perrin, A., Vasseur, A., Asma, Q., Bompont, C., Yafour, N., Yakoub-Agha, I., Jost, E., 2018. **[Stem cell transplantation unit: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].** Bull Cancer. <https://doi.org/10.1016/j.bulcan.2018.11.005>
186. Faviez, G., Bousquet, E., Rabeau, A., Rouquette, J., Collot, S., Goumarre, C., Meyer, N., Prevot, G., Mazieres, J., 2018. **[Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors].** Rev Mal Respir. <https://doi.org/10.1016/j.rmr.2018.08.003>
187. Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonier, L., Mazieres, J., Zalcmán, G., Brosseau, S., Le Moulec, S., Leroy, L., Duchemann, B., Lefebvre, C., Veillon, R., Westeel, V., Koscielny, S., Champiat, S., Ferté, C., Planchard, D., Remon, J., Boucher, M.-E., Gazzah, A., Adam, J., Bria, E., Tortora, G., Soria, J.-C., Besse, B., Caramella, C., 2018. **Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.** JAMA Oncol. <https://doi.org/10.1001/jamaoncol.2018.3676>
188. Ferrer, L., Giaj Levra, M., Brevet, M., Antoine, M., Mazieres, J., Rossi, G., Chiari, R., Westeel, V., Poudenx, M., Letreut, J., Gervais, R., Osman, G., Girard, N., Toffart, A.C., Novello, S., Moro-Sibilot, D., 2018. **A brief report of transformation from Non-small cell to small cell lung cancer: Molecular and therapeutic characteristics.** J Thorac Oncol. <https://doi.org/10.1016/j.jtho.2018.08.2028>
189. Ferrufino-Schmidt, M.C., Medeiros, L.J., Liu, H., Clemens, M.W., Hunt, K.K., Laurent, C., Lofts, J., Amin, M.B., Ming Chai, S., Morine, A., Di Napoli, A., Dogan, A., Parkash, V., Bhagat, G., Tritz, D., Quesada, A.E., Pina-Oviedo, S., Hu, Q., Garcia-Gomez, F.J., Jose Borrero, J., Horna, P., Thakral, B., Narbaitz, M., Hughes, R.C., Yang, L.-J., Fromm, J.R., Wu, D., Zhang, D., Sohani, A.R., Hunt, J., Vadlamani, I.U., Morgan, E.A., Ferry, J.A., Szigeti, R., C. Tardio, J., Granados, R., Dertinger, S., Offner, F.A., Pircher, A., Hosry, J., Young, K.H., Miranda, R.N., 2018. **Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma: The American Journal of Surgical Pathology 42, 293–305.** <https://doi.org/10.1097/PAS.0000000000000985>
190. Feugier, P., Brice, P., Maynadié, M., Franchi-Rezgui, P., Hacini, M., Laurent, G., Suc, E., Fitoussi, O., Solal-Celigny, P., Damaj, G., Haioun, C., Leconte, P., Lazreg, F., Boissard, F., Pau, D., Salles, G., 2018. **Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study.** Leuk. Lymphoma 1–4. <https://doi.org/10.1080/10428194.2018.1434878>
191. Filleron, T., 2018. **Comparing sensitivity and specificity of medical imaging tests when verification bias is present: The concept of relative diagnostic accuracy.** Eur J Radiol 98, 32–35. <https://doi.org/10.1016/j.ejrad.2017.10.022>
192. Filleron, T., Lusque, A., Dalenc, F., Ferron, G., Roche, H., Martinez, A., Jouve, E., 2018. **Alternative methodological approach to randomized trial for surgical procedures routinely used.** Contemp Clin Trials. <https://doi.org/10.1016/j.cct.2018.03.016>
193. Flux, G.D., Sjogreen Gleisner, K., Chiesa, C., Lassmann, M., Chouin, N., Gear, J., Bardiès, M., Walrand, S., Bacher, K., Eberlein, U., Ljungberg, M., Strigari, L., Visser, E., Konijnenberg, M.W., 2018. **From fixed activities to personalized treatments in radionuclide therapy: lost in translation?** Eur. J. Nucl. Med. Mol. Imaging 45, 152–154. <https://doi.org/10.1007/s00259-017-3859-1>
194. Fonteyne, V., Ost, P., Bellmunt, J., Droz, J.P., Mongiat-Artus, P., Inman, B., Paillaud, E., Saad, F., Ploussard, G., 2018. **Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.** Eur. Urol. 73, 40–50. <https://doi.org/10.1016/j.eururo.2017.03.019>
195. Fouquet, G., Guidez, S., Richez, V., Stoppa, A.-M., Le Tourneau, C., Macro, M., Gruchet, C., Bobin, A., Moya, N., Syschenko, T., Sabirou, F., Levy, A., Franques, P., Gardeney, H., Karlin, L., Benboubker, L., Ouali, M., Vedovato, J.-C., Ferre, P., Pavlyuk, M., Attal, M., Facon, T., Leleu, X., 2018a. **Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.** Oncotarget 9, 23890–23899. <https://doi.org/10.18632/oncotarget.25156>
196. Fouquet, G., Karlin, L., Macro, M., Caillot, D., Roussel, M., Arnulf, B., Pegourie, B., Petillon, M.O., Mathiot, C., Hulin, C., Kolb, B., Stoppa, A.-M., Brechiniac, S., Rodon, P., Dib, M., Tiab, M., Richez, V., Araujo, C., Wetterwald, M., Garderet, L., Royer, B., Perrot, A., Benboubker, L., Decaux, O., Escoffre-Barbe, M., Femand, J.P., Moreau, P., Avet-Loiseau, H., Attal, M., Facon, T., Leleu, X., 2018b. **Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.** Ann. Hematol. <https://doi.org/10.1007/s00277-018-3236-6>
197. Fouquet, G., Snell, K.I., Guidez, S., Schraen, S., Boyle, E., Renaud, L., Desmier, D., Machet, A., Moya, N., Systchenko, T., Gruchet, C., Decaux, O., Arnulf, B., Fohrer, C., Richez, V., Kolb, B., Macro, M., Karlin, L., Royer, B., Pegourie, B., Hebraud, B., Caillot, D., Perrot, A., Moreau, P., Facon, T., Avet-Loiseau, H., Dejoie, T., Hulin, C., Harding, S., Leleu, X., 2018c. **Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.** Leuk. Lymphoma 59, 583–589. <https://doi.org/10.1080/10428194.2017.1339876>
198. Fournié, J.-J., Poupot, M., 2018. **The Pro-tumorigenic IL-33 Involved in Antitumor Immunity: A Yin and Yang**

- Cytokine.** Front Immunol 9, 2506. <https://doi.org/10.3389/fimmu.2018.02506>
199. Freitag, S., Lamant, L., 2018. [Dermatopathology histoseminar: Introduction]. Ann Pathol. <https://doi.org/10.1016/j.annpat.2018.05.003>
200. Frasca, M., Soubeyran, P., Bellera, C., Rainfray, M., Leffondre, K., Mathoulin-Pélissier, S., oncologie group, 2018 [collab : Balardy, L., Mourey, L.]. **Alterations in comprehensive geriatric assessment decrease survival of elderly patients with cancer.** Eur. J. Cancer 90, 10–18. <https://doi.org/10.1016/j.ejca.2017.11.013>
201. Frère, C., Bournet, B., Benzidia, I., Jamelot, M., Deboudeau, P., Hij, A., Rafii-Elayoubi, H., Buscail, L., Farge, D., Groupe francophone thrombose et cancer, 2018. [Venous thromboembolism and pancreatic cancer]. J Med Vasc 43, 246–254. <https://doi.org/10.1016/j.jdmv.2018.05.003>
202. Fujiso, Y., Perrin, N., van der Giessen, J., Vrana, N.E., Neveu, F., Woisard, V., 2018. **Swallow-E: A robotic in-vitro simulation of human swallowing.** PLoS ONE 13, e0208193. <https://doi.org/10.1371/journal.pone.0208193>
203. Fulciniti, M., Lin, C.Y., Samur, M.K., Lopez, M.A., Singh, I., Lawlor, M.A., Szalat, R.E., Ott, C.J., Avet-Loiseau, H., Anderson, K.C., Young, R.A., Bradner, J.E., Munshi, N.C., 2018. **Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.** Cell Rep 25, 3693–3705.e6. <https://doi.org/10.1016/j.celrep.2018.12.016>
204. Fuzier, R., Aveline, C., Zetlaoui, P., Choquet, O., Bouaziz, H., members of the i-ALR Association, 2018a. **Spinal anaesthesia in outpatient and conventional surgery: A point of view from experienced French anaesthetists.** Anaesth Crit Care Pain Med 37, 239–244. <https://doi.org/10.1016/j.accpm.2016.12.002>
205. Fuzier, R., Despres, C., 2018a. **Serratus Plane Block: New Insights But Still Many Questions.** Reg Anesth Pain Med 43, 644. <https://doi.org/10.1097/AAP.0000000000000799>
206. Fuzier, R., Despres, C., 2018b. **Serratus Plane Block: New Insights But Still Many Questions.** Reg Anesth Pain Med 43, 644. <https://doi.org/10.1097/AAP.0000000000000799>
207. Fuzier, R., Izard, P., Daboussi, A., Pouymayou, J., Pierre, S., 2018b. **A case report of sustained resolution of cancer pain by continuous perineural infusion of local anesthetic.** Eur J Pain. <https://doi.org/10.1002/ejp.1295>
208. Fuzier, R., Serres, I., Bourrel, R., Palmaro, A., Lapeyre-Mestre, M., 2018c. **Analgesic Drug Prescription After Carpal Tunnel Surgery: A Pharmacoepidemiological Study Investigating Postoperative Pain.** Reg Anesth Pain Med 43, 19–24. <https://doi.org/10.1097/AAP.0000000000000685>
209. Galant, C., Bouvier, C., Larousserie, F., Aubert, S., Audard, V., Brouchet, A., Marie, B., Guinebretière, J.-M., de Pinieux du Bouexic, G., Groupe de Pathologistes du réseau INCA d'expertise pour les sarcomes osseux de RESOS, 2018. [Histological diagnosis of bone tumors: Guidelines of the French committee of bone pathologists reference network on bone tumors (RESOS)]. Bull Cancer. <https://doi.org/10.1016/j.bulcan.2017.11.018>
210. Galateau Salle, F., Le Stang, N., Nicholson, A.G., Pissaloux, D., Churg, A., Klebe, S., Roggli, V., Tazelaar, H., Vignaud, J.M., Attanoos, R., Beasley, M.B., Begueret, H., Capron, F., Chirieac, L., Copin, M.C., Dacic, S., Danel, C., Foulet-Roge, A., Gibbs, A., Giusiano-Courcambecq, S., Hiroshima, K., Hofman, V., Husain, A., Kerr, K., Marchevsky, A., Nabeshima, K., Picquetot, J.M., Rouquette, I., Sagan, C., Sauter, J., Thivolet, F., Travis, W.D., Tsao, M.S., Weynand, B., Damiola, F., Scherpereel, A., Pairon, J.C., Lantuejoul, S., Rusch, V., Girard, N., 2018. **New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center.** J Thorac Oncol. <https://doi.org/10.1016/j.jtho.2018.04.023>
211. Gallardo, F., Mariamé, B., Gence, R., Tilkin-Mariamé, A.-F., 2018. **Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth.** Drug Des Devel Ther 12, 2805–2814. <https://doi.org/10.2147/DDDT.S172538>
212. Gandaglia, G., Ploussard, G., Valerio, M., Mattei, A., Fiori, C., Fossati, N., Stabile, A., Beauval, J.-B., Malavaud, B., Roumiguié, M., Robesti, D., Dell'Oglio, P., Moschini, M., Zamboni, S., Rakauskas, A., De Cobelli, F., Porpiglia, F., Montorsi, F., Briganti, A., 2018a. **A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.** Eur. Urol. <https://doi.org/10.1016/j.eururo.2018.10.012>
213. Gandaglia, G., van den Bergh, R.C.N., Tilki, D., Fossati, N., Ost, P., Surcel, C.I., Sooriakumaran, P., Tsaur, I., Valerio, M., Kretschmer, A., Zaffuto, E., Salomon, L., Montorsi, F., Graefen, M., van der Poel, H., de la Taille, A., Briganti, A., Ploussard, G., European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP), 2018b. **How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.** BJU Int. <https://doi.org/10.1111/bju.14391>
214. Gandara, D.R., von Pawel, J., Mazieres, J., Sullivan, R., Helland, Å., Han, J.-Y., Ponce Aix, S., Rittmeyer, A., Barlesi, F., Kubo, T., Park, K., Goldschmidt, J., Gandhi, M., Yun, C., Yu, W., Matheny, C., He, P., Sandler, A., Ballinger, M., Fehrenbacher, L., 2018. **Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.** J Thorac Oncol 13, 1906–1918. <https://doi.org/10.1016/j.jtho.2018.08.2027>

215. Garandeau, D., Noujarède, J., Leclerc, J., Imbert, C., Garcia, V., Bats, M.-L., Rambow, F., Gilhodes, J., Filleron, T., Meyer, N., Brayer, S., Arcucci, S., Tartare-Deckert, S., Segui, B., Marine, J.C., Levade, T., Bertolotto, C., Andrieu-Abadie, N., 2018. **Targeting the sphingosine 1-phosphate axis exerts potent antitumor activity in BRAFI-resistant melanomas.** *Mol. Cancer Ther.* <https://doi.org/10.1158/1535-7163.MCT-17-1141>
216. Garassino, M.C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J.E., Powderly, J., Chouaid, C., Bidoli, P., Wheatley-Price, P., Park, K., Soo, R.A., Huang, Y., Wadsworth, C., Dennis, P.A., Rizvi, N.A., ATLANTIC Investigators, 2018. **Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.** *Lancet Oncol.* 19, 521–536. [https://doi.org/10.1016/S1470-2045\(18\)30144-X](https://doi.org/10.1016/S1470-2045(18)30144-X)
217. García-González, X., López-Tarruella, S., García, M.I., González-Haba, E., Blanco, C., Salvador-Martin, S., Jerez, Y., Thomas, F., Jarama, M., Sáez, M.S., Martín, M., López-Fernández, L.A., 2018. **Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene.** *Cancer Manag Res* 10, 4517–4522. <https://doi.org/10.2147/CMAR.S174470>
218. Garderet, L., Kuhnowski, F., Berge, B., Roussel, M., Escoffre-Barbe, M., Lafon, I., Facon, T., Leleu, X., Karlin, L., Perrot, A., Moreau, P., Marit, G., Stoppa, A.-M., Royer, B., Chaletteix, C., Tiab, M., Araujo, C., Lenain, P., Macro, M., Voog, E., Benboubker, L., Allangba, O., Jourdan, E., Orcsini-Piocelle, F., Brechignac, S., Eveillard, J.-R., Belhadj, K., Wetterwald, M., Pegourie, B., Jaccard, A., Eisenmann, J.-C., Glaisner, S., Mohty, M., Hulin, C., Avet Loiseau, H., Mathiot, C., Attal, M., 2018. **Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.** *Blood.* <https://doi.org/10.1182/blood-2018-07-863829>
219. Gas, J., Liaigre-Ramos, A., Caubet-Kamar, N., Beauval, J.B., Lesourd, M., Prudhomme, T., Huyghe, E., Soulié, M., Charpentier, S., Gamé, X., 2018a. **Evaluation of the impact of a clinical pathway on the progression of acute urinary retention.** *Neurourol. Urodyn.* <https://doi.org/10.1002/nau.23873>
220. Gas, J., Nouhaud, F.-X., Roumiguié, M., Lagarde, S., Delchier, M.-C., Huyghe, E., Soulié, M., Gamé, X., Beauval, J.-B., 2018b. **Management of urinary-tract fistulas using reversible balloon nephrostomy: a single-center retrospective analysis of 56 patients.** *Int Urogynecol J.* <https://doi.org/10.1007/s00192-018-3628-0>
221. Gaspard, M., Lamant, L., Tournier, E., Valentin, T., Rochaix, P., Terrier, P., Ranchere-Vince, D., Coindre, J.-M., Filleron, T., Le Guellec, S., 2018. **Evaluation of 8 melanocytic and neural crest-associated markers in a well-characterized series of 124 malignant peripheral nerve sheath tumors (MPNST): useful to distinguish MPNST from melanoma?** *Histopathology.* <https://doi.org/10.1111/his.13740>
222. Gass, B., Marrer, E., Bara, S., Ligier, K., Molinié, F., Colonna, M., Daubisse-Marliac, L., Trétarre, B., Lapôtre-Ledoux, B., Woronoff, A.-S., Guizard, A.-V., Bouvier, V., Troussard, X., Gaiddon, C., Klein, D., Velten, M., Jégu, J., 2018. **Use of a case-mix approach to study the trends in the incidence of second primary cancers.** *Ann Epidemiol.* <https://doi.org/10.1016/j.annepidem.2018.02.008>
223. Gaud, G., Roncagalli, R., Chaoui, K., Bernard, I., Familiades, J., Colacios, C., Kassem, S., Monsarrat, B., Bulet-Schiltz, O., de Peredo, A.G., Malissen, B., Saoudi, A., 2018. **The costimulatory molecule CD226 signals through VAV1 to amplify TCR signals and promote IL-17 production by CD4+ T cells.** *Sci Signal* 11. <https://doi.org/10.1126/scisignal.aar3083>
224. Gauthier, J., Poiré, X., Gac, A.-C., Leclerc, M., Guillaume, T., Chalandon, Y., Nguyen, S., Forcade, E., Régné, C., Bay, J.-O., Bazarbachi, A., Rohrlisch, P.-S., Huynh, A., Farhi, J., Marchand, T., Malfuson, J.-V., Pilorge, S., Labussière-Wallet, H., Renard, C., Fornecker, L.-M., Detrait, M., Duléry, R., Delage, J., Ménard, A.-L., Charbonnier, A., Nelken, B., Jubert, C., Suarez, F., de la Tour, R.P., Beguin, Y., Schoemans, H., Blaise, D., Yakoub-Agha, I., 2018. **Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.** *Bone Marrow Transplant.* <https://doi.org/10.1038/s41409-017-0018-z>
225. Gauthier, M., Comont, T., Vergez, F., Ysebaert, L., 2018. **[Minimal residual disease in chronic lymphocytic leukemia: A still current issue in 2018].** *Bull Cancer.* <https://doi.org/10.1016/j.bulcan.2018.07.008>
226. Gay, F., Jackson, G., Rosiñol, L., Holstein, S.A., Moreau, P., Spada, S., Davies, F., Lahuerta, J.J., Leleu, X., Bringhen, S., Evangelista, A., Hulin, C., Panzani, U., Cairns, D.A., Di Raimondo, F., Macro, M., Liberati, A.M., Pawlyn, C., Offidani, M., Spencer, A., Hájek, R., Terpos, E., Morgan, G.J., Bladé, J., Sonneveld, P., San-Miguel, J., McCarthy, P.L., Ludwig, H., Boccadoro, M., Mateos, M.-V., Attal, M., 2018. **Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.** *JAMA Oncol.* <https://doi.org/10.1001/jamaoncol.2018.2961>
227. Gelderblom, H., Cropet, C., Chevreau, C., Boyle, R., Tattersall, M., Stacchiotti, S., Italiano, A., Piperno-Neumann, S., Le Cesne, A., Ferraresi, V., Penel, N., Duffaud, F., Cassier, P., Toulmonde, M., Casali, P., Taieb, S., Guillemaut, S., Metzger, S., Pérol, D., Blay, J.-Y., 2018. **Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.** *Lancet Oncol.* [https://doi.org/10.1016/S1470-2045\(18\)30143-8](https://doi.org/10.1016/S1470-2045(18)30143-8)

228. Ghez, D., Calleja, A., Protin, C., Baron, M., Ledoux, M.-P., Damaj, G., Dupont, M., Dreyfus, B., Ferrant, E., Herbaux, C., Laribi, K., Le Calloch, R., Malphettes, M., Paul, F., Souchet, L., Truchan-Graczyk, M., Delavigne, K., Dartigeas, C., Ysebaert, L., 2018. **Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.** Blood. <https://doi.org/10.1182/blood-2017-11-818286>
229. Giebel, S., Labopin, M., Potter, M., Poiré, X., Sengeloev, H., Socié, G., Huynh, A., Afanasyev, B.V., Schanz, U., Ringden, O., Kalhs, P., Beelen, D.W., Campos, A.M., Masszi, T., Canaani, J., Mohty, M., Nagler, A., 2018. **Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT.** Eur. J. Cancer 96, 73–81. <https://doi.org/10.1016/j.ejca.2018.03.018>
230. Gillebert, Q., Huchet, V., Rousseau, C., Cochet, A., Olivier, P., Courbon, F., Gontier, E., Nataf, V., Balogova, S., Talbot, J.-N., other ICHOROPRO investigators, 2018. **18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study.** PLoS ONE 13, e0191487. <https://doi.org/10.1371/journal.pone.0191487>
231. Gilleece, M.H., Labopin, M., Yakoub-Agha, I., Volin, L., Socié, G., Ljungman, P., Huynh, A., Deconinck, E., Wu, D., Bourhis, J.H., Cahn, J.Y., Polge, E., Mohty, M., Savani, B.N., Nagler, A., 2018. **Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.** Am. J. Hematol. <https://doi.org/10.1002/ajh.25211>
232. Girard, E., Eon-Marchais, S., Olasso, R., Renault, A.-L., Damiola, F., Dondon, M.-G., Barjhoux, L., Goidin, D., Meyer, V., Le Gal, D., Beauvallet, J., Mebirouk, N., Lonjou, C., Coignard, J., Marcou, M., Cavaciuti, E., Baulard, C., Bihoreau, M.-T., Cohen-Haguenuer, O., Leroux, D., Penet, C., Fert-Ferrer, S., Colas, C., Frebourg, T., Eisinger, F., Adenis, C., Fajac, A., Gladiéff, L., Tinat, J., Floquet, A., Chiesa, J., Giraud, S., Mortemousque, I., Soubrier, F., Audebert-Bellanger, S., Limacher, J.-M., Lasset, C., Lejeune-Dumoulin, S., Dreyfus, H., Bignon, Y.-J., Longy, M., Pujol, P., Venat-Bouvet, L., Bonadona, V., Berthet, P., Luporsi, E., Maugard, C.M., Noguès, C., Delnatte, C., Fricker, J.-P., Gesta, P., Faivre, L., Lortholary, A., Buecher, B., Caron, O., Gauthier-Villars, M., Coupier, I., Servant, N., Boland, A., Mazoyer, S., Deleuze, J.-F., Stoppa-Lyonnet, D., Andrieu, N., Lesueur, F., 2018. **Familial breast cancer and DNA repair genes: insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.** Int. J. Cancer. <https://doi.org/10.1002/ijc.31921>
233. Girard, M., Delanghe, M., Domingo, L., Zamith, M., 2018. **Cas pratique de communication institutionnelle : la sollicitation des psychologues par les soignants de l'IUCT-O.** Psycho-oncologie 12, 67–72. <https://doi.org/10.3166/psn-2018-0028>
234. Girard, M., Poujois, A., Fabre, M., Lacaille, F., Debray, D., Rio, M., Fenaille, F., Cholet, S., Ruel, C., Caussé, E., Selves, J., Bridoux-Henno, L., Woimant, F., Dupré, T., Vuillaumier-Barrot, S., Seta, N., Alric, L., de Lonlay, P., Bruneel, A., 2018. **CCDC115-CDG: A new rare and misleading inherited cause of liver disease.** Mol. Genet. Metab. <https://doi.org/10.1016/j.ymgme.2018.05.002>
235. Gkazi, A.S., Margetts, B.K., Attenborough, T., Mhaldien, L., Standing, J.F., Oakes, T., Heather, J.M., Booth, J., Pasquet, M., Chiesa, R., Veys, P., Klein, N., Chain, B., Callard, R., Adams, S.P., 2018. **Clinical T Cell Receptor Repertoire Deep Sequencing and Analysis: An Application to Monitor Immune Reconstitution Following Cord Blood Transplantation.** Front Immunol 9, 2547. <https://doi.org/10.3389/fimmu.2018.02547>
236. Gobbin, E., Ezzalfani, M., Dieras, V., Bachelot, T., Brain, E., Debled, M., Jacot, W., Mouret-Reynier, M.A., Goncalves, A., Dalenc, F., Patsouris, A., Ferrero, J.M., Levy, C., Lorgis, V., Vanlemmens, L., Lefeuvre-Plesse, C., Mathoulin-Pelissier, S., Petit, T., Uwer, L., Jouannaud, C., Leheurteur, M., Lacroix-Triki, M., Cleaud, A.L., Robain, M., Courtinard, C., Cailliot, C., Perol, D., Delaloge, S., 2018. **Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.** Eur. J. Cancer 96, 17–24. <https://doi.org/10.1016/j.ejca.2018.03.015>
237. Godet, S., Protin, C., Dupuis, J., Dartigeas, C., Bastie, J.-N., Herbaux, C., Leblond, V., de Guibert, S., Ghez, D., Brion, A., Ysebaert, L., Delmer, A., Quinquenel, A., 2018. **Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO).** Am. J. Hematol. 93, E52–E54. <https://doi.org/10.1002/ajh.24981>
238. Godillot, C., Laprie, A., Eid, C., Fricain, J.-C., Boulinguez, S., Casassa, E., Vigaros, E., Sibaud, V., 2018. **[Green tongue phenomenon, or diagnosis via Google].** Ann Dermatol Venereol. <https://doi.org/10.1016/j.annder.2018.02.007>
239. Goehrig, D., Nigri, J., Samain, R., Wu, Z., Cappello, P., Gabiane, G., Zhang, X., Zhao, Y., Kim, I.-S., Chanal, M., Curto, R., Hervieu, V., de La Fouchardière, C., Novelli, F., Milani, P., Tomasini, R., Bousquet, C., Bertolino, P., Hennino, A., 2018. **Stromal protein β g-h3 reprogrammes tumour microenvironment in pancreatic cancer.** Gut. <https://doi.org/10.1136/gutjnl-2018-317570>

240. Goirand, F., Lemaitre, F., Launay, M., Tron, C., Chatelut, E., Boyer, J.-C., Bardou, M., Schmitt, A., 2018. **How can we best monitor 5-FU administration to maximize benefit to risk ratio?** *Expert Opin Drug Metab Toxicol* 14, 1303–1313. <https://doi.org/10.1080/17425255.2018.1550484>
241. Gornes, H., Vaysse, C., Deslandres, M., Perallon, R., Chantalat, E., Rimailho, J., 2018. **Discovery of a neuroendocrine tumor of the caecum by mammary metastasis using 18F-DOPA-PET.** *J. Obstet. Gynaecol. Res.* <https://doi.org/10.1111/jog.13776>
242. Gouazé-Andersson, V., Ghérardi, M.-J., Lemarié, A., Gilhodes, J., Lubrano, V., Arnauduc, F., Cohen-Jonathan Moyal, E., Toulas, C., 2018. **FGFR1/FOXM1 pathway: a key regulator of glioblastoma stem cells radioresistance and a prognosis biomarker.** *Oncotarget* 9, 31637–31649. <https://doi.org/10.18632/oncotarget.25827>
243. Graff, P., Portalez, D., Lusque, A., Brun, T., Aziza, R., Khalifa, J., Roumiguié, M., Quintyn Ranty, M.-L., Filleron, T., Bachaud, J.-M., Malavaud, B., 2018. **IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer.** *Int. J. Radiat. Oncol. Biol. Phys.* <https://doi.org/10.1016/j.ijrobp.2018.01.066>
244. Gravelle, P., Péricart, S., Tosolini, M., Fabiani, B., Coppo, P., Amara, N., Traverse-Glêhen, A., Van Acker, N., Brousset, P., Fournie, J.-J., Laurent, C., 2018. **EBV infection determines the immune hallmarks of plasmablastic lymphoma.** *Oncoimmunology* 7, e1486950. <https://doi.org/10.1080/2162402X.2018.1486950>
245. Gressin, R., Daguindau, N., Tempescul, A., Moreau, A., Carras, S., Tchernonog, E., Schmitt, A., Houot, R., Dartigeas, C., Pignon, J.M., Corm, S., Banos, A., Mounier, C., Dupuis, J., Macro, M., Fleury, J., Jardin, F., Sarkozy, C., Damaj, G., Feugier, P., Fornecker, L.M., Chabrot, C., Dorveaux, V., Bouabdallah, K., Amorin, S., Garidi, R., Voillat, L., Joly, B., Solal Celigny, P., Morineau, N., Moles, M.P., Zerazhi, H., Fontan, J., Arkam, Y., Alexis, M., Delwail, V., Vilque, J.P., Ysebaert, L., Le Gouill, S., Callanan, M.B., 2018. **A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first line treatment of older patients with mantle cell lymphoma.** *Haematologica.* <https://doi.org/10.3324/haematol.2018.191429>
246. Grgurevic, S., Montilla-Perez, P., Bradbury, A., Gilhodes, J., Queille, S., Pelofy, S., Bancaud, A., Filleron, T., Ysebaert, L., Récher, C., Laurent, G., Fournié, J.-J., Cazaux, C., Quillet-Mary, A., Hoffmann, J.-S., 2018. **DNA polymerase γ gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently from p53 status.** *Haematologica.* <https://doi.org/10.3324/haematol.2017.174243>
247. Guerby, P., Parant, O., Chantalat, E., Vayssiere, C., Vidal, F., 2018. **Operative vaginal delivery in case of persistent occiput posterior position after manual rotation failure: a 6-month follow-up on pelvic floor function.** *Arch. Gynecol. Obstet.* 298, 111–120. <https://doi.org/10.1007/s00404-018-4794-5>
248. Gui, P., Ben-Nejj, M., Belozertseva, E., Dalenc, F., Franchet, C., Gilhodes, J., Labrousse, A., Bellard, E., Golzio, M., Poincloux, R., Maridonneau-Parini, I., Le Cabec, V., 2018. **The protease-dependent mesenchymal migration of tumor-associated macrophages as a target in cancer immunotherapy.** *Cancer Immunol Res.* <https://doi.org/10.1158/2326-6066.CIR-17-0746>
249. Guibert, N., Delaunay, M., Lusque, A., Boubekeur, N., Rouquette, I., Clermont, E., Mourlanette, J., Gouin, S., Dormoy, I., Favre, G., Mazieres, J., Pradines, A., 2018a. **PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.** *Lung Cancer* 120, 108–112. <https://doi.org/10.1016/j.lungcan.2018.04.001>
250. Guibert, N., Mhanna, L., Didier, A., Moreno, B., Leyx, P., Plat, G., Mazieres, J., Hermant, C., 2018b. **Integration of 3D printing and additive manufacturing in the interventional pulmonologist's toolbox.** *Respir Med* 134, 139–142. <https://doi.org/10.1016/j.rmed.2017.11.019>
251. Guidez, S., Labreuche, J., Drumez, E., Ysebaert, L., Bakala, J., Delette, C., Hivert, B., Protin, C., Declercq, H., Verlay, M., Marolleau, J.P., Duhamel, A., Morel, P., French Innovative Leukemia Organization (FILO) CLL group, 2018. **Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.** *Blood Adv* 2, 3102–3111. <https://doi.org/10.1182/bloodadvances.2018021287>
252. Guillaume, M., Christol, C., Plessier, A., Corbic, M., Péron, J.-M., Sommet, A., Rautou, P.-E., Consigny, Y., Vinel, J.-P., Valla, C.-D., Bureau, C., 2018. **Bleeding risk of variceal band ligation in extrahepatic portal vein obstruction is not increased by oral anticoagulation.** *Eur J Gastroenterol Hepatol* 30, 563–568. <https://doi.org/10.1097/MEG.0000000000001061>
253. Guillerey, C., Harjunpää, H., Carrié, N., Kassem, S., Teo, T., Miles, K., Krumeich, S., Weulersse, M., Cuisinier, M., Stannard, K., Yu, Y., Minnie, S.A., Hill, G.R., Dougall, W.C., Avet-Loiseau, H., Teng, M.W.L., Nakamura, K., Martinet, L., Smyth, M.J., 2018. **TIGIT immune checkpoint blockade restores CD8+ T cell immunity against multiple myeloma.** *Blood.* <https://doi.org/10.1182/blood-2018-01-825265>
254. Guillot, A., Joly, C., Barthélémy, P., Meriaux, E., Negrier, S., Pouessel, D., Chevreau, C., Mahammedi, H., Houede, N., Roubaud, G., Gravis, G., Tartas, S., Albiges, L., Vassal, C., Oriol, M., Tinquaut, F., Espenel, S., Boulefour, W., Culine, S., Fizazi, K., 2018. **Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study.** *Clin Genitourin Cancer.* <https://doi.org/10.1016/j.clgc.2018.08.006>
255. Guillot, B., Charles, J., Jeudy, G., Cupissol, D., Dupuy, A., Dutriaux, C., Gangloff, D., Magne, N., Mirabel, X.,

- M'Sadek, A., Pracht, M., Sichel, C., Do Outeiro, G., 2018a. [Treatment of patients with inoperable stage III or stage IV melanoma. *Société française de dermatologie*]. *Ann Dermatol Venereol*. <https://doi.org/10.1016/j.annder.2018.03.165>
256. Guillot, B., Charles, J., Jeudy, G., Cupissol, D., Dupuy, A., Dutriaux, C., Gangloff, D., Magne, N., Mirabel, X., M'Sadek, A., Pracht, M., Sichel, C., Do Outeiro, G., 2018b. [Reprint of: Treatment of patients with inoperable stage III or stage IV melanoma. *Société française de dermatologie*]. *Bull Cancer*. <https://doi.org/10.1016/j.bulcan.2018.06.002>
257. Günther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, H.-J., Lupp, A., Korbonits, M., Castaño, J.P., Wester, H.-J., Culler, M., Melmed, S., Schulz, S., 2018. **International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.** *Pharmacol. Rev.* 70, 763–835. <https://doi.org/10.1124/pr.117.015388>
258. Hansen, A.R., Massard, C., Ott, P.A., Haas, N.B., Lopez, J.S., Ejadi, S., Wallmark, J.M., Keam, B., Delord, J.-P., Aggarwal, R., Gould, M., Yang, P., Keefe, S.M., Piha-Paul, S.A., 2018. **Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.** *Ann. Oncol.* 29, 1807–1813. <https://doi.org/10.1093/annonc/mdy232>
259. Hansson, J., Bartley, K., Karagiannis, T., Grob, J.-J., Kunstfeld, R., Dréno, B., Mortier, L., Ascierto, P.A., Licitra, L., Dutriaux, C., Thomas, L., Meyer, N., Guillot, B., Dummer, R., Fife, K., Ernst, D.S., Yim, Y.M., Dimier, N., Fittipaldo, A., Basset-Séguin, N., Hauschild, A., 2018. **Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study.** *Eur J Dermatol* 28, 775–783. <https://doi.org/10.1684/ejd.2018.3448>
260. Hedir, S., De Giorgi, M., Fogha, J., De Pascale, M., Weiswald, L.-B., Brotin, E., Marekha, B., Denoyelle, C., Denis, C., Suzanne, P., Gautier, F., Juin, P., Ligat, L., Lopez, F., Carlier, L., Legay, R., Bureau, R., Rault, S., Poulain, L., Oliveira Santos, J.S., Voisin-Chiret, A.S., 2018. **Structure-guided design of pyridoclast derivatives based on Noxa / Mcl-1 interaction mode.** *Eur J Med Chem* 159, 357–380. <https://doi.org/10.1016/j.ejmech.2018.10.003>
261. Heiblig, M., Rea, D., Chrétien, M.-L., Charbonnier, A., Rousselot, P., Coiteux, V., Escoffre-Barbe, M., Dubruille, V., Huguet, F., Cayssials, E., Hermet, E., Guerci-Bresler, A., Amé, S., Sackmann-Sala, L., Roy, L., Sobh, M., Morisset, S., Etienne, G., Nicolini, F.E., 2018. **Ponatinib Evaluation And safety in Real Life CML patients failing ≥ 2 tyrosine kinase inhibitors: The PEARL observational study.** *Exp. Hematol.* <https://doi.org/10.1016/j.exphem.2018.08.006>
262. Heinicke, T., Labopin, M., Schmid, C., Polge, E., Socié, G., Blaise, D., Mufti, G.J., Huynh, A., Brecht, A., Ledoux, M.-P., Cahn, J.Y., Milpied, N., Scheid, C., Hicheri, Y., Mohty, M., Savani, B.N., Nagler, A., 2018. **Reduced Relapse Incidence with FLAMSA-RIC conditioning compared to Busulfan/Fludarabine for AML-patients in first or second complete remission - A Study from the Acute Leukemia Working Party of the EBMT.** *Biol. Blood Marrow Transplant.* <https://doi.org/10.1016/j.bbmt.2018.07.007>
263. Hemming, M.L., Lawlor, M.A., Zeid, R., Lesluyes, T., Fletcher, J.A., Raut, C.P., Sicinska, E.T., Chibon, F., Armstrong, S.A., Demetri, G.D., Bradner, J.E., 2018. **Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome.** *Proc. Natl. Acad. Sci. U.S.A.* <https://doi.org/10.1073/pnas.1802079115>
264. Hernandez, V., Vera-Sánchez, J.A., Vieilleveigne, L., Khamphan, C., Saez, J., 2018. **A new method for modelling the tongue-and-groove in treatment planning systems.** *Phys Med Biol* 63, 245005. <https://doi.org/10.1088/1361-6560/aaf098>
265. Heydt, Q., Larrue, C., Saland, E., Bertoli, S., Sarry, J.-E., Besson, A., Manenti, S., Joffre, C., Mansat-De Mas, V., 2018. **Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.** *Oncogene* 37, 787–797. <https://doi.org/10.1038/onc.2017.376>
266. Hindié, E., Récher, C., Zerdoud, S., Leenhardt, L., Avram, A.M., 2018. **Risk of Hematologic Malignancies After Radioactive Iodine Treatment of Thyroid Cancer: An Unjustified Warning.** *J. Clin. Oncol.* JCO2018781096. <https://doi.org/10.1200/JCO.2018.78.1096>
267. Huret, S., Isambert, N., Gomez-Roca, C., Bennouna, J., Sassi, M., de Mont-Serrat, H., Fan, J., Schnell, D., Delord, J.-P., 2018. **Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.** *Invest New Drugs.* <https://doi.org/10.1007/s10637-018-0601-1>
268. Hoareau-Aveilla, C., Quelen, C., Congras, A., Caillet, N., Labourdette, D., Dozier, C., Brousset, P., Lamant, L., Meggetto, F., 2018. **Mir-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.** *Haematologica.* <https://doi.org/10.3324/haematol.2018.195131>
269. Holstein, S.A., Avet-Loiseau, H., Hahn, T., Ho, C.M., Lohr, J.G., Munshi, N.C., Paiva, B., Pasquini, M.C., Tario, J.D., Usmani, S.Z., Wallace, P.K., Weisel, K., McCarthy, P.L., 2018. **BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.** *Biol. Blood Marrow Transplant.* 24, 641–648. <https://doi.org/10.1016/j.bbmt.2017.12.774>
270. Hospital, M.-A., Jacquelin, A., Mazed, F., Saland, E., Larrue, C., Mondesir, J., Birsén, R., Green, A.S., Lambert, M., Sujobert, P., Gautier, E.-F., Salnot, V., Le Gall, M., Decroocq, J., Poulain, L., Jacque, N., Fontenay, M., Kosmider, O., Récher, C., Auberger, P., Mayeux, P., Bouscary, D., Sarry, J.-E., Tamburini, J., 2018. **RSK2 is a new Pim2 target with pro-survival functions in FLT3-**

- ITD-positive acute myeloid leukemia.** *Leukemia* 32, 597–605. <https://doi.org/10.1038/leu.2017.284>
271. Houmadi, R., Guipouy, D., Rey-Barroso, J., Vasconcelos, Z., Cornet, J., Manghi, M., Destainville, N., Valitutti, S., Allart, S., Dupré, L., 2018. **The Wiskott-Aldrich Syndrome Protein Contributes to the Assembly of the LFA-1 Nanocluster Belt at the Lytic Synapse.** *Cell Rep* 22, 979–991. <https://doi.org/10.1016/j.celrep.2017.12.088>
272. Houvenaeghel, G., Cohen, M., Raro, P., De Troyer, J., de Lara, C.T., Gimbergues, P., Gauthier, T., Faure-Virelizier, C., Vaini-Cowen, V., Lantheaume, S., Regis, C., Darai, E., Ceccato, V., D'Halluin, G., Del Piano, F., Villet, R., Jouve, E., Beedassy, B., Theret, P., Gabelle, P., Zinzindohoue, C., Opinel, P., Marsollier-Ferrer, C., Dhainaut-Speyer, C., Colombo, P.-E., Lambaudie, E., Tallet, A., Boher, J.-M., Others investigators (SERC trial group), 2018a. **Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.** *BMC Cancer* 18, 1153. <https://doi.org/10.1186/s12885-018-5053-7>
273. Houvenaeghel, G., de Nonneville, A., Cohen, M., Classe, J.-M., Reyal, F., Mazouni, C., Chopin, N., Martinez, A., Daraï, E., Coutant, C., Colombo, P.-E., Gimbergues, P., Chauvet, M.-P., Azuar, A.-S., Rouzier, R., de Lara, C.T., Muracciole, X., Agostini, A., Gonçalves, A., Lambaudie, E., 2018b. **Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact.** *Breast Cancer Res. Treat.* <https://doi.org/10.1007/s10549-018-4944-2>
274. Hoyles, L., Fernández-Real, J.-M., Federici, M., Serino, M., Abbott, J., Charpentier, J., Heymes, C., Luque, J.L., Anthony, E., Barton, R.H., Chilloux, J., Myridakis, A., Martinez-Gili, L., Moreno-Navarrete, J.M., Benhamed, F., Azalbert, V., Blasco-Baque, V., Puig, J., Xifra, G., Ricart, W., Tomlinson, C., Woodbridge, M., Cardellini, M., Davato, F., Cardolini, I., Porzio, O., Gentileschi, P., Lopez, E., Foufelle, F., Butcher, S.A., Holmes, E., Nicholson, J.K., Postic, C., Burcelin, R., Dumas, M.-E., 2018a. **Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women.** *Nat. Med.* 24, 1070–1080. <https://doi.org/10.1038/s41591-018-0061-3>
275. Hoyles, L., Fernández-Real, J.-M., Federici, M., Serino, M., Abbott, J., Charpentier, J., Heymes, C., Luque, J.L., Anthony, E., Barton, R.H., Chilloux, J., Myridakis, A., Martinez-Gili, L., Moreno-Navarrete, J.M., Benhamed, F., Azalbert, V., Blasco-Baque, V., Puig, J., Xifra, G., Ricart, W., Tomlinson, C., Woodbridge, M., Cardellini, M., Davato, F., Cardolini, I., Porzio, O., Gentileschi, P., Lopez, E., Foufelle, F., Butcher, S.A., Holmes, E., Nicholson, J.K., Postic, C., Burcelin, R., Dumas, M.-E., 2018b. **Publisher Correction: Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women.** *Nat. Med.* <https://doi.org/10.1038/s41591-018-0169-5>
276. Huguet, F., Chevret, S., Leguay, T., Thomas, X., Boissel, N., Escoffre-Barbe, M., Chevallier, P., Hunault, M., Vey, N., Bonmati, C., Lepretre, S., Marolleau, J.-P., Pabst, T., Rousselot, P., Buzyn, A., Cahn, J.-Y., Lhéritier, V., Béné, M.C., Asnafi, V., Delabesse, E., Macintyre, E., Chalandon, Y., Ifrah, N., Dombret, H., Group of Research on Adult ALL (GRAALL), 2018. **Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.** *J. Clin. Oncol.* JCO2017768192. <https://doi.org/10.1200/JCO.2017.76.8192>
277. Hulea, L., Gravel, S.-P., Morita, M., Cargnello, M., Uchenunu, O., Im, Y.K., Lehuédé, C., Ma, E.H., Leibovitch, M., McLaughlan, S., Blouin, M.-J., Parisotto, M., Papavasiliou, V., Lavoie, C., Larsson, O., Ohh, M., Ferreira, T., Greenwood, C., Bridon, G., Avizonis, D., Ferbeyre, G., Siegel, P., Jones, R.G., Muller, W., Ursini-Siegel, J., St-Pierre, J., Pollak, M., Topisirovic, I., 2018. **Translational and HIF-1 α -Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides.** *Cell Metab.* 28, 817–832.e8. <https://doi.org/10.1016/j.cmet.2018.09.001>
278. Illouz, F., Drui, D., Caron, P., Do Cao, C., 2018. **Expert opinion on thyroid complications in immunotherapy.** *Ann. Endocrinol. (Paris)* 79, 555–561. <https://doi.org/10.1016/j.ando.2018.07.007>
279. Incerti, S., Kyriakou, I., Bernal, M.A., Bordage, M.C., Francis, Z., Guatelli, S., Ivanchenko, V., Karamitros, M., Lampe, N., Lee, S.B., Meylan, S., Min, C.H., Shin, W.G., Nieminen, P., Sakata, D., Tang, N., Villagrasa, C., Tran, H., Brown, J.M.C., 2018. **Geant4-DNA example applications for track structure simulations in liquid water: a report from the Geant4-DNA Project.** *Med Phys.* <https://doi.org/10.1002/mp.13048>
280. Jacquet, E., Lardy-Cléaud, A., Pistilli, B., Franck, S., Cottu, P., Delalogue, S., Debled, M., Vanlemmens, L., Leheurteur, M., Guizard, A.V., Laborde, L., Uwer, L., Jacot, W., Berchery, D., Desmoulins, I., Ferrero, J.M., Perrocheau, G., Courtinard, C., Brain, E., Chabaud, S., Robain, M., Bachelot, T., 2018. **Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.** *Eur. J. Cancer* 95, 93–101. <https://doi.org/10.1016/j.ejca.2018.03.013>
281. Jamrog, L., Chemin, G., Fregona, V., Coster, L., Pasquet, M., Oudinet, C., Rouquié, N., Prade, N., Lagarde, S., Cresson, C., Hébrard, S., Nguyen Huu, N.S., Bousquet, M., Quelen, C., Brousset, P., Mancini, S.J.C., Delabesse, E., Khamlichi, A.A., Gerby, B., Broccardo, C., 2018. **PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.** *Proc. Natl. Acad. Sci. U.S.A.* <https://doi.org/10.1073/pnas.1721678115>
282. Jouinot, A., Royer, B., Chatelut, E., Moeung, S., Assié, G., Thomas-Schoemann, A., Bertherat, J., Goldwasser, F., Blanchet, B., 2018. **Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma:**

- a pilot study. *Endocr Connect* 7, 1409–1414. <https://doi.org/10.1530/EC-18-0428>
283. Kanoun, S., Rossi, C., Casasnovas, O., 2018. **[18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives.** *Cancers* (Basel) 10. <https://doi.org/10.3390/cancers10050145>
284. Kaufman, P.A., Wildiers, H., Freyer, G., Kemeny, M., Gonçalves, A., Jerusalem, G., Stopeck, A., Vrindavanam, N., Dalenc, F., Nanayakkara, N., Wu, B., Pickett, C.A., 2018. **Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer.** *Clin. Breast Cancer*. <https://doi.org/10.1016/j.clbc.2018.09.012>
285. Keller, L., Guibert, N., Casanova, A., Brayer, S., Farella, M., Delaunay, M., Gilhodes, J., Martin, E., Balagué, G., Favre, G., Pradines, A., Meyer, N., 2018. **Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.** *Acta Derm. Venereol.* <https://doi.org/10.2340/00015555-3080>
286. Khallouki, F., Owen, R.W., Silvente-Poirot, S., Poirot, M., 2018. **Bryonolic Acid Blocks Cancer Cell Clonogenicity and Invasiveness through the Inhibition of Fatty Acid: Cholesteryl Ester Formation.** *Biomedicines* 6. <https://doi.org/10.3390/biomedicines6010021>
287. Komrokji, R., Garcia-Manero, G., Ades, L., Prebet, T., Steensma, D.P., Jurcic, J.G., Sekeres, M.A., Berdeja, J., Savona, M.R., Beyne-Rauzy, O., Stamatoullas, A., DeZern, A.E., Delaunay, J., Borthakur, G., Rifkin, R., Boyd, T.E., Laadem, A., Vo, B., Zhang, J., Puccio-Pick, M., Attie, K.M., Fenaux, P., List, A.F., 2018. **Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.** *Lancet Haematol.* [https://doi.org/10.1016/S2352-3026\(18\)30002-4](https://doi.org/10.1016/S2352-3026(18)30002-4)
288. Koraïchi, F., Gence, R., Bouchenot, C., Grosjean, S., Lajoie-Mazenc, I., Favre, G., Cabantous, S., 2018. **High-content tripartite split-GFP cell-based assays to screen for modulators of small GTPase activation.** *J. Cell. Sci.* 131. <https://doi.org/10.1242/jcs.210419>
289. Kotecki, N., Le Cesne, A., Tresch-Bruneel, E., Ray-Coquard, I., Chevreau, C., Bertucci, F., Bogart, E., Mir, O., Pautier, P., Decoupigny, E., Clisant, S., Blay, J.-Y., Penel, N., 2018. **Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma: Long-term Follow-up of the T-DIS trial.** *Am. J. Clin. Oncol.* <https://doi.org/10.1097/COC.0000000000000430>
290. Kowalski-Chauvel, A., Modesto, A., Gouaze-Andersson, V., Baricault, L., Gilhodes, J., Delmas, C., Lemarie, A., Toulas, C., Cohen-Jonathan-Moyal, E., Seva, C., 2018a. **Alpha-6 integrin promotes radioresistance of glioblastoma by modulating DNA damage response and the transcription factor Zeb1.** *Cell Death Dis* 9, 872. <https://doi.org/10.1038/s41419-018-0853-x>
291. Kowalski-Chauvel, A., Teissier, G., Toulas, C., Cohen-Jonathan-Moyal, E., Seva, C., 2018b. **By modulating $\alpha 2\beta 1$ integrin signalling, gastrin increases adhesion of AGS-GR gastric cancer cells.** *Exp. Cell Res.* 362, 498–503. <https://doi.org/10.1016/j.yexcr.2017.12.014>
292. Kreimerman, I., Mora-Ramirez, E., Reyes, A.L., Bardies, M., Savio, E., Engler, H., 2018. **Dosimetry and toxicity studies of the novel sulfonamide derivative of Sulforhodamine 101([18F]SRF101) at a preclinical level.** *Curr Radiopharm.* <https://doi.org/10.2174/1874471011666180830145304>
293. Lacouture, M., Sibaud, V., 2018. **Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.** *Am J Clin Dermatol.* <https://doi.org/10.1007/s40257-018-0384-3>
294. Lacroix, C., Redon, G., Verger, D., 2018. **[V2014 certification and care teams.]** *Soins* 63, 34–37. <https://doi.org/10.1016/j.soin.2018.07.010>
295. Lagabrielle, S., Durand, X., Droupy, S., Iazard, V., Marcelli, F., Huyghe, E., Ferriere, J.-M., Ferretti, L., 2018. **Testicular tumours discovered during infertility workup are predominantly benign and could initially be managed by sparing surgery.** *J Surg Oncol* 118, 630–635. <https://doi.org/10.1002/jso.25203>
296. Lamant, L., 2018a. **[Dermatopathology histoseminar. Case 5].** *Ann Pathol.* <https://doi.org/10.1016/j.annpat.2018.05.009>
297. Lamant, L., 2018b. **[Dermatopathology histoseminar. Case 6].** *Ann Pathol.* <https://doi.org/10.1016/j.annpat.2018.05.008>
298. Lamy, S., Guimbaud, R., Digue, L., Cirilo-Cassaigne, I., Bousser, V., Oum-Sack, E., Goddard, J., Bauvin, E., Delpierre, C., Grosclaude, P., EvaCCoR Group, 2018. **Are there variations in adherence to colorectal cancer clinical guidelines depending on treatment place and recommendation novelty? The French EvaCCoR observational study.** *Clin Res Hepatol Gastroenterol.* <https://doi.org/10.1016/j.clinre.2018.10.008>
299. Lantuejoul, S., Adam, J., Girard, N., Duruisseaux, M., Mansuet-Lupo, A., Cazes, A., Rouquette, I., Gibault, L., Garcia, S., Antoine, M., Vignaud, J.M., Galateau-Sallé, F., Sagan, C., Badoual, C., Penault-Llorca, F., Damotte, D., pour le groupe PATTERN (pathologistes thoraciques de valorisation de l'expertise, de la recherche et de l'innovation). **Fondation Synergie Lyon Cancer, 2018. [PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].** *Ann Pathol.* <https://doi.org/10.1016/j.annpat.2018.01.007>
300. Laprie, A., Bernier, V., Carrie, C., French Group of Pediatric Radiotherapy GFRP .a.k.a. Radiotherapy Committee of French Society of Children's Cancer SFCE, 2018. **Letter to the Editor of Radiotherapy and Oncology regarding the paper entitled "Prospective Data Registration and Clinical Trials for Particle Therapy" by Langendijk et al.** *Radiother Oncol.* <https://doi.org/10.1016/j.radonc.2018.10.004>
301. Laumonerie, P., Blasco, L., Tibbo, M.E., Leclair, O., Kerezoudis, P., Chantalat, E., Mansat, P., 2018a.

- Peripheral Nerve Injury Associated with a Subdermal Contraceptive Implant: Illustrative Cases and Systematic Review of Literature.** *World Neurosurg* 111, 317–325. <https://doi.org/10.1016/j.wneu.2017.12.160>
302. Laumonerie, P., Ferré, F., Cances, J., Tibbo, E.M., Roumiguié, M., Mansat, P., Minville, V., 2018b. **Ultrasound-guided proximal suprascapular nerve block: A cadaveric study.** *Clin Anat.* <https://doi.org/10.1002/ca.23199>
303. Laurent, C., Haioun, C., Brousset, P., Gaulard, P., 2018. **New insights into breast implant-associated anaplastic large cell lymphoma.** *Curr Opin Oncol* 30, 292–300. <https://doi.org/10.1097/CCO.0000000000000476>
304. Laustriat, G., Ruysen-Witrand, A., Constantin, A., Barnetche, T., Adoue, D., Cantagrel, A., Degboé, Y., 2018. **Anti-citrullinated peptides antibodies in systemic sclerosis: Meta-analysis of frequency and meaning.** *Joint Bone Spine* 85, 147–153. <https://doi.org/10.1016/j.jbspin.2017.11.006>
305. Lavaud, P., Gravis, G., Foulon, S., Joly, F., Oudard, S., Priou, F., Latorzeff, I., Mourey, L., Soulié, M., Delva, R., Krakowski, I., Laguerre, B., Théodore, C., Ferrero, J.M., Beuzeboc, P., Habibian, M., Rolland, F., Deplanque, G., Pouessel, D., Zanetta, S., Berdah, J.F., Dauba, J., Baciuchka, M., Platini, C., Linassier, C., Tubiana-Mathieu, N., Machiels, J.P., Kouri, C.E., Ravaud, A., Suc, E., Eymard, J.C., Hasbini, A., Bousquet, G., Culine, S., Boher, J.-M., Tergemina-Clain, G., Legoupil, C., Fizazi, K., 2018. **Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.** *Eur. Urol.* 73, 696–703. <https://doi.org/10.1016/j.eururo.2017.09.022>
306. Lazarevic, V.L., Labopin, M., Depei, W., Yakoub-Agha, I., Huynh, A., Ljungman, P., Schaap, N., Cornelissen, J.J., Maillard, N., Pioltelli, P., Gedde-Dahl, T., Lenhoff, S., Houhou, M., Esteve, J., Mohty, M., Nagler, A., 2018. **Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT).** *Am. J. Hematol.* 93, 31–39. <https://doi.org/10.1002/ajh.24928>
307. Le Bouc, R., Clarençon, F., Meseguer, E., Lapergue, B., Consoli, A., Turc, G., Naggara, O., Duong, D.L., Servan, J., Reiner, P., Labeyrie, M.A., Fisselier, M., Blanc, R., Farhat, W., Pires, C., Zuber, M., Obadia, M., Mazighi, M., Pico, F., Mas, J.-L., Amarenco, P., Samson, Y., Paris Stroke Consortium [collab: Evrard, S.], 2018. **Efficacy of Endovascular Therapy in Acute Ischemic Stroke Depends on Age and Clinical Severity.** *Stroke* 49, 1686–1694. <https://doi.org/10.1161/STROKEAHA.117.020511>
308. Le Guellec, S., Lesluyes, T., Sarot, E., Valle, C., Filleron, T., Rochaix, P., Valentin, T., Pérot, G., Coindre, J.-M., Chibon, F., 2018. **Validation of the Complexity INDEX in SARCComas prognostic signature on formalin-fixed, paraffin-embedded, soft tissue sarcomas.** *Ann. Oncol.* <https://doi.org/10.1093/annonc/mdy194>
309. Le Naour, A., Mevel, R., Thibault, B., Courtais, E., Chantalat, E., Delord, J.P., Couderc, B., Guillermet-Guibert, J., Martinez, A., 2018. **Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.** *Oncotarget* 9, 27220–27232. <https://doi.org/10.18632/oncotarget.25513>
310. Le Roy, A., Prébet, T., Castellano, R., Goubard, A., Riccardi, F., Fauriat, C., Granjeaud, S., Benyamine, A., Castanier, C., Orlanducci, F., Ben Amara, A., Pont, F., Fournié, J.-J., Collette, Y., Mege, J.-L., Vey, N., Olive, D., 2018. **Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.** *Front Immunol* 9, 977. <https://doi.org/10.3389/fimmu.2018.00977>
311. Leary, A., Le Tourneau, C., Varga, A., Sablin, M.-P., Gomez-Roca, C., Guilbaud, N., Petain, A., Pavlyuk, M., Delord, J.-P., 2018. **Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.** *Invest New Drugs.* <https://doi.org/10.1007/s10637-018-0688-4>
312. Leclerc, J., Flament, C., Lovecchio, T., Delattre, L., Ait Yahya, E., Baert-Desurmont, S., Burnichon, N., Bronner, M., Cabaret, O., Lejeune, S., Guimbaud, R., Morin, G., Mauillon, J., Jonveaux, P., Laurent-Puig, P., Frébourg, T., Porchet, N., Buisine, M.-P., 2018. **Diversity of genetic events associated with MLH1 promoter methylation in Lynch syndrome families with heritable constitutional epimutation.** *Genet. Med.* <https://doi.org/10.1038/gim.2018.47>
313. Leclerc, J., Garandeau, D., Pandiani, C., Gaudel, C., Bille, K., Nottet, N., Garcia, V., Colosetti, P., Pagnotta, S., Bahadoran, P., Tondeur, G., Mograbi, B., Dalle, S., Caramel, J., Levade, T., Ballotti, R., Andrieu-Abadie, N., Bertolotto, C., 2018. **Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells.** *Oncogene.* <https://doi.org/10.1038/s41388-018-0500-0>
314. Lecomte, P., Binquet, C., Le Bras, M., Tabarin, A., Cardot-Bauters, C., Borson-Chazot, F., Lombard-Bohas, C., Baudin, E., Delemer, B., Klein, M., Vergès, B., Aparicio, T., Cosson, E., Beckers, A., Caron, P., Chabre, O., Chanson, P., Du Boullay, H., Guilhem, I., Niccoli, P., Rohmer, V., Guigay, J., Vulpoi, C., Scoazec, J.Y., Goudet, P., 2018. **Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study.** *World J Surg* 42, 143–152. <https://doi.org/10.1007/s00268-017-4135-z>
315. Leenhardt, L., Leboulleux, S., Bournaud, C., Zerdoud, S., Schvartz, C., Ciappuccini, R., Kelly, A., Morel, O., Dygai-Cochet, I., Rusu, D., Chougnat, C.N., Lion, G., Eberlé-Pouzeratte, M.-C., Catargi, B., Kabir-Ahmadi, M., Le Peillet Feuillet, E., Taïeb, D., 2018. **Recombinant**

- thyrotropin vs levothyroxine withdrawal in 1311 therapy of N1 thyroid cancer: a large matched cohort study (ThyrNod).** *J. Clin. Endocrinol. Metab.* <https://doi.org/10.1210/jc.2018-01589>
316. Legouté, F., Padovani, L., Claude, L., Bolle, S., Attal, J., Gonzalez-Moya, A., Lizée, T., Paumier, A., Jadaud, É., Pointreau, Y., Dufreneix, S., Laprie, A., 2018. [Interest of image-guided radiotherapy for brain tumors and positioning control]. *Cancer Radiother.* <https://doi.org/10.1016/j.canrad.2018.06.006>
317. Lemaitre, F., Goirand, F., Launay, M., Chatelut, E., Boyer, J.-C., Evrard, A., Paludetto, M.-N., Guilhaumou, R., Ciccolini, J., Schmitt, A., 2018. [5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Uncancer]. *Bull. Cancer.* <https://doi.org/10.1016/j.bulcan.2018.06.008>
318. Lenfant, L., Verhoest, G., Campi, R., Parra, J., Graffeuille, V., Masson-Lecomte, A., Vordos, D., de La Taille, A., Roumiguie, M., Lesourd, M., Taksin, L., Misraï, V., Grande, P., Vaessen, C., Ploussard, G., Granger, B., Rouprêt, M., 2018. Perioperative outcomes and complications of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy for bladder cancer: a real-life, multi-institutional french study. *World J Urol.* <https://doi.org/10.1007/s00345-018-2313-8>
319. Lewin, J., Soria, J.-C., Stathis, A., Delord, J.-P., Peters, S., Awada, A., Aftimos, P.G., Bekradda, M., Rezaï, K., Zeng, Z., Hussain, A., Perez, S., Siu, L.L., Massard, C., 2018. Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. *J. Clin. Oncol.* JCO2018782292. <https://doi.org/10.1200/JCO.2018.78.2292>
320. Lièvre, A., Ouine, B., Canet, J., Cartier, A., Amar, Y., Cacheux, W., Mariani, O., Guimbaud, R., Selves, J., Lecomte, T., Guyétant, S., Bieche, I., Berger, F., de Koning, L., 2018. Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. *Br. J. Cancer.* <https://doi.org/10.1038/s41416-018-0130-x>
321. Litton, J.K., Rugo, H.S., Ettl, J., Hurvitz, S.A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L.A., Martin, M., Roché, H., Im, Y.-H., Quek, R.G.W., Markova, D., Tudor, I.C., Hannah, A.L., Eiermann, W., Blum, J.L., 2018. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. *N. Engl. J. Med.* 379, 753–763. <https://doi.org/10.1056/NEJMoa1802905>
322. Lougué, M., Cabarrou, B., Wallet, J., Brodowicz, T., Roché, H., Boher, J.M., Delord, J.P., Penel, N., Filleron, T., 2018. The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients. *Ann. Oncol.* <https://doi.org/10.1093/annonc/mdy168>
323. Lorient, M.-A., Ciccolini, J., Thomas, F., Barin-Le-Guellec, C., Royer, B., Milano, G., Picard, N., Becquemont, L., Verstuyft, C., Narjoz, C., Schmitt, A., Bobin-Dubigeon, C., Harle, A., Paci, A., Poinsignon, V., Quaranta, S., Evrard, A., Hennart, B., Broly, F., Fonrose, X., Lafay-Chebassier, C., Wozny, A.-S., Masskouri, F., Boyer, J.-C., Etienne-Grimaldi, M.-C., 2018. [Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Uncancer and RNPgX networks]. *Bull. Cancer.* <https://doi.org/10.1016/j.bulcan.2018.02.001>
324. Lorient, Y., Supiot, S., Beauval, J.-B., Schlürmann, F., Pasticier, G., Sargos, P., Barthélémy, P., Pignot, G., Maillet, D., Vincendeau, S., Gross, E., Ploussard, G., Timsit, M.-O., Borchiellini, D., 2018. Management of non-metastatic castrate-resistant prostate cancer: A systematic review. *Cancer Treat. Rev.* 70, 223–231. <https://doi.org/10.1016/j.ctrv.2018.09.006>
325. Loubière, S., Drezet, A., Beau-Faller, M., Moro-Sibilot, D., Friard, S., Wislez, M., Blons, H., Daniel, C., Westeel, V., Madroszyk, A., Léna, H., Merle, P., Mazières, J., Zalcman, G., Lacave, R., Antoine, M., Morin, F., Missy, P., Barlesi, F., Auquier, P., Cadranet, J., French Cooperative Thoracic Intergroup (IFCT), 2018. Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced non-small cell lung carcinoma: the French IFCT-PREDICT.amm study. *Eur. Respir. J.* 51. <https://doi.org/10.1183/13993003.01467-2017>
326. Lucas, P., Boulinguez, S., Sibaud, V., Mourey, L., Lamant, L., Paul, C., Meyer, N., 2018. Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma. *Dermatology (Basel)* 1–7. <https://doi.org/10.1159/000490891>
327. Ludwig, H., Delforge, M., Facon, T., Einsele, H., Gay, F., Moreau, P., Avet-Loiseau, H., Boccadoro, M., Hajek, R., Mohty, M., Cavo, M., Dimopoulos, M.A., San-Miguel, J.F., Terpos, E., Zweegman, S., Garderet, L., Mateos, M.-V., Cook, G., Leleu, X., Goldschmidt, H., Jackson, G., Kaiser, M., Weisel, K., van de Donk, N.W.C.J., Waage, A., Beksac, M., Mellqvist, U.H., Engelhardt, M., Caers, J., Driessen, C., Bladé, J., Sonneveld, P., 2018. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. *Leukemia.* <https://doi.org/10.1038/s41375-018-0040-1>
328. Macagno, N., Caselles, K., Aubert, S., Audard, V., Gomez-Brouchet, A., Galant, C., Guinebretière, J.-M., Karanian, M., Larousserie, F., Marie, B., de Pinieux, G., Bouvier, C., 2018. [Benign and malignant giant-cell rich lesions of bone: Pathological diagnosis with special emphasis on recent immunohistochemistry and molecular techniques]. *Ann. Pathol.* <https://doi.org/10.1016/j.annpat.2018.01.008>
329. Maidorn, M., Olichon, A., Rizzoli, S.O., Opazo, F., 2018. Nanobodies reveal an extra-synaptic population of

- SNAP-25 and Syntaxin 1A in hippocampal neurons.** MAbs. <https://doi.org/10.1080/19420862.2018.1551675>
330. Maio, M., Lewis, K., Demidov, L., Mandalà, M., Bondarenko, I., Ascierto, P.A., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., Goodman, G.R., Simmons, B., Ye, C., Yan, Y., Schadendorf, D., BRIM8 Investigators [collab : Meyer, N.], 2018. **Adjuvant vemurafenib in resected, BRAFV600mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.** *Lancet Oncol.* 19, 510–520. [https://doi.org/10.1016/S1470-2045\(18\)30106-2](https://doi.org/10.1016/S1470-2045(18)30106-2)
331. Malavaud, B., Daniel, G., Ranty, M.-L., 2018. Comments on Brimo F, Downes MR, Jamaspishvili T, Berman D, Barkan G, Athanzio D, Abro S, Visram K, Yilmaz A, Solanki S, Hahn E, Siemens R, Kassouf W, Trpkov K. **Prognostic pathological factors in radical cystectomy after neoadjuvant chemotherapy.** *Histopathology* 2018; DOI: 10.1111/his.13654. *Histopathology.* <https://doi.org/10.1111/his.13766>
332. Malgras, B., Gayat, E., Aoun, O., Dico, R.L., Eveno, C., Pautrat, K., Delhorme, J.-B., Passot, G., Marchal, F., Sgarbura, O., Ferron, G., Goéré, D., Andre, T., Pocard, M., on behalf the RENAPE Network [collab : Gladiéff, L., Mery, E.], 2018. **Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.** *Ann. Surg. Oncol.* <https://doi.org/10.1245/s10434-018-6631-2>
333. Malric, L., Monferran, S., Delmas, C., Arnauduc, F., Dahan, P., Boyrie, S., Deshors, P., Lubrano, V.F., Ferreira Da Mota, D., Gilhodes, J., Filleron, T., Siegfried, A., Evrard, S.M., Kowalski-Chauvel, A., Cohen-Jonathan Moyal, E., Toulas, C., Lemarié, A., 2018. **Inhibiting Integrin $\beta 8$ to Differentiate and Radiosensitize Glioblastoma-initiating Cells.** *Mol. Cancer Res.* <https://doi.org/10.1158/1541-7786.MCR-18-0386>
334. Mangray, S., Kelly, D.R., LeGuellec, S., Fridman, E., Aggarwal, S., Shago, M., Matoso, A., Madison, R., Pramanik, S., Zhong, S., Li, R., Lombardo, K.A., Cramer, S., Pressey, J., Ross, J.S., Corona, R.J., Bratslavsky, G., Argani, P., Coindre, J.-M., Somers, G.R., Ali, S.M., Yakirevich, E., 2018. **Clinicopathologic Features of a Series of Primary Renal CIC-rearranged Sarcomas With Comprehensive Molecular Analysis.** *Am. J. Surg. Pathol.* <https://doi.org/10.1097/PAS.0000000000001098>
335. Mansouri, I., Allodji, R.S., Hill, C., El-Fayech, C., Pein, F., Diallo, S., Schwartz, B., Vu-Bezin, G., Veres, C., Souchard, V., Dumas, A., Bolle, S., Thomas-Teinturier, C., Pacquement, H., Munzer, M., Bondiau, P.-Y., Berchery, D., Fresneau, B., Oberlin, O., Diallo, I., De Vathaire, F., Haddy, N., 2018. **The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer.** *Eur. J. Heart Fail.* <https://doi.org/10.1002/ejhf.1376>
336. Mariette, C., Renaud, F., Piessen, G., Gele, P., Copin, M.-C., Leteurtre, E., Delaeter, C., Dib, M., Clisant, S., Harter, V., Bonnetain, F., Duhamel, A., Christophe, V., Adenis, A., Fregat Working Group [collab : Carrère, N., Selves, J.], 2018. **The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers.** *BMC Cancer* 18, 139. <https://doi.org/10.1186/s12885-018-3991-8>
337. Marisa, L., Svrcek, M., Collura, A., Becht, E., Cervera, P., Wanherdrick, K., Buhard, O., Goloudina, A., Jonchère, V., Selves, J., Milano, G., Guenot, D., Cohen, R., Colas, C., Laurent-Puig, P., Olschwang, S., Lefèvre, J.H., Parc, Y., Boige, V., Lepage, C., André, T., Fléjou, J.-F., Dérangère, V., Ghiringhelli, F., de Reynies, A., Duval, A., 2018. **The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.** *J. Natl. Cancer Inst.* 110. <https://doi.org/10.1093/jnci/djx136>
338. Marmé, F., Gomez-Roca, C., Graudenz, K., Huang, F., Lettieri, J., Peña, C., Trnkova, Z.J., Eucker, J., 2018. **Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.** *Cancer Chemother. Pharmacol.* 81, 727–737. <https://doi.org/10.1007/s00280-018-3540-9>
339. Marques da Costa, M.E., Daudigeos-Dubus, E., Gomez-Brouchet, A., Bawa, O., Rouffiac, V., Serra, M., Scotlandi, K., Santos, C., Georger, B., Gaspar, N., 2018. **Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice.** *Cancer Med.* <https://doi.org/10.1002/cam4.1346>
340. Marra, G., Ploussard, G., Ost, P., De Visschere, P.J.L., Briganti, A., Gandaglia, G., Tilki, D., Surcel, C.I., Tsaor, I., Van Den Bergh, R.C.N., Kretschmer, A., Borgmann, H., Gontero, P., Ahmed, H.U., Valerio, M., EAU-YAU Prostate Cancer Working Party, 2018. **Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey.** *Urol. Oncol.* <https://doi.org/10.1016/j.urolonc.2018.08.013>
341. Martin, J., Vayr, F., Paris, C., Vergez, S., Krief, P., Luc, A., Corvisier, J., CERBois members, de Gabory, L., Herin, F., 2018. **Nasal fibroscopy as a routine screening procedure of sinonasal adenocarcinoma of woodworkers: French longitudinal case study.** *Head Neck* 40, 2193–2198. <https://doi.org/10.1002/hed.25315>
342. Martin, N., Isambert, N., Gomez-Roca, C., Goeldner, R.-G., Zanetta, S., Sadrolhefazi, B., de Mont-Serrat, H., Campone, M., Delord, J.-P., 2018. **Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.** *Cancer Chemother. Pharmacol.* <https://doi.org/10.1007/s00280-018-3689-2>
343. Martinez, A., Filleron, T., Rouanet, P., Mééus, P., Lambaudie, E., Classe, J.M., Foucher, F., Narducci, F., Gouy, S., Guyon, F., Marchal, F., Jouve, E., Colombo, P.E., Mourregot, A., Rivoire, M., Chopin, N., Houvenaeghel, G., Jaffre, I., Leveque, J., Lavoue, V., Leblanc, E., Morice,

- P., Stoeckle, E., Verheaghe, J.L., Querleu, D., Ferron, G., 2018. **Prospective Assessment of First-Year Quality of Life After Pelvic Exenteration for Gynecologic Malignancy: A French Multicentric Study.** *Ann. Surg. Oncol.* 25, 535–541. <https://doi.org/10.1245/s10434-017-6120-z>
344. Martínez-Gómez, C., Angeles, M.A., Martinez, A., Ferron, G., 2018a. **Laparoscopic anterior pelvic exenteration in 10 steps.** *Gynecol. Oncol.* <https://doi.org/10.1016/j.ygyno.2018.04.561>
345. Martínez-Gómez, C., Angeles, M.A., Martinez, A., Ferron, G., 2018b. **Creation of a Miami Pouch in 10 logical steps.** *Gynecol. Oncol.* <https://doi.org/10.1016/j.ygyno.2018.08.003>
346. Massabeau, C., Khalifa, J., Filleron, T., Modesto, A., Bigay-Gamé, L., Plat, G., Dierickx, L., Aziza, R., Rouquette, I., Gomez-Roca, C., Mounier, M., Delord, J.-P., Toulas, C., Olivier, P., Chatelut, E., Mazières, J., Cohen-Jonathan Moyal, E., 2018. **Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.** *Clin Lung Cancer* 19, e277–e285. <https://doi.org/10.1016/j.clcc.2017.11.002>
347. Maura, F., Petljak, M., Lionetti, M., Cifola, I., Liang, W., Pinatel, E., Alexandrov, L.B., Fullam, A., Martincorena, I., Dawson, K.J., Angelopoulos, N., Samur, M.K., Szalat, R., Zamora, J., Tarpey, P., Davies, H., Corradini, P., Anderson, K.C., Minvielle, S., Neri, A., Avet-Loiseau, H., Keats, J., Campbell, P.J., Munshi, N.C., Bolli, N., 2018. **Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.** *Leukemia* 32, 1044–1048. <https://doi.org/10.1038/leu.2017.345>
348. Mazerolle, P., Philouze, P., Garrel, R., Aubry, K., Morinière, S., El Bedoui, S., Ton Van, J., Ferron, C., Malard, O., Jegoux, F., Berard, E., Vergez, S., 2018. **Oncological and functional outcomes of trans-oral robotic surgery for pyriform sinus carcinoma: A French GETTEC group study.** *Oral Oncol.* 86, 165–170. <https://doi.org/10.1016/j.oraloncology.2018.09.014>
349. Mazzotti, C., Buisson, L., Maheo, S., Perrot, A., Chretien, M.-L., Leleu, X., Hulin, C., Manier, S., Hébraud, B., Roussel, M., Do Souto, L., Attal, M., Avet-Loiseau, H., Corre, J., 2018. **Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.** *Blood Adv* 2, 2811–2813. <https://doi.org/10.1182/bloodadvances.2018025197>
350. McCormack, A., Dekkers, O.M., Petersenn, S., Popovic, V., Trouillas, J., Raverot, G., Burman, P., ESE survey collaborators [collab : Caron, P.], 2018. **Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.** *Eur. J. Endocrinol.* 178, 265–276. <https://doi.org/10.1530/EJE-17-0933>
351. Mehta, S., Schwarz, L., Spiliotis, J., Hsieh, M.-C., Akaishi, E.H., Goere, D., Sugarbaker, P.H., Baratti, D., Quenet, F., Bartlett, D.L., Villeneuve, L., Kepenekian, V., PSOGI and BIG-RENAPE Working Groups [collab : Ferron, G.], 2018a. **Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study.** *Eur J Surg Oncol* 44, 1786–1792. <https://doi.org/10.1016/j.ejso.2018.05.021>
352. Mehta, S., Schwarz, L., Spiliotis, J., Hsieh, M.-C., Akaishi, E.H., Goere, D., Sugarbaker, P.H., Baratti, D., Quenet, F., Bartlett, D.L., Villeneuve, L., Kepenekian, V., PSOGI and BIG-RENAPE Working Groups [collab : Ferron, G.], 2018b. **Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study.** *Eur J Surg Oncol.* <https://doi.org/10.1016/j.ejso.2018.05.021>
353. Meilleroux, J., Daniel, G., Aziza, J., d'Aure, D.M., Quintyn-Ranty, M.-L., Basset, C.M., Evrard, S.M., Courtade-Saidi, M.M., 2018. **One year of experience using the Paris System for Reporting Urinary Cytology.** *Cancer Cytopathol.* <https://doi.org/10.1002/cncy.21999>
354. Méjean, A., Ravaud, A., Thezenas, S., Colas, S., Beauval, J.-B., Bensalah, K., Geoffrois, L., Thiery-Vuillemin, A., Cormier, L., Lang, H., Guy, L., Gravis, G., Rolland, F., Linassier, C., Lechevallier, E., Beisland, C., Aitchison, M., Oudard, S., Patard, J.-J., Theodore, C., Chevreau, C., Laguerre, B., Hubert, J., Gross-Goupil, M., Bernhard, J.-C., Albiges, L., Timsit, M.-O., Lebret, T., Escudier, B., 2018. **Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.** *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoa1803675>
355. Menguy, T., Briaux, A., Jeunesse, E., Giustiniani, J., Calcei, A., Guyon, T., Mizrahi, J., Haegel, H., Duong, V., Soler, V., Brousset, P., Bensussan, A., Raymond Letron, I., Le Bouteiller, P., 2018. **Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models.** *Invest. Ophthalmol. Vis. Sci.* 59, 2687–2698. <https://doi.org/10.1167/iovs.18-24024>
356. Mercier, F., Bakrin, N., Bartlett, D.L., Goere, D., Quenet, F., Dumont, F., Heyd, B., Abboud, K., Marolho, C., Villeneuve, L., Glehen, O., PSOGI Working Group, BIG-RENAPE Working Group [collab : Ferron, G.], 2018. **Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE.** *Ann. Surg. Oncol.* 25, 1668–1675. <https://doi.org/10.1245/s10434-018-6464-z>
357. Mercier, F., Passot, G., Villeneuve, L., Levine, E.A., Yonemura, Y., Goéré, D., Sugarbaker, P.H., Marolho, C., Bartlett, D.L., Glehen, O., BIG-RENAPE Working Group [collab : Ferron, G.], 2018. **Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients.** *Ann. Surg.*

- Oncol. 25, 1094–1100. <https://doi.org/10.1245/s10434-017-6299-z>
358. Merveilleux du Vignaux, C., Dansin, E., Mhanna, L., Greillier, L., Pichon, E., Kerjouan, M., Clement-Duchene, C., Menecier, B., Westeel, V., Robert, M., Quantin, X., Zalcman, G., Thiberville, L., Lena, H., Molina, T., Calcagno, F., Fournel, P., Mazieres, J., Besse, B., Girard, N., 2018. **Systemic therapy in advanced thymic epithelial tumors: Insights from the RHYMIC prospective cohort.** J Thorac Oncol. <https://doi.org/10.1016/j.jtho.2018.08.005>
359. Meyer, C., Burmeister, T., Gröger, D., Tsaour, G., Fechina, L., Renneville, A., Sutton, R., Venn, N.C., Emerenciano, M., Pombo-de-Oliveira, M.S., Barbieri Blunck, C., Almeida Lopes, B., Zuna, J., Trka, J., Ballerini, P., Lapillonne, H., De Braekeleer, M., Cazzaniga, G., Corral Abascal, L., van der Velden, V.H.J., Delabesse, E., Park, T.S., Oh, S.H., Silva, M.L.M., Lund-Aho, T., Juvonen, V., Moore, A.S., Heidenreich, O., Vormoor, J., Zerkalenkova, E., Olshanskaya, Y., Bueno, C., Menendez, P., Teigler-Schlegel, A., Zur Stadt, U., Lentès, J., Göhring, G., Kustanovich, A., Aleinikova, O., Schäfer, B.W., Kubetzko, S., Madsen, H.O., Gruhn, B., Duarte, X., Gameiro, P., Lippert, E., Bidet, A., Cayuela, J.M., Clappier, E., Alonso, C.N., Zwaan, C.M., van den Heuvel-Eibrink, M.M., Izraeli, S., Trakhtenbrot, L., Archer, P., Hancock, J., Möricke, A., Alten, J., Schrappe, M., Stanulla, M., Strehl, S., Attarbaschi, A., Dworzak, M., Haas, O.A., Panzer-Grümayer, R., Sedék, L., Szczepański, T., Caye, A., Suarez, L., Cavé, H., Marschalek, R., 2018. **The MLL recombinome of acute leukemias in 2017.** Leukemia 32, 273–284. <https://doi.org/10.1038/leu.2017.213>
360. Mezquita, L., Auclin, E., Ferrara, R., Charrier, M., Remon, J., Planchard, D., Ponce, S., Ares, L.P., Leroy, L., Audigier-Valette, C., Filip, E., Zerón-Medina, J., Garrido, P., Brosseau, S., Zalcman, G., Mazieres, J., Caramela, C., Lahmar, J., Adam, J., Chaput, N., Soria, J.C., Besse, B., 2018. **Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.** JAMA Oncol. <https://doi.org/10.1001/jamaoncol.2017.4771>
361. Mignard, C., Deschamps Huvier, A., Gillibert, A., Duval Modeste, A.B., Dutriaux, C., Khammari, A., Avril, M.-F., Kramkimel, N., Mortier, L., Marcant, P., Lesimple, T., Gaudy-Marqueste, C., Lesage, C., Machet, L., Aubin, F., Meyer, N., Beneton, N., Jeudy, G., Montaudié, H., Arnault, J.-P., Visseaux, L., Trabelsi, S., Amini-Adle, M., Maubec, E., Le Corre, Y., Lipsker, D., Wierzbicka-Hainaut, E., Litrowski, N., Stefan, A., Brunet-Possenti, F., Leccia, M.-T., Joly, P., 2018. **Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma.** J Oncol 2018, 1908065. <https://doi.org/10.1155/2018/1908065>
362. Mignard, X., Ruppert, A.-M., Antoine, M., Vasseur, J., Girard, N., Mazières, J., Moro-Sibilo, D., Fallet, V., Rabbe, N., Thivolet-Bejui, F., Rouquette, J., Lantuejoul, S., Cortot, A., Saffroy, R., Cadranet, J., Lemoine, A., Wislez, M., 2018. **Brief report: c-MET overexpression as a poor predictor of MET amplifications or exon 14 mutations in lung sarcomatoid carcinomas.** J Thorac Oncol. <https://doi.org/10.1016/j.jtho.2018.08.008>
363. Moeung, S., Chevreau, C., Poinsignon, V., Guitton, J., Lelièvre, B., Ciccolini, J., Gladieff, L., Massart, C., Fléchon, A., Delva, R., Gravis, G., Lotz, J.-P., Bay, J.-O., Gross-Goupil, M., Delahousse, J., Filleron, T., Lochon, L., Chatelut, E., Thomas, F., 2018. **Estimation of unbound carboplatin clearance from total plasma concentrations as a means of facilitating therapeutic drug monitoring.** Ther Drug Monit. <https://doi.org/10.1097/FTD.0000000000000569>
364. Mohkam, K., Rayar, M., Adam, J.-P., Muscari, F., Rode, A., Merle, P., Pradat, P., Bauler, S., Delfour, I., Chiche, L., Ducerf, C., Boudjema, K., Lesurtel, M., Laurent, C., Mabrut, J.-Y., 2018. **Evaluation of postoperative ascites after somatostatin infusion following hepatectomy for hepatocellular carcinoma by laparotomy: a multicenter randomized double-blind controlled trial (SOMAPROTECT).** BMC Cancer 18, 844. <https://doi.org/10.1186/s12885-018-4667-0>
365. Moktefi, A., Pouessel, D., Liu, J., Sirab, N., Maille, P., Soyeux, P., Bergman, C.C., Auriault, M.L., Vordos, D., Taille, A. de la, Culine, S., Allory, Y., 2018. **Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.** Mod. Pathol. <https://doi.org/10.1038/s41379-018-0023-9>
366. Montastruc, F., Khosrow-Khavar, F., de Germay, S., Renoux, C., Rousseau, V., Durrieu, G., Montastruc, M., Rascol, O., Sommet, A., Lapeyre-Mestre, M., Benevent, J., Montastruc, J.-L., 2018. **Tamoxifen and the risk of Parkinsonism: a case/non-case study.** Eur. J. Clin. Pharmacol. <https://doi.org/10.1007/s00228-018-2496-3>
367. Montfort, A., Colacios, C., Levade, T., Andrieu-Abadie, N., Meyer, N., Ségui, B., 2018. **[Anti-TNF α antibodies in melanoma immunotherapy].** Med Sci (Paris) 34, 788–791. <https://doi.org/10.1051/medsci/2018202>
368. Morfoisse, F., Tatin, F., Chapût, B., Therville, N., Vaysse, C., Métivier, R., Malloizel-Delaunay, J., Pujol, F., Godet, A.-C., De Toni, F., Boudou, F., Grenier, K., Dubuc, D., Lacazette, E., Prats, A.-C., Guillermet-Guibert, J., Lenfant, F., Garmy-Susini, B., 2018. **Lymphatic Vasculature Requires ER (Estrogen Receptor)- α Signaling to Protect From Lymphedema.** Arterioscler. Thromb. Vasc. Biol. <https://doi.org/10.1161/ATVBAHA.118.310997>
369. Morschhauser, F., Fowler, N.H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M.L., Fruchart, C., Libby, E.N., Casasnovas, R.-O., Flinn, I.W., Haioun, C., Maisonneuve, H., Ysebaert, L., Bartlett, N.L., Bouabdallah, K., Brice, P., Ribrag, V., Daguindau, N., Le Gouill, S., Pica, G.M., Martin Garcia-Sancho, A., López-Guillermo, A., Larouche, J.-F., Ando, K., Gomes da Silva, M., André, M., Zachée, P., Sehn, L.H., Tobinai, K., Cartron, G., Liu, D., Wang, J., Xerri, L., Salles, G.A., **RELEVANCE Trial Investigators,**

- 2018. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.** *N. Engl. J. Med.* 379, 934–947. <https://doi.org/10.1056/NEJMoa1805104>
370. Moulis, G., Germain, J., Comont, T., Arrouy, A., Lapeyre-Mestre, M., Adoue, D., and the Carmen investigators group., 2018. **Cardiovascular risk factors in immune thrombocytopenia adults.** Results from the CARMEN registry. *Am. J. Hematol.* <https://doi.org/10.1002/ajh.25127>
371. Mouly, L., Mamouni, K., Gence, R., Cristini, A., Cherier, J., Castinel, A., Legrand, M., Favre, G., Sordet, O., Monferran, S., 2018. **PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin.** *Cell Death Dis* 9, 931. <https://doi.org/10.1038/s41419-018-0981-3>
372. Mourguet, M., Chauveau, D., Faguer, S., Ruidavets, J.B., Béjot, Y., Ribes, D., Huart, A., Alric, L., Balardy, L., Astudillo, L., Adoue, D., Sailler, L., Pugnet, G., 2018. **Increased ischemic stroke, acute coronary artery disease and mortality in patients with granulomatosis with polyangiitis and microscopic polyangiitis.** *J. Autoimmun.* <https://doi.org/10.1016/j.jaut.2018.09.004>
373. Musto, P., Anderson, K.C., Attal, M., Richardson, P.G., Badros, A., Hou, J., Comenzo, R., Du, J., Durie, B.G.M., San Miguel, J., Einsele, H., Chen, W.M., Garderet, L., Pietrantonio, G., Hillengass, J., Kyle, R.A., Moreau, P., Lahuerta, J.J., Landgren, O., Ludwig, H., Larocca, A., Mahindra, A., Cavo, M., Mazumder, A., McCarthy, P.L., Nouel, A., Rajkumar, S.V., Reiman, A., Riva, E., Sezer, O., Terpos, E., Turesson, I., Usmani, S., Weiss, B.M., Palumbo, A., **International Myeloma Working Group, 2018. Second primary malignancies in multiple myeloma: an overview and IMWG consensus.** *Ann. Oncol.* 29, 1074. <https://doi.org/10.1093/annonc/mdx160>
374. Nagarajan, N., Dupret-Bories, A., Karabulut, E., Zorlutuna, P., Vrana, N.E., 2018. **Enabling personalized implant and controllable biosystem development through 3D printing.** *Biotechnol. Adv.* <https://doi.org/10.1016/j.biotechadv.2018.02.004>
375. Nakamura, K., Kassem, S., Cleynen, A., Chrétien, M.-L., Guilleroy, C., Putz, E.M., Bald, T., Förster, I., Vuckovic, S., Hill, G.R., Masters, S.L., Chesi, M., Bergsagel, P.L., Avet-Loiseau, H., Martinet, L., Smyth, M.J., 2018. **Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.** *Cancer Cell.* <https://doi.org/10.1016/j.ccell.2018.02.007>
376. Napoleon, B., Palazzo, M., Lemaistre, A.-I., Caillol, F., Palazzo, L., Aubert, A., Buscail, L., Maire, F., Morellon, B.M., Pujol, B., Giovannini, M., 2018. **Needle-based confocal laser endomicroscopy of pancreatic cystic lesions: a prospective multicenter validation study in patients with definite diagnosis.** *Endoscopy.* <https://doi.org/10.1055/a-0732-5356>
377. Neuzillet, C., Tijeras-Raballand, A., Ragulan, C., Cros, J., Patil, Y., Martinet, M., Erkan, M., Kleeff, J., Wilson, J., Apte, M., Tosolini, M., Wilson, A.S., Delvecchio, F.R., Bousquet, C., Paradis, V., Hammel, P., Sadanandam, A., Kocher, H.M., 2018. **Inter- and intra-tumoral heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.** *J. Pathol.* <https://doi.org/10.1002/path.5224>
378. Novello, S., Mazières, J., Oh, I.-J., de Castro, J., Migliorino, M.R., Helland, Å., Dziadziuszko, R., Griesinger, F., Kotb, A., Zeaiter, A., Cardona, A., Balas, B., Johannsdottir, H.K., Das-Gupta, A., Wolf, J., 2018. **Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.** *Ann. Oncol.* <https://doi.org/10.1093/annonc/mdy121>
379. Ofran, Y., Beohou, E., Labopin, M., Blaise, D., Cornelissen, J.J., de Groot, M.R., Socié, G., Huynh, A., Maertens, J., Baron, F., Mohty, M., Nagler, A., 2018. **Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission - a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation.** *Br. J. Haematol.* <https://doi.org/10.1111/bjh.15131>
380. Ogier, C., Colombo, P.-E., Bousquet, C., Canterel-Thouennon, L., Sicard, P., Garambois, V., Thomas, G., Gaborit, N., Jarlier, M., Piro, N., Pugnière, M., Vie, N., Gongora, C., Martineau, P., Robert, B., Pèlerin, A., Chardès, T., Larbouret, C., 2018. **Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.** *Cancer Letters* 432, 227–236. <https://doi.org/10.1016/j.canlet.2018.06.023>
381. Orbach, D., Mosseri, V., Pissaloux, D., Pierron, G., Brennan, B., Ferrari, A., Chibon, E., Bisogno, G., De Salvo, G.L., Chakiba, C., Corradini, N., Minard-Colin, V., Kelsey, A., Ranchère-Vince, D., 2018. **Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience.** *Cancer Med.* <https://doi.org/10.1002/cam4.1415>
382. Oumar, A.A., Bagayoko-Maiga, K., Bahachimi, A., Maiga, M., Cere, M.-C., Diarra, Z., Chatelut, E., Sylla, M., Murphy, R., Dao, S., Gandia, P., 2018. **Efavirenz and Lopinavir Levels in HIV-infected Women and their Nursing Infants, in Mali.** *J. Pharmacol. Exp. Ther.* <https://doi.org/10.1124/jpet.118.249938>
383. Overs, C., Beauval, J.B., Mourey, L., Rischmann, P., Soulié, M., Roumiguié, M., Doumerc, N., 2018. **Robot-assisted post-chemotherapy retroperitoneal lymph node dissection in germ cell tumor: is the single-docking with lateral approach relevant?** *World J Urol*

- 36, 655–661. <https://doi.org/10.1007/s00345-018-2177-y>
384. Padovani, L., Chapon, F., André, N., Boucekine, M., Geoffray, A., Bourdeau, F., Masliah-Planchon, J., Claude, L., Huchet, A., Laprie, A., Supiot, S., Coche-Dequéant, B., Kerr, C., Alapetite, C., Leseur, J., Nguyen, T., Chapet, S., Bernier, V., Bondiau, P.-Y., Noel, G., Habrand, J.L., Bolle, S., Doz, F., Dufour, C., Muracciole, X., Carrie, C., 2018. **Hippocampal Sparing During Craniospinal Irradiation: What Did We Learn About the Incidence of Perihippocampus Metastases?** *Int. J. Radiat. Oncol. Biol. Phys.* 100, 980–986. <https://doi.org/10.1016/j.ijrobp.2017.12.265>
385. Paillassa, J., Leguay, T., Thomas, X., Huguet, F., Audrain, M., Lheritier, V., Vianey-Saban, C., Acquaviva-Bourdain, C., Pagan, C., Dombret, H., Ifrah, N., Boissel, N., Hunault-Berger, M., 2018. **Monitoring of asparagine depletion and anti-L-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial.** *Blood Cancer J* 8, 45. <https://doi.org/10.1038/s41408-018-0084-5>
386. Paillaud, E., Soubeyran, P., Caillet, P., Cudennec, T., Brain, E., Terret, C., Etchepare, F., Mourey, L., Aparicio, T., Pamoukdjian, F., Audisio, R.A., Rostoft, S., Hurria, A., Bellera, C., Mathoulin-Pélissier, S., G-CODE collaborators, 2018. **Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: A French initiative with international survey.** *Eur. J. Cancer* 103, 61–68. <https://doi.org/10.1016/j.ejca.2018.07.137>
387. Pal, S.K., Rosenberg, J.E., Hoffman-Censits, J.H., Berger, R., Quinn, D.I., Galsky, M.D., Wolf, J., Dittrich, C., Keam, B., Delord, J.-P., Schellens, J.H.M., Gravis, G., Medioni, J., Maroto, P., Sriuranpong, V., Charoentum, C., Burris, H.A., Grünwald, V., Petrylak, D., Vaishampayan, U., Gez, E., De Giorgi, U., Lee, J.-L., Voortman, J., Gupta, S., Mortazavi, A., Vaughn, D.J., Isaacs, R.E., Parker, K., Chen, X., Yu, K., Porter, D., Sharma, S., Graus Porta, D., Bajorin, D.F., 2018. **Efficacy of BGI398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations.** *Cancer Discov.* <https://doi.org/10.1158/2159-8290.CD-18-0229>
388. Paludetto, M.-N., Bijani, C., Puisset, F., Bernardes-Génisson, V., Arellano, C., Robert, A., 2018a. **Metalloporphyrin-Catalyzed Oxidation of Sunitinib and Pazopanib, Two Anticancer Tyrosine Kinase Inhibitors: Evidence for New Potentially Toxic Metabolites.** *J. Med. Chem.* 61, 7849–7860. <https://doi.org/10.1021/acs.jmedchem.8b00812>
389. Paludetto, M.-N., Puisset, F., Le Louedec, F., Allal, B., Lafont, T., Chatelut, E., Arellano, C., 2018b. **Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS.** *J Pharm Biomed Anal* 154, 373–383. <https://doi.org/10.1016/j.jpba.2018.03.013>
390. Pascal, P., Derclé, L., Weyts, K., Meyer, N., Courbon, F., 2018. **Complete Metabolic Response of Advanced Melanoma to Vemurafenib Assessed with FDG-PET-CT at 85 Hours.** *Clin Nucl Med* 43, 333–334. <https://doi.org/10.1097/RLU.0000000000002032>
391. Passet, M., Boissel, N., Sigaux, F., Saillard, C., Bargetzi, M., Ba, I., Thomas, X., Graux, C., Chalandon, Y., Leguay, T., Lengliné, E., Konopacki, J., Quentin, S., Delabesse, E., Lafage-Pochitaloff, M., Pastoret, C., Gardel, N., Asnafi, V., Lhéritier, V., Soulier, J., Dombret, H., Clappier, E., 2018. **PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome.** *Blood.* <https://doi.org/10.1182/blood-2018-10-882142>
392. Passot, G., Kim, B.J., Glehen, O., Mehran, R.J., Kopetz, S.E., Goere, D., Overman, M.J., Pocard, M., Marchal, F., Conrad, C., Aloia, T.A., Vauthey, J.-N., Chun, Y.S., BIG-RENAPE Working Group [collab : Guimbaud, R.], 2018. **Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter?** *Ann. Surg. Oncol.* 25, 179–187. <https://doi.org/10.1245/s10434-017-6141-7>
393. Paupert, J., Espinosa, E., Cenac, N., Robert, V., Laharrague, P., Evrard, S.M., Casteilla, L., LORSIGNOL, A., Cousin, B., 2018. **Rapid and Efficient Production of Human Functional Mast Cells Through a Three-Dimensional Culture of Adipose Tissue-Derived Stromal Vascular Cells.** *J. Immunol.* <https://doi.org/10.4049/jimmunol.1701751>
394. Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K.H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G.M., Piperdi, B., Kowalski, D.M., KEYNOTE-407 Investigators, 2018. **Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.** *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoa1810865>
395. Peeters, S., Pagès, M., Gauchotte, G., Miquel, C., Cartalat-Carel, S., Guillamo, J.-S., Capelle, L., Delattre, J.-Y., Beauchesne, P., Debouverie, M., Fontaine, D., Jouanneau, E., Stecken, J., Menei, P., De Witte, O., Colin, P., Frappaz, D., Lesimple, T., Bauchet, L., Lopes, M., Bozec, L., Moyal, E., Deroulers, C., Varlet, P., Zanello, M., Chretien, F., Oppenheim, C., Duffau, H., Taillandier, L., Pallud, J., for the Club de Neuro-Oncologie de la Société Française de Neurochirurgie and the Association des Neuro-Oncologues d'Expression Française, 2018. **Interactions between glioma and pregnancy: insight from a 52-case multicenter series.** *J. Neurosurg.* 128, 3–13. <https://doi.org/10.3171/2016.10.JNS16710>
396. Peffault de Latour, R., Tabrizi, R., Marcas, A., Leblanc, T., Lamy, T., Mohty, M., Tavitian, S., Jubert, C., Pasquet, M., Galambrun, C., Nguyen, S., Cahn, J.Y., Braun, T., Deconinck, E., Bay, J.O., Sicre de Fontbrune, F., Barraco, F., Socié, G., 2018. **Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia.** *Am.*

- J. Hematol. 93, 635–642.
<https://doi.org/10.1002/ajh.25050>
397. Penault-Llorca, F., Filleron, T., Asselain, B., Baehner, F.L., Fumoleau, P., Lacroix-Triki, M., Anderson, J.M., Yoshizawa, C., Cherbavaz, D.B., Shak, S., Roca, L., Sagan, C., Lemonnier, J., Martin, A.-L., Roché, H., 2018. **The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).** BMC Cancer 18, 526. <https://doi.org/10.1186/s12885-018-4331-8>
398. Perchey, R.T., Serres, M.P., Nowosad, A., Creff, J., Callot, C., Gay, A., Manenti, S., Margolis, R.L., Hatzoglou, A., Besson, A., 2018. **p27Kip1 regulates the microtubule bundling activity of PRC1.** Biochim Biophys Acta Mol Cell Res 1865, 1630–1639. <https://doi.org/10.1016/j.bbamcr.2018.08.010>
399. Pereda-Loth, V., Franceries, X., Afonso, A.S., Ayala, A., Eche, B., Ginibrière, D., Gauquelin-Koch, G., Bardières, M., Lacoste-Collin, L., Courtade-Saïdi, M., 2018. **An innovative in vitro device providing continuous low doses of γ -rays mimicking exposure to the space environment: A dosimetric study.** Life Sci Space Res (Amst) 16, 38–46. <https://doi.org/10.1016/j.lssr.2017.10.004>
400. Péricart, S., Tosolini, M., Gravelle, P., Rossi, C., Traverse-Glehen, A., Amara, N., Franchet, C., Martin, E., Bezombes, C., Laurent, G., Brousset, P., Fournié, J.-J., Laurent, C., 2018. **Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.** Cancers (Basel) 10. <https://doi.org/10.3390/cancers10110415>
401. Perron, E., Pissaloux, D., Charon Barra, C., Karanian, M., Lamant, L., Parfait, S., Alberti, L., de la Fouchardière, A., 2018. **Melanocytic Myxoid Spindle Cell Tumor With ALK Rearrangement (MMySTAR): Report of 4 Cases of a Nevus Variant With Potential Diagnostic Challenge.** Am. J. Surg. Pathol. 42, 595–603. <https://doi.org/10.1097/PAS.0000000000000973>
402. Perrot, A., Corre, J., Avet-Loiseau, H., 2018a. **Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside.** Am Soc Clin Oncol Educ Book 675–680. https://doi.org/10.1200/EDBK_200879
403. Perrot, A., Lauwers-Cances, V., Corre, J., Robillard, N., Hulin, C., Chretien, M.-L., Dejoie, T., Maheo, S., Stoppa, A.-M., Pegourie, B., Karlin, L., Garderet, L., Arnulf, B., Doyen, C., Meuleman, N., Royer, B., Eveillard, J.-R., Benboubker, L., Dib, M., Decaux, O., Jaccard, A., Belhadj, K., Brechignac, S., Kolb, B., Fohrer, C., Mohty, M., Macro, M., Richardson, P.G., Carlton, V., Moorhead, M., Willis, T., Faham, M., Anderson, K.C., Harousseau, J.-L., Leleu, X., Facon, T., Moreau, P., Attal, M., Avet-Loiseau, H., Munshi, N., 2018b. **Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.** Blood. <https://doi.org/10.1182/blood-2018-06-858613>
404. Perry, M., Bertoli, S., Rocher, C., Hayette, S., Ducastelle, S., Barraco, F., Labussière-Wallet, H., Salles, G., Recher, C., Thomas, X., Paubelle, E., 2018. **FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.** Clin Lymphoma Myeloma Leuk. <https://doi.org/10.1016/j.clml.2018.06.006>
405. Peyraga, G., Robaine, N., Khalifa, J., Cohen-Jonathan-Moyal, E., Payoux, P., Laprie, A., 2018. **Molecular PET imaging in adaptive radiotherapy: brain.** Q J Nucl Med Mol Imaging 62, 337–348. <https://doi.org/10.23736/S1824-4785.18.03116-3>
406. Peyronnet, B., Tondut, L., Bernhard, J.-C., Vaessen, C., Doumerc, N., Sebe, P., Pradere, B., Guillonnet, B., Khene, Z.-E., Nouhaud, F.-X., Brichart, N., Seisen, T., Alimi, Q., Beauval, J.-B., Mathieu, R., Rammal, A., de la Taille, A., Baumert, H., Droupy, S., Bruyere, F., Roupêt, M., Mejean, A., Bensalah, K., members of the French Committee of Urologic Oncology (CCAFU), 2018. **Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy outcomes: a multicentre study.** BJU Int. 121, 916–922. <https://doi.org/10.1111/bju.14175>
407. Phillips, A.H., Li, O., Gay, A., Besson, A., Kriwacki, R.W., 2018. **Mapping interactions between p27 and RhoA that stimulate cell migration.** J. Mol. Biol. <https://doi.org/10.1016/j.jmb.2018.01.017>
408. Piel-Julian, M.-L., Mahévas, M., Germain, J., Languille, L., Comont, T., Lapeyre-Mestre, M., Payrastre, B., Beyne-Rauzy, O., Michel, M., Godeau, B., Adoue, D., Moulis, G., CARMEN investigators group, 2018a. **Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults.** J. Thromb. Haemost. 16, 1830–1842. <https://doi.org/10.1111/jth.14227>
409. Piel-Julian, M.-L., Moulis, G., Fournier, P., Dupont, R., Geiger, D., Astudillo, L., Faurie, T., Pozzo, J., Petermann, A., Lairez, O., Pugnet, G., Sailler, L., 2018b. **Early use of anakinra in adult-onset Still's disease myocarditis.** Scand. J. Rheumatol. 1–2. <https://doi.org/10.1080/03009742.2017.1387672>
410. Pigneux, A., Béné, M.C., Salmi, L.-R., Dumas, P.-Y., Delaunay, J., Bonmati, C., Guièze, R., Luquet, I., Cornillet-Lefebvre, P., Delabesse, E., Ianotto, J.-C., Ojeda-Urbe, M., Hunault, M., Banos, A., Fornecker, L.M., Bernard, M., Jourdan, E., Vey, N., Zerazhi, H., Hishri, Y., Mineur, A., Asselineau, J., Delepine, R., Cahn, J.-Y., Ifrah, N., Récher, C., French Innovative Leukemia Organization, 2018. **Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial.** J. Clin. Oncol. JCO2018787366. <https://doi.org/10.1200/JCO.2018.78.7366>
411. Pignot, G., Houédé, N., Roumiguié, M., Audenet, F., Brunelle, S., Colin, P., Compérat, E., Larré, S., Masson-

- Lecomte, A., Neuzillet, Y., Xylinas, E., Méjean, A., Rouprêt, M., les membres du CCAFU Vessie, 2018. [ypTONO after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology]. *Prog. Urol.* 28, 567–574. <https://doi.org/10.1016/j.purol.2018.07.003>
412. Pignot, G., Maillet, D., Gross, E., Barthelemy, P., Beauval, J.-B., Constans-Schlurmann, F., Lorient, Y., Ploussard, G., Sargos, P., Timsit, M.-O., Vincendeau, S., Pasticier, G., Borchiellini, D., 2018. *Systemic treatments for high-risk localized prostate cancer.* *Nat Rev Urol.* <https://doi.org/10.1038/s41585-018-0017-x>
413. Pinazza, M., Ghisi, M., Minuzzo, S., Agnusdei, V., Fossati, G., Ciminale, V., Pezzè, L., Ciribilli, Y., Pilotto, G., Venturoli, C., Amadori, A., Indraccolo, S., 2018. **Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.** *Oncogene* 37, 3839–3851. <https://doi.org/10.1038/s41388-018-0234-z>
414. Pistilli, B., Mazouni, C., Zingarello, A., Faron, M., Saghatchian, M., Grynberg, M., Spielmann, M., Kerbrat, P., Roché, H., Lorgis, V., Bachelot, T., Campone, M., Levy, C., Gonçalves, A., Lesur, A., Veyret, C., Vanlemmens, L., Lemonnier, J., Delalogue, S., 2018. **Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials.** *Clin. Breast Cancer.* <https://doi.org/10.1016/j.clbc.2018.08.005>
415. Platzer, V., Perez, G., Galinier, A., Genestal, M., Riu-Poulenc, B., Gonzalez, L., Huyghe, E., Caspar-Bauguil, S., 2018. **Protein and micronutrient deficiencies in patients with radiation cystitis and outcome after hyperbaric oxygen therapy.** *Clin Nutr ESPEN* 23, 141–147. <https://doi.org/10.1016/j.clnesp.2017.10.012>
416. Ploquin, A., Pistilli, B., Tresch, E., Frenel, J.S., Lerebours, F., Lesur, A., Loustalot, C., Bachelot, T., Provansal, M., Ferrero, J.M., Coussy, F., Debled, M., Kerbrat, P., Vinceneux, A., Allouache, D., Morvan, F., Dalenc, F., Guiu, S., Rouzier, R., Vanlemmens, L., 2018. **5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.** *Eur. J. Cancer* 95, 30–37. <https://doi.org/10.1016/j.ejca.2018.02.030>
417. Ploussard, G., 2018. [Editorial]. *Prog. Urol.* 28, 1. <https://doi.org/10.1016/j.purol.2017.12.011>
418. Ploussard, G., 2018a. **Re: Salvage High-intensity Focused Ultrasound (HIFU) for Locally Recurrent Prostate Cancer After Failed Radiation Therapy: Multi-institutional Analysis of 418 Patients.** *Eur. Urol.* 73, 140–141. <https://doi.org/10.1016/j.eururo.2017.09.031>
419. Ploussard, G., 2018b. **Robotic surgery in urology: facts and reality. What are the real advantages of robotic approaches for prostate cancer patients?** *Curr Opin Urol* 28, 153–158. <https://doi.org/10.1097/MOU.0000000000000470>
420. Ploussard, G., Borgmann, H., Briganti, A., de Visschere, P., Fütterer, J.J., Gandaglia, G., Heidegger, I., Kretschmer, A., Mathieu, R., Ost, P., Sooriakumaran, P., Surcel, C., Tilki, D., Tsaur, I., Valerio, M., van den Bergh, R., EAU-YAU Prostate Cancer Working Group, 2018a. **Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?** *World J Urol.* <https://doi.org/10.1007/s00345-018-2399-z>
421. Ploussard, G., de la Taille, A., 2018. **The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection.** *Expert Rev Anticancer Ther.* <https://doi.org/10.1080/14737140.2018.1502086>
422. Ploussard, G., Gandaglia, G., Borgmann, H., de Visschere, P., Heidegger, I., Kretschmer, A., Mathieu, R., Surcel, C., Tilki, D., Tsaur, I., Valerio, M., van den Bergh, R., Ost, P., Briganti, A., EAU-YAU Prostate Cancer Working Group, 2018b. **Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review.** *Eur. Urol.* <https://doi.org/10.1016/j.eururo.2018.10.041>
423. Poirot, M., Silvente-Poirot, S., 2018. **The tumor-suppressor cholesterol metabolite, dandroginin A, is a new class of LXR modulator activating lethal autophagy in cancers.** *Biochem. Pharmacol.* <https://doi.org/10.1016/j.bcp.2018.01.046>
424. Poirot, M., Soules, R., Mallinger, A., Dalenc, F., Silvente-Poirot, S., 2018. **Chemistry, biochemistry, metabolic fate and mechanism of action of 6-oxo-cholestan-3 β ,5 α -diol (OCDO), a tumor promoter and cholesterol metabolite.** *Biochimie.* <https://doi.org/10.1016/j.biochi.2018.04.008>
425. Poiroux, G., Barre, A., Rouge, P., Benoist, H., 2018. **Targeting Glycosylation Aberrations To Improve The Efficiency Of Cancer Phototherapy.** *Curr Cancer Drug Targets.* <https://doi.org/10.2174/1568009618666180628101059>
426. Polge, C., Cabantous, S., Deval, C., Claustre, A., Hauvette, A., Bouchenot, C., Aniot, J., Béchet, D., Combaret, L., Attaix, D., Taillandier, D., 2018. **A muscle-specific MuRF1-E2 network requires stabilization of MuRF1-E2 complexes by telethonin, a newly identified substrate.** *J Cachexia Sarcopenia Muscle* 9, 129–145. <https://doi.org/10.1002/jcsm.12249>
427. Pommier, M., Deslandes, M., Chave, L., Detraz, J., Nord, B., Panassie, L., Le Floc'h, C., Cavaşin, Y., Vanleberghe, C., Boyer, M., Ory, M.-J., Jaborska, A., 2018. [State of the art in medical imaging]. *RSNA.*
428. Pons-Tostivint, E., Kirova, Y., Lusque, A., Campone, M., Geffrelot, J., Mazouni, C., Mailliez, A., Pasquier, D., Madranges, N., Firmin, N., Crouzet, A., Gonçalves, A., Jankowski, C., De La Motte Rouge, T., Pouget, N., de La Lande, B., Mouttet-Boizat, D., Ferrero, J.-M., Uwer, L., Eymard, J.-C., Mouret-Reynier, M.-A., Petit, T., Robain, M., Filleron, T., Cailliot, C., Dalenc, F., 2018. **Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large**

- Multicentric Cohort Study: A Propensity Score-Matched Analysis.** Ann. Surg. Oncol. <https://doi.org/10.1245/s10434-018-6831-9>
429. Pouëdras, J., Izar, F., Muscari, F., Parent, L., Breibach, F., Péron, J.-M., Otal, P., Suc, B., Rives, M., Modesto, A., 2018. **[Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: Case report of a complete pathological response and review of the literature].** Cancer Radiother 22, 797–801. <https://doi.org/10.1016/j.canrad.2018.04.001>
430. Pradel, S., Brun, S., Victor, G., Pascal, P., Fournier, P., Ribes, D., Lavie-Badie, Y., Galinier, M., Carrié, D., Berry, L., Lairez, O., Toulouse Amyloidosis Research Network collaborators, 2018. **Pattern of myocardial 99mTc-HMDP uptake and impact on myocardial function in patients with transthyretin cardiac amyloidosis.** J Nucl Cardiol. <https://doi.org/10.1007/s12350-018-1316-6>
431. Prata, P.H., Bally, C., Prebet, T., Recher, C., Venton, G., Thomas, X., Raffoux, E., Pigneux, A., Cluzeau, T., Desoutter, J., Gay, J., Preudhomme, C., Fenaux, P., Adès, L., 2018. **NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents.** Haematologica. <https://doi.org/10.3324/haematol.2018.189886>
432. Preusser, M., Winkler, F., Valiente, M., Manegold, C., Moyal, E., Widhalm, G., Tonn, J.-C., Zielinski, C., 2018. **Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion.** ESMO Open 3, e000262. <https://doi.org/10.1136/esmoopen-2017-000262>
433. Puisset, F., Bigay-Game, L., Paludetto, M.-N., Martel, A., Perriat, S., Rabeau, A., Canonge, J.M., Mazieres, J., 2018. **Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit.** Support Care Cancer. <https://doi.org/10.1007/s00520-018-4415-7>
434. Pulido, M., Roubaud, G., Cazeau, A.-L., Mahammed, H., Vedrine, L., Joly, F., Mourey, L., Pfister, C., Goberna, A., Lortal, B., Bellera, C., Pourquier, P., Houédé, N., 2018. **Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer.** BMC Cancer 18, 194. <https://doi.org/10.1186/s12885-018-4059-5>
435. Puzkiel, A., Bauriaud-Mallet, M., Bourgeois, R., Dierickx, L., Courbon, F., Chatelut, E., 2018a. **Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors.** Clin Pharmacokinet. <https://doi.org/10.1007/s40262-018-0674-1>
436. Puzkiel, A., Noé, G., Bellesoeur, A., Kramkimel, N., Paludetto, M.-N., Thomas-Schoemann, A., Vidal, M., Goldwasser, F., Chatelut, E., Blanchet, B., 2018b. **Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.** Clin Pharmacokinet. <https://doi.org/10.1007/s40262-018-0703-0>
437. Quaranta, M., Laborde, N., Ferrand, A., Danjoux, M., Vergnolle, N., Barreau, F., Racaud-Sultan, C., Mas, E., 2018. **Sustainable Positive Response to Sirolimus in Juvenile Polyposis of Infancy.** J. Pediatr. Gastroenterol. Nutr. <https://doi.org/10.1097/MPG.0000000000002179>
438. Quérou, L., Guimbaud, R., 2018. **[Place of chemotherapy and chemoradiotherapy in locally evolved stomach cancer].** Cancer/Radiothérapie 22, 546–551. <https://doi.org/10.1016/j.canrad.2018.07.134>
439. Rault-Petit, B., Do Cao, C., Guyétant, S., Guimbaud, R., Rohmer, V., Julié, C., Baudin, E., Goichot, B., Coriat, R., Tabarin, A., Ramos, J., Goudet, P., Hervieu, V., Scoazec, J.-Y., Walter, T., 2018. **Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study from the French Group of Endocrine Tumors (GTE).** Ann. Surg. <https://doi.org/10.1097/SLA.0000000000002736>
440. Ravandi, F., Ritchie, E.K., Sayar, H., Lancet, J.E., Craig, M.D., Vey, N., Strickland, S.A., Schiller, G.J., Jabbour, E., Pigneux, A., Horst, H.-A., Recher, C., Klimek, V.M., Cortes, J.E., Carella, A.-M., Egyed, M., Krug, U., Fox, J.A., Craig, A.R., Ward, R., Smith, J.A., Acton, G., Kantarjian, H.M., Stuart, R.K., 2018. **Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.** Haematologica. <https://doi.org/10.3324/haematol.2018.191361>
441. Record, M., Silvente-Poirot, S., Poirot, M., Wakelam, M.J.O., 2018. **Extracellular vesicles: lipids as key components of their biogenesis and functions.** J. Lipid Res. <https://doi.org/10.1194/jlr.E086173>
442. Reix, B., Bernhard, J.-C., Patard, J.-J., Bigot, P., Villers, A., Suer, E., Vuong, N.S., Verhoest, G., Alimi, Q., Beauval, J.-B., Benoit, T., Nouhaud, F.-X., Lenormand, C., Hamidi, N., Cai, J., Eto, M., Larre, S., El Bakhri, A., Ploussard, G., Hung, A., Koutlidis, N., Schneider, A., Carrouget, J., Droupy, S., Marchal, S., Doerfler, A., Seddik, S., Matsugasumi, T., Orsoni, X., Descazeau, A., Pfister, C., Bensalah, K., Soulie, M., Gill, I., Flamand, V., Kidney Cancer group of the CCAFU, 2018. **Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR.** Prog. Urol. <https://doi.org/10.1016/j.purol.2017.12.004>
443. Renaudin, K., Smati, S., Wargny, M., Al Ghuzlan, A., Aubert, S., Leteurtre, E., Patey, M., Sibony, M., Sturm, N., Tissier, F., Amar, L., Bertherat, J., Berthozat, C., Chabre, O., Do Cao, C., Haissaguerre, M., Pierre, P., Briet, C., Vezzosi, D., Lifante, J.C., Pattou, F., Mirallie, E., Baudin, E., Cariou, B., Libe, R., Drui, D., for Comete-Cancer Network, 2018. **Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of**

- Ki-67 in histoprognostic evaluation.** *Mod. Pathol.* <https://doi.org/10.1038/s41379-018-0077-8>
444. Renault, A.-L., Mebirouk, N., Fuhrmann, L., Bataillon, G., Cavaciuti, E., Le Gal, D., Girard, E., Popova, T., La Rosa, P., Beauvallet, J., Eon-Marchais, S., Dondon, M.-G., d'Enghien, C.D., Laugé, A., Chemlali, W., Raynal, V., Labbé, M., Bièche, I., Baulande, S., Bay, J.-O., Berthet, P., Caron, O., Buecher, B., Faivre, L., Fresnay, M., Gauthier-Villars, M., Gesta, P., Janin, N., Lejeune, S., Maugard, C., Moutton, S., Venat-Bouvet, L., Zattara, H., Fricker, J.-P., Gladieff, L., Coupier, I., CoF-AT, GENESIS, kConFab, Chenevix-Trench, G., Hall, J., Vincent-Salomon, A., Stoppa-Lyonnet, D., Andrieu, N., Lesueur, F., 2018. **Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.** *Breast Cancer Res.* 20, 28. <https://doi.org/10.1186/s13058-018-0951-9>
445. Renault, L., Perrot, E., Pradat, E., Bartoli, C., Greillier, L., Remacle-Bonnet, A., Telmon, N., Mazières, J., Molinier, L., Couraud, S., 2018. **Concerns About Lung Cancer Among Prisoners.** *Lung* 196, 115–124. <https://doi.org/10.1007/s00408-017-0066-6>
446. Renneville, A., Attias, P., Thomas, X., Bally, C., Hayette, S., Farhat, H., Eclache, V., Marceau-Renaut, A., Cassinat, B., Feuillard, J., Terré, C., Delabesse, E., Park, S., Lejeune, J., Chevret, S., Adès, L., Preudhomme, C., Fenaux, P., 2018. **Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.** *Leukemia.* <https://doi.org/10.1038/s41375-018-0137-6>
447. Ribes, D., Hachem, H.E.L., Oberic, L., Vergez, F., Delas, A., Belliere, J., Protin, C., Kamar, N., Ferrandiz, I., Tavitian, S., Laurent, C., Huart, A., Chauveau, D., Ysebaert, L., Faguer, S., 2018. **Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.** *Am. J. Hematol.* 93, 356–362. <https://doi.org/10.1002/ajh.24984>
448. Richardson, P.G., Attal, M., Campana, F., Le-Guenec, S., Hui, A.-M., Risse, M.-L., Corzo, K., Anderson, K.C., 2018. **Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.** *Future Oncol* 14, 1035–1047. <https://doi.org/10.2217/fon-2017-0616>
449. Richet, C., Huynh, A., Dimeglio, C., Borel, C., Lepage, B., Boulinguez, S., Marguery, M.C., Paul, C., Bulai Livideanu, C., 2018. **Extracorporeal Photopheresis: An Efficacious and Well-Tolerated Treatment for Cutaneous and Oral Mucosal Chronic Graft-versus-Host Disease.** *Dermatology (Basel)* 1–8. <https://doi.org/10.1159/000488238>
450. Richez, V., Gruchet, C., Guidez, S., Fouquet, G., Azais, I., Durand, G., Javaugue, V., Brigaud, A., Plasse, F., Diolez, J., Machet, A., Moya, N., Gardeney, H., Franques, P., Bobin, A., Levy, A., Sabirou, F., Bonnin, A., Dieval, C., Primault, S., Barrier, J., Fleck, E., Bouyier, S., Daras, C., Princet, I., Bauwens, D., Legros, L., Fuzibet, J.-G., Gil, A., Bridoux, F., Avet-Loiseau, H., Leleu, X., 2019. **Carfilzomib weekly 20/56 mg/m², lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.** *American Journal of Hematology* 94, E17–E20. <https://doi.org/10.1002/ajh.25327>
451. Rioufol, C., Lamy, S., Conte, C., Jeanneau, P., Compaci, G., Delpierre, C., Lapeyre-Mestre, M., Laurent, G., Despas, F., 2018. **Non-cancer drug consumption during the early trajectory of lymphoma survivorship.** *Therapie* 73, 307–317. <https://doi.org/10.1016/j.therap.2017.10.007>
452. Rochaix, P., 2018a. [Carcinoma of unknown primary. Case no. 1]. *Ann Pathol.* <https://doi.org/10.1016/j.annpat.2018.04.010>
453. Rochaix, P., 2018b. [Carcinoma of unknown primary. Case no. 2]. *Ann Pathol.* <https://doi.org/10.1016/j.annpat.2018.04.011>
454. Roché, H., Eymard, J.-C., Radji, A., Prevost, A., Diab, R., Lamuraglia, M., Soumoudronga, R.-F., Gasnereau, I., Toledano, A., 2018. **Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).** *BMC Cancer* 18, 1127. <https://doi.org/10.1186/s12885-018-4986-1>
455. Rodon, J., Curigliano, G., Delord, J.-P., Harb, W., Azaro, A., Han, Y., Wilke, C., Donnet, V., Sellami, D., Beck, T., 2018. **A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.** *Oncotarget* 9, 31709–31718. <https://doi.org/10.18632/oncotarget.25854>
456. Roos-Weil, D., Nguyen-Khac, F., Chevret, S., Touzeau, C., Roux, C., Lejeune, J., Cosson, A., Mathis, S., Feugier, P., Leprêtre, S., Béné, M.-C., Baron, M., Raynaud, S., Struski, S., Eclache, V., Sutton, L., Lesty, C., Merle-Béral, H., Cymbalista, F., Ysebaert, L., Davi, F., Leblond, V., FILO working group, 2018. **Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.** *Genes Chromosomes Cancer.* <https://doi.org/10.1002/gcc.22650>
457. Roquin, G., Baudin, E., Lombard-Bohas, C., Cadiot, G., Dominguez, S., Guimbaud, R., Niccoli, P., Legoux, J.-L., Mitry, E., Rohmer, V., Ruzsniowski, P., Walter, T., Ducreux, M., Couvelard, A., Scoazec, J.-Y., Ramond-Roquin, A., Caroli-Bosc, F.-X., Hentic, O., 2018. **Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).** *Neuroendocrinology* 106, 38–46. <https://doi.org/10.1159/000457955>
458. Rose, C., Lenoir, C., Gyan, E., Hacini, M., Amé, S., Corront, B., Beyne-Rauzy, O., Adiko, D., Loppinet, E., Ali-Ammar, N., Laribi, K., Wattel, E., Dreyfus, F., Roué, C.S., Cheze, S., 2018. **Prospective Evaluation of the Effect of Deferasirox on Hematologic Response in Transfusion-**

- Dependent Patients with Low-Risk MDS and Iron Overload.** Eur. J. Haematol. <https://doi.org/10.1111/ejh.13088>
459. Rossi, C., Bastie, J.N., 2018. [New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma]. Rev Med Interne. <https://doi.org/10.1016/j.revmed.2018.04.015>
460. Rossi, C., Chrétien, M.-L., Casasnovas, R.-O., 2018a. **Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.** Target Oncol. <https://doi.org/10.1007/s11523-018-0558-1>
461. Rossi, C., Gilhodes, J., Maerevoet, M., Herbaux, C., Morschhauser, F., Brice, P., Garciaz, S., Borel, C., Ysebaert, L., Obéric, L., Lazarovici, J., Deau, B., Dupuis, J., Chauchet, A., Abraham, J., Bijou, F., Stamatoullas-Bastard, A., Malfuson, J.-V., Golfier, C., Laurent, C., Pericart, S., Traverse-Glehen, A., Kanoun, S., Filleron, T., Casasnovas, R.-O., Ghesquière, H., 2018b. **Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.** Am. J. Hematol. <https://doi.org/10.1002/ajh.25154>
462. Rouanne, M., Roumiguié, M., Houédé, N., Masson-Lecomte, A., Colin, P., Pignot, G., Larré, S., Xylinas, E., Rouprêt, M., Neuzillet, Y., 2018. **Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.** World J Urol. <https://doi.org/10.1007/s00345-018-2332-5>
463. Rousset-Jablonski, C., Selle, F., Adda-Herzog, E., Planchamp, F., Selleret, L., Pomel, C., Chabbert-Buffet, N., Daraï, E., Pautier, P., Trémollières, F., Guyon, F., Rouzier, R., Laurence, V., Chopin, N., Faure-Conter, C., Bentivegna, E., Vacher-Lavenu, M.-C., Lhomme, C., Floquet, A., Treilleux, I., Lecuru, F., Gouy, S., Kalbacher, E., Genestie, C., de la Motte Rouge, T., Ferron, G., Devouassoux-Shisheboran, M., Kurtz, J.-E., Namer, M., Joly, F., Pujade-Lauraine, E., Grynberg, M., Querleu, D., Morice, P., Gompel, A., Ray-Coquard, I., 2018. [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]. Bull Cancer. <https://doi.org/10.1016/j.bulcan.2017.10.032>
464. Rouvière, O., Puech, P., Renard-Penna, R., Claudon, M., Roy, C., Mège-Lechevallier, F., Decaussin-Petrucci, M., Dubreuil-Chambardel, M., Magaud, L., Remontet, L., Ruffion, A., Colombel, M., Crouzet, S., Schott, A.-M., Lemaitre, L., Rabilloud, M., Grenier, N., MRI-FIRST Investigators [collab : Malavaud, B., Portalez, D.], 2018. **Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naïve patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.** Lancet Oncol. [https://doi.org/10.1016/S1470-2045\(18\)30569-2](https://doi.org/10.1016/S1470-2045(18)30569-2)
465. Rozet, F., Hennequin, C., Beauval, J.-B., Beuzebec, P., Cormier, L., Fromont-Hankard, G., Mongiat-Artus, P., Ploussard, G., Mathieu, R., Brureau, L., Ouzzane, A., Azria, D., Brenot-Rossi, I., Cancel-Tassin, G., Cussenot, O., Rebillard, X., Lebret, T., 2018. [French ccAFU guidelines - Update 2018-2020: Prostate cancer]. Prog. Urol. <https://doi.org/10.1016/j.purol.2018.08.011>
466. Rozman, J., Rathkolb, B., Oestereicher, M.A., Schütt, C., Ravindranath, A.C., Leuchtenberger, S., Sharma, S., Kistler, M., Willershäuser, M., Brommage, R., Meehan, T.F., Mason, J., Haselimashhadi, H., IMPC Consortium, Hough, T., Mallon, A.-M., Wells, S., Santos, L., Lelliott, C.J., White, J.K., Sorg, T., Champy, M.-F., Bower, L.R., Reynolds, C.L., Flenniken, A.M., Murray, S.A., Nutter, L.M.J., Svenson, K.L., West, D., Tocchini-Valentini, G.P., Beaudet, A.L., Bosch, F., Braun, R.B., Dobbie, M.S., Gao, X., Herault, Y., Moshiri, A., Moore, B.A., Kent Lloyd, K.C., McKerlie, C., Masuya, H., Tanaka, N., Flicek, P., Parkinson, H.E., Sedlacek, R., Seong, J.K., Wang, C.-K.L., Moore, M., Brown, S.D., Tschöp, M.H., Wurst, W., Klingenspor, M., Wolf, E., Beckers, J., Machicao, F., Peter, A., Staiger, H., Häring, H.-U., Grallert, H., Campillos, M., Maier, H., Fuchs, H., Gailus-Durner, V., Werner, T., Hrabe de Angelis, M. [collab : Huynh, A.], 2018. **Identification of genetic elements in metabolism by high-throughput mouse phenotyping.** Nat Commun 9, 288. <https://doi.org/10.1038/s41467-017-01995-2>
467. Rudà, R., Reifenberger, G., Frappaz, D., Pfister, S.M., Laprie, A., Santarius, T., Roth, P., Tonn, J.C., Soffietti, R., Weller, M., Moyal, E.C.-J., 2018. **EANO guidelines for the diagnosis and treatment of ependymal tumors.** Neuro-oncology 20, 445–456. <https://doi.org/10.1093/neuonc/nox166>
468. Rugo, H.S., Delord, J.-P., Im, S.-A., Ott, P.A., Piha-Paul, S.A., Bedard, P.L., Sachev, J., Le Tourneau, C., van Brummelen, E.M.J., Varga, A., Salgado, R., Loi, S., Saraf, S., Pietrangelo, D., Karantza, V., Tan, A.R., 2018a. **Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.** Clin. Cancer Res. <https://doi.org/10.1158/1078-0432.CCR-17-3452>
469. Rugo, H.S., Roche, H., Thomas, E., Chung, H.C., Lerzo, G.L., Vasyutin, I., Patel, A., Vahdat, L., 2018b. **Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials.** Clin. Breast Cancer. <https://doi.org/10.1016/j.clbc.2018.07.024>
470. Ruhstaller, T., Giobbie-Hurder, A., Colleoni, M., Jensen, M.-B., Ejlersen, B., de Azambuja, E., Neven, P., Láng, I., Jakobsen, E.H., Gladieff, L., Bonnefoi, H., Harvey, V.J., Spazzapan, S., Tondini, C., Del Mastro, L., Veyret, C., Simoncini, E., Gianni, L., Rochlitz, C., Kralidis, E., Zaman, K., Jassem, J., Piccart-Gebhart, M., Di Leo, A., Gelber, R.D., Coates, A.S., Goldhirsch, A., Thürlimann, B., Regan, M.M., members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group, 2018. **Adjuvant Letrozole and Tamoxifen Alone or**

- Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. *J. Clin. Oncol.* JCO1800440. <https://doi.org/10.1200/JCO.18.00440>
471. Russano de Paiva Silva, G., Tournier, E., Sarian, L.O., Bulai-Livideanu, C., Delso, G., Lamant, L., Vassallo, J., Brousset, P., Laurent, C., 2018. **Prevalence of CD30 immunostaining in neoplastic mast cells: A retrospective immunohistochemical study.** *Medicine (Baltimore)* 97, e10642. <https://doi.org/10.1097/MD.00000000000010642>
472. Sabatier, R., Diéras, V., Pivot, X., Brain, E., Roché, H., Extra, J.-M., Monneur, A., Provansal, M., Tarpin, C., Bertucci, F., Viens, P., Zemmour, C., Gonçalves, A., 2018. **Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.** *Cancer Res Treat* 50, 1226–1237. <https://doi.org/10.4143/crt.2017.446>
473. Sakata, D., Kyriakou, I., Okada, S., Tran, H.N., Lampe, N., Guatelli, S., Bordage, M.C., Ivanchenko, V.N., Murakami, K., Sasaki, T., Emfietzoglou, D., Incerti, S., 2018. **Geant4-DNA track-structure simulations for gold nanoparticles: the importance of electron discrete models in nanometer volumes.** *Med Phys.* <https://doi.org/10.1002/mp.12827>
474. Salabert, A.-S., Mora-Ramirez, E., Beaurain, M., Alonso, M., Fontan, C., Tahar, H.B., Boizeau, M.L., Tafani, M., Bardès, M., Payoux, P., 2018. **Evaluation of [18F]FNM biodistribution and dosimetry based on whole-body PET imaging of rats.** *Nucl. Med. Biol.* 59, 1–8. <https://doi.org/10.1016/j.nucmedbio.2017.12.003>
475. Salazar, R., Garcia-Carbonero, R., Libutti, S.K., Hendifar, A.E., Custodio, A., Guimbaud, R., Lombard-Bohas, C., Ricci, S., Klümpen, H.-J., Capdevila, J., Reed, N., Walenkamp, A., Grande, E., Safina, S., Meyer, T., Kong, O., Salomon, H., Tavorath, R., Yao, J.C., 2018. **Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.** *Oncologist* 23, 766-e90. <https://doi.org/10.1634/theoncologist.2017-0144>
476. Salomon, G., Maza, A., Boulinguez, S., Paul, C., Lamant, L., Tournier, E., Mazereeuw-Hautier, J., Meyer, N., 2018. **Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.** *Br. J. Dermatol.* 178, 1199–1203. <https://doi.org/10.1111/bjd.16270>
477. Salvatore, D., Labopin, M., Ruggeri, A., Battipaglia, G., Ghavamzadeh, A., Ciceri, F., Blaise, D., Arcese, W., Socié, G., Bourhis, J.H., Van Lint, M., Bruno, B., Huynh, A., Santarone, S., Deconinck, E., Mohty, M., Nagler, A., 2018. **Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.** *Haematologica.* <https://doi.org/10.3324/haematol.2018.189258>
478. Samur, M.K., Minvielle, S., Gulla, A., Fulciniti, M., Cleynen, A., Aktas Samur, A., Szalat, R., Shammas, M., Magrangeas, F., Tai, Y.-T., Auclair, D., Keats, J., Richardson, P., Attal, M., Moreau, P., Anderson, K.C., Parmigiani, G., Avet-Loiseau, H., Munshi, N.C., 2018. **Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.** *Leukemia.* <https://doi.org/10.1038/s41375-018-0116-y>
479. Santoro, L., Mora-Ramirez, E., Trauchessec, D., Chouaf, S., Eustache, P., Pouget, J.-P., Kotzki, P.-O., Bardès, M., Deshayes, E., 2018. **Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-DOTA0, Tyr3]-octreotate.** *EJNMMI Res* 8, 103. <https://doi.org/10.1186/s13550-018-0459-4>
480. Sarda, S., Iafisco, M., Pascaud-Mathieu, P., Adamiano, A., Montesi, M., Panseri, S., Marsan, O., Thouron, C., Dupret-Bories, A., Tampieri, A., Drouet, C., 2018. **Interaction of folic acid with nanocrystalline apatites and extension to methotrexate (antifolate) in view of anticancer applications.** *Langmuir.* <https://doi.org/10.1021/acs.langmuir.8b02602>
481. Sargos, P., Charleux, T., Haas, R.L., Michot, A., Llacer, C., Moureau-Zabotto, L., Vogin, G., Le Péchoux, C., Verry, C., Ducassou, A., Delannes, M., Mervoyer, A., Wiazane, N., Thariat, J., Sunyach, M.P., Benchalal, M., Laredo, J.D., Kind, M., Gillon, P., Kantor, G., 2018. **Pre- and postoperative radiotherapy for extremity soft tissue sarcoma: Evaluation of inter-observer target volume contouring variability among French sarcoma group radiation oncologists.** *Cancer Radiother* 22, 131–139. <https://doi.org/10.1016/j.canrad.2017.09.004>
482. Sarkozy, C., Copie-Bergmand, C., Damotte, D., Ben-Neriah, S., Burrioni, B., Cornillon, J., Lemal, R., Golfier, C., Fabiani, B., Chassagne-Clément, C., Parrens, M., Herbaux, C., Xerri, L., Bossard, C., Laurent, C., Cheminant, M., Cartron, G., Cabecadas, J., Molina, T., Salles, G., Steidl, C., Ghesquières, H., Mottok, A., Traverse-Glehen, A., 2018. **Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.** *Am. J. Surg. Pathol.* <https://doi.org/10.1097/PAS.0000000000001198>
483. Sarradin, V., Dalenc, F., Sibaud, V., Tournier, E., Roché, H., 2018a. **Acute Generalized Exanthematous Pustulosis Induced by Docetaxel and Recurrent With Letrozole: A Case Report.** *Clin. Breast Cancer.* <https://doi.org/10.1016/j.clbc.2018.06.009>
484. Sarradin, V., Siegfried, A., Uro-Coste, E., Delord, J.-P., 2018b. **[WHO classification of head and neck tumours 2017: Main novelties and update of diagnostic**

- methods]. Bull Cancer 105, 596–602. <https://doi.org/10.1016/j.bulcan.2018.04.004>
485. Sarradin, V., Simon, L., Huynh, A., Gilhodes, J., Filleron, T., Izar, F., 2018. **Total body irradiation using Helical Tomotherapy®: Treatment technique, dosimetric results and initial clinical experience.** Cancer Radiother 22, 17–24. <https://doi.org/10.1016/j.canrad.2017.06.014>
486. Saussele, S., Richter, J., Guilhot, J., Gruber, F.X., Hjorth-Hansen, H., Almeida, A., Janssen, J.J.W.M., Mayer, J., Koskenvesa, P., Panayiotidis, P., Olsson-Strömberg, U., Martinez-Lopez, J., Rousselot, P., Vestergaard, H., Ehrencrona, H., Kairisto, V., Machová Poláková, K., Müller, M.C., Mustjoki, S., Berger, M.G., Fabarius, A., Hofmann, W.-K., Hochhaus, A., Pfirmann, M., Mahon, F.-X., EURO-SKI investigators [collab : [Huguet, F.](https://doi.org/10.1016/j.ejmg.2018.08.003)], 2018. **Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.** Lancet Oncol. 19, 747–757. [https://doi.org/10.1016/S1470-2045\(18\)30192-X](https://doi.org/10.1016/S1470-2045(18)30192-X)
487. Scherer, E.E., Iriart, X., Bellanger, A.P., Dupont, D., Guitard, J., Gabriel, F., Cassaing, S., Charpentier, E., Guenounou, S., Cornet, M., Botterel, F., Rocchi, S., Berceanu, A., Millon, L., 2018. **QPCR detection of Mucorales DNA in bronchoalveolar lavage fluid to diagnose pulmonary mucormycosis.** J. Clin. Microbiol. <https://doi.org/10.1128/JCM.00289-18>
488. Schlumberger, M., Leboulleux, S., Catargi, B., Deandreis, D., [Zerdoud, S.](https://doi.org/10.1016/S2213-8587(18)30113-X), Bardet, S., Rusu, D., Godbert, Y., Buffet, C., Schwartz, C., Vera, P., Morel, O., Benisvy, D., Bournaud, C., Toubert, M.-E., Kelly, A., Benhamou, E., Borget, I., 2018. **Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.** Lancet Diabetes Endocrinol. [https://doi.org/10.1016/S2213-8587\(18\)30113-X](https://doi.org/10.1016/S2213-8587(18)30113-X)
489. Schultz, P., [Dupret-Bories, A.](https://doi.org/10.1016/j.anorl.2018.01.003), Ciftci, S., Fath, L., 2018. **Hypopharyngeal reconstruction using a circular stapler.** Eur Ann Otorhinolaryngol Head Neck Dis. <https://doi.org/10.1016/j.anorl.2018.01.003>
490. Seigneurin, A., Delafosse, P., Trétarre, B., Woronoff, A.S., Velten, M., [Grosclaude, P.](https://doi.org/10.1186/s12885-018-5000-7), Guizard, A.V., Lapôtre-Ledoux, B., Bara, S., Molinié, F., Colonna, M., 2018. **Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries.** BMC Cancer 18, 1091. <https://doi.org/10.1186/s12885-018-5000-7>
491. [Selves, J.](https://doi.org/10.1016/j.annpat.2018.04.012), 2018a. [Carcinoma of unknown primary. Case no. 3]. Ann Pathol. <https://doi.org/10.1016/j.annpat.2018.04.012>
492. [Selves, J.](https://doi.org/10.1016/j.annpat.2018.04.013), 2018b. [Carcinoma of unknown primary. Case no. 4]. Ann Pathol. <https://doi.org/10.1016/j.annpat.2018.04.013>
493. [Selves, J.](https://doi.org/10.3390/cancers10040108), Long-Mira, E., Mathieu, M.-C., [Rochaix, P.](https://doi.org/10.1016/j.annpat.2018.04.008), Ilié, M., 2018a. **Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site.** Cancers (Basel) 10. <https://doi.org/10.3390/cancers10040108>
494. [Selves, J.](https://doi.org/10.1016/j.annpat.2018.04.008), Long-Mira, E., Mathieu, M.-C., [Rochaix, P.](https://doi.org/10.1016/j.annpat.2018.04.008), Ilié, M., 2018b. [Carcinoma of unknown primary. Role of the pathologist in 2018: Introduction]. Ann Pathol. <https://doi.org/10.1016/j.annpat.2018.04.008>
495. [Selves, J.](https://doi.org/10.1016/j.annpat.2018.04.007), Terris, B., Cazals-Hatem, D., Fléjou, J.-F., 2018c. [Guidelines for the management of malignant colo-rectal polyps (pTis and pT1) treated by endoscopic resection]. Ann Pathol 38, 331–337. <https://doi.org/10.1016/j.annpat.2018.04.007>
496. Severino-Freire, M., Maza, A., Kuentz, P., Duffourd, Y., Faivre, L., Brazet, E., Chassaing, N., [Mery-Lemarche, E.](https://doi.org/10.1016/j.ejmg.2018.08.003), Vabres, P., Mazereeuw-Hautier, J., 2018. **Severe gynaecological involvement in Proteus Syndrome.** Eur J Med Genet. <https://doi.org/10.1016/j.ejmg.2018.08.003>
497. [Sibaud, V.](https://doi.org/10.1007/s40257-017-0336-3), 2018a. **Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy.** Am J Clin Dermatol 19, 345–361. <https://doi.org/10.1007/s40257-017-0336-3>
498. [Sibaud, V.](https://doi.org/10.1016/j.annder.2018.01.047), 2018b. [Dermatologic toxicities of systemic anticancer treatments]. Rev Prat 68, 1051–1056.
499. [Sibaud, V.](https://doi.org/10.1016/j.annpat.2018.04.012), Boulinguez, S., Pagès, C., Riffaud, L., Lamant, L., Chira, C., Boyrie, S., Vigarios, E., Tournier, E., Meyer, N., 2018. [Dermatologic toxicities of immune checkpoint inhibitors]. Ann Dermatol Venereol. <https://doi.org/10.1016/j.annpat.2018.04.012>
500. [Siegfried, A.](https://doi.org/10.1016/j.neuchi.2017.12.006), Delisle, M.-B., 2018. [Medulloblastoma. Pathology]. Neurochirurgie. <https://doi.org/10.1016/j.neuchi.2017.12.006>
501. [Siegfried, A.](https://doi.org/10.1002/gcc.22521), Romary, C., Escudie, F., Nicaise, Y., Grand, D., [Rochaix, P.](https://doi.org/10.1016/j.annpat.2018.04.012), Barres, B., [Vergez, S.](https://doi.org/10.1016/j.annpat.2018.04.012), [Chevreau, C.](https://doi.org/10.1016/j.annpat.2018.04.012), Coindre, J.-M., [Uro-Coste, E.](https://doi.org/10.1111/bpa.12619), [Le Guellec, S.](https://doi.org/10.1111/bpa.12619), 2018a. **RREB1-MKL2 fusion in biphenotypic “oropharyngeal” sarcoma: New entity or part of the spectrum of biphenotypic sinonasal sarcomas?** Genes Chromosomes Cancer 57, 203–210. <https://doi.org/10.1002/gcc.22521>
502. [Siegfried, A.](https://doi.org/10.1111/bpa.12619), Rousseau, A., Maurage, C.-A., [Pericart, S.](https://doi.org/10.1111/bpa.12619), Nicaise, Y., Escudie, F., Grand, D., [Delrieu, A.](https://doi.org/10.1111/bpa.12619), [Gomez-Brouchet, A.](https://doi.org/10.1111/bpa.12619), [Le Guellec, S.](https://doi.org/10.1111/bpa.12619), [Franchet, C.](https://doi.org/10.1111/bpa.12619), Boetto, S., Vinchon, M., Sol, J.-C., Roux, F.-E., Rigau, V., Bertozzi, A.-I., Jones, D.T., Figarella-Branger, D., [Uro-Coste, E.](https://doi.org/10.1111/bpa.12619), 2018b. **EWSR1-PATZ1 gene fusion may define a new glioneuronal tumor entity.** Brain Pathol. <https://doi.org/10.1111/bpa.12619>
503. [Silvente-Poirot, S.](https://doi.org/10.1158/0008-5472.CAN-18-1487), Dalenc, F., Poirot, M., 2018a. **The Effects of Cholesterol-Derived Oncometabolites on Nuclear Receptor Function in Cancer.** Cancer Res. <https://doi.org/10.1158/0008-5472.CAN-18-1487>
504. [Silvente-Poirot, S.](https://doi.org/10.1080/15548627.2018.1425059), Segala, G., Poirot, M.C., Poirot, M., 2018b. **Ligand-dependent transcriptional induction of lethal autophagy: A new perspective for cancer treatment.** Autophagy 14, 555–557. <https://doi.org/10.1080/15548627.2018.1425059>
505. Siu, L.L., Even, C., Mesía, R., Remenar, E., Daste, A., [Delord, J.-P.](https://doi.org/10.1016/j.annpat.2018.04.012), Krauss, J., Saba, N.F., Nabell, L., Ready, N.E., Braña, I., Kotecki, N., Zandberg, D.P., Gilbert, J.,

- Mehanna, H., Bonomi, M., Jarkowski, A., Melillo, G., Armstrong, J.M., Wildsmith, S., Fayette, J., 2018. **Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.** *JAMA Oncol.* <https://doi.org/10.1001/jamaoncol.2018.4628>
506. Sixou, S., Müller, K., Jalaguier, S., Kuhn, C., Harbeck, N., Mayr, D., Engel, J., Jeschke, U., Ditsch, N., Cavallès, V., 2018. **Importance of RIP140 and LCoR Sub-Cellular Localization for Their Association With Breast Cancer Aggressiveness and Patient Survival.** *Transl Oncol* 11, 1090–1096. <https://doi.org/10.1016/j.tranon.2018.06.006>
507. Skálová, A., Vanecek, T., Uro-Coste, E., Bishop, J.A., Weinreb, I., Thompson, L.D.R., de Sanctis, S., Schiavo-Lena, M., Laco, J., Badoual, C., Santana Conceição, T., Ptáková, N., Baněčková, M., Miesbauerová, M., Michal, M., 2018. **Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions: A Report of 17 cases.** *Am. J. Surg. Pathol.* 42, 1445–1455. <https://doi.org/10.1097/PAS.0000000000001133>
508. Socinski, M.A., Jotte, R.M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C.A., Barlesi, F., Finley, G., Kelsch, C., Lee, A., Coleman, S., Deng, Y., Shen, Y., Kowanetz, M., Lopez-Chavez, A., Sandler, A., Reck, M., IMpower150 Study Group [collab : Mazières, J.], 2018. **Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.** *N. Engl. J. Med.* 378, 2288–2301. <https://doi.org/10.1056/NEJMoa1716948>
509. Solassol, J., Quantin, X., Larrieux, M., Senal, R., Audran, P., Grand, D., Mangé, A., Diamandis, E.P., Vendrell, J.A., 2018. **Comparison of five cell-free DNA isolation methods to detect the EGFR T790M mutation in plasma samples of patients with lung cancer.** *Clin. Chem. Lab. Med.* <https://doi.org/10.1515/cclm-2017-0967>
510. Somasundar, P., Mourey, L., Lozza, L., Maggi, S., Stepney, R., 2018. **Advances in geriatric oncology: a multidisciplinary perspective.** *Tumori* 104, 252–257. <https://doi.org/10.5301/tj.5000661>
511. Spencer, A., Lentzsch, S., Weisel, K., Avet-Loiseau, H., Mark, T.M., Spicka, I., Masszi, T., Lauri, B., Levin, M.-D., Bosi, A., Hungria, V., Cavo, M., Lee, J.-J., Nooka, A.K., Quach, H., Lee, C., Barreto, W., Corradini, P., Min, C.-K., Scott, E.C., Chanan-Khan, A.A., Horvath, N., Capra, M., Beksac, M., Ovilla, R., Jo, J.-C., Shin, H.-J., Sonneveld, P., Soong, D., Casneuf, T., Chiu, C., Amin, H., Qi, M., Thiagarajah, P., Sasser, A.K., Schecter, J.M., Mateos, M.-V., 2018. **Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.** *Haematologica.* <https://doi.org/10.3324/haematol.2018.194118>
512. Stuani, L., Riols, F., Millard, P., Sabatier, M., Batut, A., Saland, E., Viars, F., Tonini, L., Zaghoudi, S., Linares, L.K., Portais, J.-C., Sarry, J.-E., Bertrand-Michel, J., 2018. **Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia.** *Int J Mol Sci* 19. <https://doi.org/10.3390/ijms19113325>
513. Szalat, R., Samur, M.K., Fulciniti, M., Lopez, M., Nanjappa, P., Cleyne, A., Wen, K., Kumar, S., Perini, T., Calkins, A.S., Reznichenko, E., Chauhan, D., Tai, Y.-T., Shammass, M.A., Anderson, K.C., Femand, J.-P., Arnulf, B., Avet-Loiseau, H., Lazaro, J.-B., Munshi, N.C., 2018. **Nucleotide excision repair is a potential therapeutic target in multiple myeloma.** *Leukemia* 32, 111–119. <https://doi.org/10.1038/leu.2017.182>
514. Taïeb, D., Foletti, J.-M., Bardières, M., Rocchi, P., Hicks, R., Haberkorn, U., 2018. **PSMA-Targeted Radionuclide Therapy and salivary gland toxicity: why does it matter?** *J. Nucl. Med.* <https://doi.org/10.2967/jnumed.118.207993>
515. Talbot, A., Royer, B., Roussel, M., 2018. **[Multiple myeloma treatment].** *Rev Prat* 68, 787–791.
516. Tallegas, M., Miquelstarena-Standley, É., Labit-Bouvier, C., Badoual, C., Francois, A., Gomez-Brouchet, A., Aubert, S., Collin, C., Tallet, A., de Pinieux, G., 2018. **IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the Skull Base and tumors involving the facial skeleton and the Layngotracheal tract.** *Hum. Pathol.* <https://doi.org/10.1016/j.humpath.2018.09.015>
517. Tao, Y., Faivre, L., Laprie, A., Boisselier, P., Ferron, C., Jung, G.M., Racadot, S., Gery, B., Even, C., Breuskin, I., Bourhis, J., Janot, F., 2018. **Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.** *Radiother Oncol.* <https://doi.org/10.1016/j.radonc.2018.05.005>
518. Tensaouti, F., Ducassou, A., Chaltiel, L., Sevely, A., Bolle, S., Padovani, L., Jouin, A., Alapetite, C., Supiot, S., Huchet, A., Bernier, V., Claude, L., Kerr, C., Le Prisé, E., Bertozzi-Salamon, A.-I., Liceaga, S., Lotterrie, J.A., Péran, P., Laprie, A., French Society for Childhood Cancer (SFCE), 2018. **Imaging biomarkers of outcome after radiotherapy for pediatric ependymoma.** *Radiother Oncol* 127, 103–107. <https://doi.org/10.1016/j.radonc.2018.02.008>
519. Territo, A., Gausa, L., Alcaraz, A., Musquera, M., Doumerc, N., Decaestecker, K., Desender, L., Stockle, M., Janssen, M., Fornara, P., Mohammed, N., Siena, G., Serni, S., Sahin, S., Tuğcu, V., Basile, G., Breda, A., 2018. **The European experience on robot-assisted kidney transplantation: minimum of one-year follow-up.** *BJU Int.* <https://doi.org/10.1111/bju.14247>
520. Terry, M.B., Liao, Y., Kast, K., Antoniou, A.C., McDonald, J.A., Mooij, T.M., Engel, C., Nogues, C., Buecher, B., Mari, V., Moretta-Serra, J., Gladieff, L., Luporsi, E., Barrowdale, D., Frost, D., Henderson, A., Brewer, C., Evans, D.G.,

- Eccles, D., Cook, J., Ong, K.-R., Izatt, L., Ahmed, M., Morrison, P.J., Dommering, C.J., Oosterwijk, J.C., Ausems, M.G.E.M., Kriege, M., Buys, S.S., Andrulis, I.L., John, E.M., Daly, M., Friedlander, M., McLachlan, S.A., Osorio, A., Caldes, T., Jakubowska, A., Simard, J., Singer, C.F., Tan, Y., Olah, E., Navratilova, M., Foretova, L., Gerdes, A.-M., Roos-Blom, M.-J., Arver, B., Olsson, H., Schmutzler, R.K., Hopper, J.L., van Leeuwen, F.E., Goldgar, D., Milne, R.L., Easton, D.F., Rookus, M.A., Andrieu, N., EMBRACE, GENEPSO, BCFR, HEBON, kConFab and IBCCS, 2018. **The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations.** *JNCI Cancer Spectr* 2, pky078. <https://doi.org/10.1093/jncics/pky078>
521. Tétu, P., Mangana, J., Dummer, R., Dutriaux, C., Beneton, N., Dalle, S., Meyer, N., Oriano, B., Michielin, O., Lebbe, C., 2018. **Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.** *Eur. J. Cancer* 93, 147–149. <https://doi.org/10.1016/j.ejca.2018.01.062>
522. Thévenin-Lemoine, C., Destombes, L., Vial, J., Wargny, M., Bonnevalle, P., Lefevre, Y., Gomez Brouchet, A., Sales de Gauzy, J., 2018. **Planning for Bone Excision in Ewing Sarcoma: Post-Chemotherapy MRI More Accurate Than Pre-Chemotherapy MRI Assessment.** *J Bone Joint Surg Am* 100, 13–20. <https://doi.org/10.2106/JBJS.16.01461>
523. Thibault, B., Genre, L., Le Naour, A., Broca, C., Mery, E., Vuagniaux, G., Delord, J.P., Wiedemann, N., Couderc, B., 2018. **DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death.** *Sci Rep* 8, 17862. <https://doi.org/10.1038/s41598-018-35860-z>
524. Thomas, F., Veal, G.J., El Balkhi, S., Lafont, T., Picard, N., Brugières, L., Chatelut, E., Pigué, C., 2018. **Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report.** *Cancer Chemother. Pharmacol.* <https://doi.org/10.1007/s00280-018-3625-5>
525. Thouvenin-Doulet, S., Berger, C., Casagrande, L., Oberlin, O., Marec-Berard, P., Pacquement, H., Guibout, C., Freycon, C., N'Guyen, T.D., Bondiau, P.-Y., Laprie, A., Berchery, D., El-Fayech, C., Trombert-Paviot, B., de Vathaire, F., 2018. **Fecundity and Quality of Life of Women Treated for Solid Childhood Tumors Between 1948 and 1992 in France.** *J Adolesc Young Adult Oncol.* <https://doi.org/10.1089/jayao.2017.0126>
526. Tichauer, R.H., Favre, G., Cabantous, S., Landa, G., Hemeryck, A., Brut, M., 2018. **Water Distribution within Wild-Type NRas Protein and Q61 Mutants during Unrestrained QM/MM Dynamics.** *Biophys. J.* 115, 1417–1430. <https://doi.org/10.1016/j.bpj.2018.07.042>
527. Timbergen, M.J.M., Janssen, M.L., Verhoef, C., Grünhagen, D.J., Chibon, F., Smid, M., Sleijfer, S., Wiemer, E.A.C., 2018. **Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β -catenin mutations.** *Eur J Surg Oncol.* <https://doi.org/10.1016/j.ejso.2018.09.019>
528. Tordo, J., O'Leary, C., Antunes, A.S.L.M., Palomar, N., Aldrin-Kirk, P., Basche, M., Bennett, A., D'Souza, Z., Gleitz, H., Godwin, A., Holley, R.J., Parker, H., Liao, A.Y., Rouse, P., Youshani, A.S., Dridi, L., Martins, C., Levede, T., Stacey, K.B., Davis, D.M., Dyer, A., Clément, N., Björklund, T., Ali, R.R., Agbandje-McKenna, M., Rahim, A.A., Pshezhetsky, A., Waddington, S.N., Linden, R.M., Bigger, B.W., Henckaerts, E., 2018. **A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency.** *Brain.* <https://doi.org/10.1093/brain/awy126>
529. Toren, P., Hoffman, A., Ding, K., Joncas, F.-H., Turcotte, V., Caron, P., Pouliot, F., Fradet, Y., Lévesque, É., Guillemette, C., Klotz, L., 2018. **Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial.** *Clin. Cancer Res.* 24, 5305–5312. <https://doi.org/10.1158/1078-0432.CCR-18-1187>
530. Toucheffeu, Y., Guimbaud, R., Louvet, C., Dahan, L., Samalin, E., Barbier, E., Le Malicot, K., Cohen, R., Gornet, J.M., Aparicio, T., Nguyen, S., Azzedine, A., Etienne, P.L., Phelip, J.M., Hammel, P., Chapelle, N., Sefrioui, D., Mineur, L., Lepage, C., Bouche, O., 2018. **Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.** *Gastric Cancer.* <https://doi.org/10.1007/s10120-018-0885-z>
531. Toulmonde, M., Penel, N., Adam, J., Chevreau, C., Blay, J.-Y., Le Cesne, A., Bompas, E., Piperno-Neumann, S., Cousin, S., Grellety, T., Ryckewaert, T., Bessedé, A., Ghiringhelli, F., Pulido, M., Italiano, A., 2018. **Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.** *JAMA Oncol* 4, 93–97. <https://doi.org/10.1001/jamaoncol.2017.1617>
532. Trouillet, J.L., Collange, O., Belafia, F., Blot, F., Capellier, G., Cesareo, E., Constantin, J.-M., Demoule, A., Diehl, J.-L., Guinot, P.-G., Jegoux, F., L'Her, E., Luyt, C.-E., Mahjoub, Y., Mayaux, J., Quintard, H., Ravat, F., Vergez, S., Amour, J., Guillot, M., 2018. **Tracheotomy in the intensive care unit: guidelines from a French expert panel.** *Ann Intensive Care* 8, 37. <https://doi.org/10.1186/s13613-018-0381-y>
533. Trouillet, J.-L., Collange, O., Belafia, F., Blot, F., Capellier, G., Cesareo, E., Constantin, J.-M., Demoule, A., Diehl, J.-L., Guinot, P.-G., Jegoux, F., L'Her, E., Luyt, C.-E., Mahjoub, Y., Mayaux, J., Quintard, H., Ravat, F., Vergez, S., Amour, J., Guillot, M., Collange, O., 2018. **Tracheotomy in the intensive care unit: Guidelines from a French expert panel: The French Intensive Care Society and the French Society of Anaesthesia and Intensive Care Medicine.** *Anaesthesia Critical Care &*

534. Tsaour, I., Borgmann, H., Surcel, C.I., Ost, P., Ploussard, G., 2018a. **AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?** World J Urol 36, 149–151. <https://doi.org/10.1007/s00345-017-2107-4>
535. Tsaour, I., Borgmann, H., Surcel, C.I., Ost, P., Ploussard, G., 2018b. **AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked?** World J Urol 36, 149–151. <https://doi.org/10.1007/s00345-017-2107-4>
536. Tsaour, I., Heidegger, I., Kretschmer, A., Borgmann, H., Mirvald, C., Gandaglia, G., Briganti, A., van den Bergh, R., Tilki, D., Ost, P., Ploussard, G., Surcel, C., EAU-YAU Prostate Cancer Working Party, 2018c. **Combining anticancer drugs with osteoprotective agents in prostate cancer-A contemporary update.** Urol. Oncol. <https://doi.org/10.1016/j.urolonc.2018.08.016>
537. Ulrich, B.C., Guibert, N., 2018. **Immunotherapy efficacy and gender: discovery in precision medicine.** Transl Lung Cancer Res 7, S211–S213. <https://doi.org/10.21037/tlcr.2018.08.05>
538. Uro-Coste, E., 2018a. [ENT benign lesions and pseudo-tumors: Case No. 5]. Ann Pathol. <https://doi.org/10.1016/j.annpat.2018.07.010>
539. Uro-Coste, E., 2018b. [ENT benign lesions and pseudo-tumors: Case No. 6]. Ann Pathol. <https://doi.org/10.1016/j.annpat.2018.07.011>
540. Uro-Coste, E., Masliah-Planchon, J., Siegfried, A., Blanluet, M., Lambo, S., Kool, M., Roujeau, T., Boetto, S., Palenzuela, G., Bertozzi, A.-I., Gambart, M., Coupier, I., Oliver-Petit, I., Golmard, L., Julia, S., Savagner, F., Mohand-Oumoussa, B., Tauziède-Espariat, A., Delisle, M.-B., Figarella-Branger, D., Bourdeaut, F., Rigau, V., 2018. **ETMR-like infantile cerebellar embryonal tumors in the extended morphologic spectrum of DICER1-related tumors.** Acta Neuropathol. <https://doi.org/10.1007/s00401-018-1935-7>
541. Usmani, S.Z., Hoering, A., Cavo, M., Miguel, J.S., Goldschmidt, H., Hajek, R., Turesson, I., Lahuerta, J.J., Attal, M., Barlogie, B., Lee, J.H., Kumar, S., Lenhoff, S., Morgan, G., Rajkumar, S.V., Durie, B.G.M., Moreau, P., 2018. **Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.** Blood Cancer J 8, 123. <https://doi.org/10.1038/s41408-018-0155-7>
542. Valentin, T., Lesluyes, T., Le Guellec, S., Chibon, F., 2018. **Chemotherapy in localized Soft Tissue Sarcoma: will we soon have to treat grade 1 tumours? Update on CINSARC performances.** Ann. Oncol. <https://doi.org/10.1093/annonc/mdy465>
543. van den Bergh, R.C.N., Ost, P., Surcel, C., Valerio, M., Fütterer, J.J., Gandaglia, G., Sooriakumaran, P., Tilki, D., Tsaour, I., Ploussard, G., European Association of Urology Working Party on Prostate Cancer (EAU-YAUWP), 2018. **Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urology.** World J Urol. <https://doi.org/10.1007/s00345-018-2278-7>
544. Vande Perre, P., Siegfried, A., Corsini, C., Bonnet, D., Toulas, C., Hamzaoui, N., Selves, J., Chipoulet, E., Hoffmann, J.S., Uro-Coste, E., Guimbaud, R., 2018. **Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma.** Fam. Cancer. <https://doi.org/10.1007/s10689-018-0102-6>
545. Vaysse, C., Chantalat, E., Beyne-Rauzy, O., Morineau, L., Despas, F., Bachaud, J.-M., Caunes, N., Poublic, M., Serrano, E., Bugat, R., Rougé Bugat, M.-E., Fize, A.-L., 2018. **The Impact of a Small Private Online Course as a New Approach to Teaching Oncology: Development and Evaluation.** JMIR Med Educ 4, e6. <https://doi.org/10.2196/mededu.9185>
546. Verger, D., Boissières, I., 2018. [Leadership influence on safety in cancer care]. Bull Cancer. <https://doi.org/10.1016/j.bulcan.2018.04.009>
547. Vergnolle, I., Sigur, N., Corre, J., 2018. **IgG lymphoplasmacytic lymphoma: a case report.** Ann. Biol. Clin. (Paris) 76, 665–668. <https://doi.org/10.1684/abc.2018.1384>
548. Verine, J., Colin, D., Nheb, M., Prapotnich, D., Ploussard, G., Cathelineau, X., Desgrandchamps, F., Mongiat-Artus, P., Feugeas, J.-P., 2018. **Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment: Comparisons With WHO/ISUP Grade and Integrated Staging Systems.** Am. J. Surg. Pathol. 42, 423–441. <https://doi.org/10.1097/PAS.0000000000001025>
549. Vezzosi, D., Do Cao, C., Hescot, S., Bertherat, J., Haissaguerre, M., Bongard, V., Druil, D., De La Fouchardière, C., Illouz, F., Borson-Chazot, F., Djobo, B., Berdelou, A., Tabarin, A., Schlumberger, M., Briet, C., Caron, P., Leboulleux, S., Libe, R., Baudin, E., For Comete-Cancer Network, 2018. **Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors.** Horm Cancer 9, 62–69. <https://doi.org/10.1007/s12672-017-0313-6>
550. Vigaros, E., Beylot-Barry, M., Jegou, M.-H., Oberic, L., Ysebaert, L., Sibaud, V., 2018. **Dose-limiting stomatitis associated with ibrutinib therapy: a case series.** Br. J. Haematol. <https://doi.org/10.1111/bjh.15620>
551. Vija Racaru, L., Sinigaglia, M., Kanoun, S., Ben Bouallègue, F., Tal, I., Brillouet, S., Bauriaud-Mallet, M., Zerdoud, S., Dierickx, L., Vallot, D., Caselles, O., Gabiache, E., Pascal, P., Courbon, F., 2018. **Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.** Nucl Med Commun. <https://doi.org/10.1097/MNM.0000000000000850>
552. Villagrana, C., Bordage, M.-C., Bueno, M., Bug, M., Chirioti, S., Gargioni, E., Heide, B., Nettelbeck, H., Parisi, A., Rabus, H., 2018. **Assessing the contribution of cross-**

- sections to the uncertainty of monte carlo calculations in micro- and nanodosimetry. *Radiat Prot Dosimetry*. <https://doi.org/10.1093/rpd/ncy240>
553. Villaret, J., Marti, G., Dubois, F., Reybier, K., Gaudre, N., Haddad, M., Valentin, A., 2018. **Adaptation of a microbead assay for the easy evaluation of traditional anti-sickling medicines: application to DREPANOSTAT and FACA.** *Pharm Biol* 56, 385–392. <https://doi.org/10.1080/13880209.2018.1501585>
554. Villepelet, A., Lefèvre, M., Verillaud, B., Janot, F., Garrel, R., Vergez, S., Bertolus, C., Malard, O., de Gabory, L., Mauvais, O., Baujat, B., REFCOR members, 2018. **Salivary duct carcinoma: A prospective multicenter study of 61 cases of the Réseau d'Expertise Français des Cancers ORL Rares.** *Head Neck*. <https://doi.org/10.1002/hed.25194>
555. Vinault, S., Mariet, A.-S., Le Bras, M., Mirallié, E., Cardot-Bauters, C., Pattou, F., Ruszniewski, P., Sauvanet, A., Chanson, P., Baudin, E., Elias, D., Menegaux, F., Gaujoux, S., Borson-Chazot, F., Lifante, J.-C., Caron, P., Carrère, N., Tabarin, A., Laurent, C., Klein, M., Brunaud, L., Niccoli, P., Sebag, F., Cadiot, G., Kianmanesh, R., Luu, M., Binquet, C., Goudet, P., 2018. **Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study (Groupe d'étude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne).** *Ann. Surg.* <https://doi.org/10.1097/SLA.0000000000003162>
556. Vitellius, G., Trabado, S., Hoeffel, C., Bouligand, J., Bennet, A., Castinetti, F., Decoudier, B., Guiochon-Mantel, A., Lombes, M., Delemer, B., investigators of the MUTA-GR Study [collab : Caron, P.], 2018. **Significant prevalence of NR3C1 mutations in incidentally discovered bilateral adrenal hyperplasia: results of the French MUTA-GR Study.** *Eur. J. Endocrinol.* 178, 411–423. <https://doi.org/10.1530/EJE-17-1071>
557. Walker, B.A., Mavrommatis, K., Wardell, C.P., Ashby, T.C., Bauer, M., Davies, F., Rosenthal, A., Wang, H., Qu, P., Hoering, A., Samur, M., Towfic, F., Ortiz, M., Flynt, E., Yu, Z., Yang, Z., Rozelle, D., Obenauer, J., Trotter, M., Auclair, D., Keats, J., Bolli, N., Fulciniti, M., Szalat, R., Moreau, P., Durie, B., Stewart, A.K., Goldschmidt, H., Raab, M.S., Einsele, H., Sonneveld, P., San Miguel, J., Lonial, S., Jackson, G.H., Anderson, K.C., Avet-Loiseau, H., Munshi, N., Thakurta, A., Morgan, G., 2018a. **A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.** *Leukemia*. <https://doi.org/10.1038/s41375-018-0196-8>
558. Walker, B.A., Mavrommatis, K., Wardell, C.P., Ashby, T.C., Bauer, M., Davies, F.E., Rosenthal, A., Wang, H., Qu, P., Hoering, A., Samur, M., Towfic, F., Ortiz, M., Flynt, E., Yu, Z., Yang, Z., Rozelle, D., Obenauer, J., Trotter, M., Auclair, D., Keats, J., Bolli, N., Fulciniti, M., Szalat, R., Moreau, P., Durie, B., Stewart, A.K., Goldschmidt, H., Raab, M.S., Einsele, H., Sonneveld, P., San Miguel, J., Lonial, S., Jackson, G.H., Anderson, K.C., Avet-Loiseau, H., Munshi, N., Thakurta, A., Morgan, G.J., 2018b. **Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.** *Blood*. <https://doi.org/10.1182/blood-2018-03-840132>
559. Wendum, D., Layese, R., Ganne-Carrié, N., Bourcier, V., Merabtene, F., Cagnot, C., Sauce, E., Bedossa, P., Terris, B., Selves, J., Bioulac-Sage, P., Sturm, N., Sattounet, C., Nahon, P., Roudot-Thoraval, F., Ziol, M., ANRS CO 12 CirVir group, 2018. **Influence of progenitor-derived regeneration markers on HCV-related cirrhosis outcome (ANRS CO12 CirVir cohort).** *Hepatology*. <https://doi.org/10.1002/hep.29927>
560. White-Koning, M., Osborne, C., Paci, A., Boddy, A.V., Chatelut, E., Veal, G.J., 2018. Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence. *Eur. J. Cancer* 91, 56–67. <https://doi.org/10.1016/j.ejca.2017.11.029>
561. Wojtuszczyz, A., Branchereau, J., Esposito, L., Badet, L., Buron, F., Chetboun, M., Kessler, L., Morelon, E., Berney, T., Pattou, F., Benhamou, P.-Y., Vantuyghem, M.-C., TREPID group [collab : Muscari, E.], 2018. Indications for islet or pancreatic transplantation: Statement of the TREPID working group on behalf of the Société francophone du diabète (SFD), Société française d'endocrinologie (SFE), Société francophone de transplantation (SFT) and Société française de néphrologie - dialyse - transplantation (SFNDT). *Diabetes Metab.* <https://doi.org/10.1016/j.diabet.2018.07.006>
562. Wu, X., Kabalane, H., Kahli, M., Petryk, N., Laperrousaz, B., Jaszczyszyn, Y., Drillon, G., Nicolini, F.-E., Perot, G., Robert, A., Fund, C., Chibon, F., Xia, R., Wiels, J., Argoul, F., Maguer-Satta, V., Arneodo, A., Audit, B., Hyrien, O., 2018. **Developmental and cancer-associated plasticity of DNA replication preferentially targets GC-poor, lowly expressed and late-replicating regions.** *Nucleic Acids Res.* <https://doi.org/10.1093/nar/gky849>
563. Xerri, L., Adélaïde, J., Popovici, C., Garnier, S., Guille, A., Mescam-Mancini, L., Laurent, C., Brousset, P., Coze, C., Michel, G., Chaffanet, M., Bouabdallah, R., Coso, D., Bertucci, F., Birnbaum, D., 2018. **CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors.** *Am. J. Surg. Pathol.* 42, 150–159. <https://doi.org/10.1097/PAS.0000000000000989>
564. Young, J., Bertherat, J., Vantuyghem, M.C., Chabre, O., Senoussi, S., Chadarevian, R., Castinetti, F., Compassionate use Programme [collab : Vezzosi, D.], 2018. **Hepatic safety of ketoconazole in Cushing's syndrome: results of a Compassionate Use Programme in France.** *Eur. J. Endocrinol.* 178, 447–458. <https://doi.org/10.1530/EJE-17-0886>
565. Yu, F.P.S., Amintas, S., Levade, I., Medin, J.A., 2018a. **Acid ceramidase deficiency: Farber disease and SMA-PME.** *Orphanet J Rare Dis* 13, 121. <https://doi.org/10.1186/s13023-018-0845-z>

566. Yu, F.P.S., Islam, D., Sikora, J., Dworski, S., Gurka, J., López-Vásquez, L., Liu, M., Kuebler, W.M., Levade, T., Zhang, H., Medin, J.A., 2018b. **Chronic lung injury and impaired pulmonary function in a mouse model of acid ceramidase deficiency.** *Am. J. Physiol. Lung Cell Mol. Physiol.* 314, L406–L420. <https://doi.org/10.1152/ajplung.00223.2017>
567. Zenagui, R., Lacourt, D., Pegeot, H., Yaou, K., Morales, R.J., Theze, C., Rivier, F., Cances, C., Sole, G., Renard, D., Walther-Louvier, U., Ferrer-Monasterio, X., Espil, C., Arné-Bes, M.-C., Cintas, P., Uro-Coste, E., Martin Negrier, M.-L., Rigau, V., Bieth, E., Goizet, C., Claustres, M., Koenig, M., Cossée, M., 2018. **A Reliable Targeted Next-Generation Sequencing Strategy for Diagnosis of Myopathies and Muscular Dystrophies, Especially for the Giant Titin and Nebulin Genes.** *J Mol Diagn.* <https://doi.org/10.1016/j.jmoldx.2018.04.001>
568. Zhou, Q., Dong, J., He, J., Liu, D., Tian, D.H., Gao, S., Li, S., Liu, L., He, J., Huang, Y., Xu, S., Mao, W., Tan, Q., Chen, C., Li, X., Zhang, Z., Jiang, G., Xu, L., Zhang, L., Fu, J., Li, H., Wang, Q., Tan, L., Li, D., Zhou, Q., Fu, X., Jiang, Z., Chen, H., Fang, W., Zhang, X., Li, Y., Tong, T., Yu, Z., Liu, Y., Zhi, X., Yan, T., Zhang, X., Casal, R.F., Pompeo, E., Carretta, A., Riquet, M., Rena, O., Falcoz, P.-E., Saji, H., Khan, A.Z., Danguilan, J.L., Gonzalez-Rivas, D., Guibert, N., Zhu, C., Shen, J., 2018. **The Society for Translational Medicine: indications and methods of percutaneous transthoracic needle biopsy for diagnosis of lung cancer.** *J Thorac Dis* 10, 5538–5544. <https://doi.org/10.21037/jtd.2018.09.28>